Characterisation of liver progenitor cells and their microenvironment during chronic liver disease and hepatocarcinogenesis by Köhn, Julia
 





Characterisation of liver progenitor cells and their 











This thesis is presented for the Degree of 












To the best of my knowledge and belief this thesis contains no material previously 
published by any other person except where due acknowledgment has been made. 
 
This thesis contains no material, which has been accepted for the award of any other 
degree or diploma in any university. 
 
Human Ethics The research presented and reported in this thesis was conducted in 
accordance with the National Health and Medical Research Council National 
Statement on Ethical Conduct in Human Research (2007) – updated March 2014. 
The proposed research study received human research ethics approval from the 
Fremantle Hospital Human Research Ethics Committee (96/37) and the Alfred 
Hospital Ethics Committee (280/13). 
Animal Ethics The research presented and reported in this thesis was conducted in 
compliance with the National Health and Medical Research Council Australian code 
for the care and use of animals for scientific purposes 8
th
 edition (2013). The 
proposed research study received animal ethics approval from the Curtin University 
Animal Ethics Committee, Approval Number AEC_2012_23, AEC_2012_24, 









The journey through this PhD has been a very exciting but also challenging 
experience on a personal and professional level. I would like to express my special 
appreciation and gratitude to all of you who made this possible and accompanied me 
over the last four years locally or from far away.  
First and foremost I would like to thank my supervisor Dr. Nina Tirnitz-Parker for 
giving me the opportunity to come to Australia and to undertake this PhD project in 
her research group. I am grateful for all the support, the contributions of ideas, time 
and funding, the enthusiastic and motivational atmosphere, but also for teaching me 
to become an independent and conscientious researcher. I am also grateful to my 
second supervisor Prof. John Olynyk for his support and expertise, in particular with 
the human study within my project. To Dr. Caryn Elsegood for her valuable advice 
on immunohistology and for always having an open ear even without being one of 
my supervisors. 
A big thank you goes to my lab colleagues Jully and Frankie. We worked well 
together as a team, especially during our animal experiments. Jully, thanks for your 
encouragement, your warm words and chocolate supply in the final stage of my PhD. 
I also want to acknowledge my “office buddies” from room 145 who created a 
friendly, enjoyable working environment and for several stimulating discussions. I 
am particularly grateful to Ganga and Gae for all the conversations, the many laughs 
we shared, your advice and for entertaining my children when I needed to finish 
experiments in the lab or during the last period of my thesis write up. 
A huge thank you to all my friends from near and far, you guys are the best. I am 
grateful to Georgia and Kobi who always offered their help when needed, especially 
during the final countdown. Matt, you took us in warmly when we arrived in 
Australia helping us to get started down under. Merci to Honorine, my special 
“French girl”, we were so lucky to have you here for three months as friend and an 
extra pair of hands for the children. Dankeschön to my German friends, who 
supported me from far away or came for a visit. A special thanks goes to Verena for 
being an encouraging and caring friend throughout many years. I rejoiced in the 
many parcels sent from Germany which brought “home” a little closer to Australia. 
iii 
 
Last but not least, Dankeschön to my family for their love and encouragement: For 
my parents who supported me throughout all my journeys and adventures. My Mum 
for the three months she spent with us in Australia which meant so much to me and 
the kids. Thanks to my partner Fillippo for encouraging and supporting me along the 
way and to my children Mia and Matteo for their patience when I had to work on 





Chronic liver disease (CLD) is a major health and economic burden and its 
respective end-stage complications, cirrhosis and hepatocellular carcinoma (HCC), 
cause high rates of mortality worldwide. The number of patients with a high risk to 
develop end-stage CLD are increasing in western countries due to changing life 
styles, obesity, diabetes mellitus and insulin resistance, and also more frequently 
include children. Despite the diversity of causal factors, most CLDs share the 
common characteristics of hepatocellular necrosis, inflammation, fibrosis and the 
activation of liver progenitor cells (LPCs) as part of ductular reactions (DRs). The 
latter has been associated with HCC development, and thus LPCs are of particular 
interest in the study of hepatocarcinogenesis.  
There can be vast differences between experimental models that aim to mimic CLD-
related processes and their identification is fundamental for translational research. 
Chapter 3 of this thesis characterises and compares two common murine CLD 
models based on (i) choline deficiency and ethionine supplementation (CDE), and 
(ii) thioacetamide (TAA) supplementation. Overall, great discrepancies were 
revealed between both regimens. Liver injury markers, including serum alanine 
transaminase levels, apoptosis, hepatic fat loading and oxidative stress, as well as 
inflammatory, fibrogenic and LPC responses were analysed at early stages of CLD, 
defined as injury induction (day 3 and 7), establishment (day 14 and 21) and 
maintenance phase (day 42). The data defined CDE-driven periportal injury and 
fibrosis with an early peak and slow normalisation of all parameters. In contrast, 
TAA induced pericentral patterns of progressive injury and fibrosis, resulting in a 
more severe hepatic injury phenotype. Importantly, this study is the first to resolve 
two different patterns of injury and fibrosis in the CDE and TAA model, and to 
indisputably identify the fibrosis pattern in the TAA model as driven initially from 
the pericentral vein region. In Chapter 4, a detailed characterisation of the LPC 
response using common markers in the field, including panCK, CK19, CD133, 
EpCAM, E cadherin, MIC1-1C3, and Sox9 identified a broad homogenous 
population of LPCs provoked in both regimens. In addition, small subpopulations 
with distinct phenotypes were detected within the LPC responses, which were more 
v 
 
prominent in the TAA model. Chapter 5 describes CDE- and TAA-induced disease 
progression and carcinogenesis that were assessed in a long-term study. Injury 
dynamics, including hepatocellular tissue damage, and the inflammatory, fibrogenic 
and LPC response, as well as tumour development were assessed in mice treated for 
3, 5, and 7 months. Both regimens provoked progressively increasing levels of all 
investigated disease parameters throughout the time course study and eventually 
neoplasms were formed, starting after three months (CDE model) and five months of 
treatment (TAA), respectively. Importantly, in this thesis, both CDE- and TAA-
induced carcinogenesis resulted in the formation of HCC, which is controversial to 
several studies that reported TAA-associated cholangiocarcinoma development. 
Interestingly, increased LPC numbers were associated with carcinogenesis in both 
regimens, and CD44 was proposed to represent a marker that may potentially 
identify cancer-related LPC populations. To investigate the relevance of the results 
obtained in experimental models in the human setting, the relationship between the 
DR, LPC responses and HCC development was investigated in a retrospective study, 
described in Chapter 6. The data propose a positive correlation between the 
magnitude and distribution of DRs/LPCs and the development of HCC in CLD 
patients. 
This thesis provides a valuable foundation for future work utilising the CDE and 
TAA regimens to model a variety of human CLDs that feature DRs, LPC responses, 
and that predispose to hepatocarcinogenesis. It also highlights the importance of 
standardised protocols when using experimental models. Furthermore, the data from 
the human study may be of potential clinical relevance and may help to develop 
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1.1 The liver 
1.1.1 Anatomy and physiology of the liver 
The liver is the largest abdominal organ in the body and represents a central organ 
with highly diverse functions, including the metabolism of proteins, fat and 
carbohydrates, regulation of the blood-glucose level, bile production, storage of 
vitamins and nutrients, plasma protein synthesis, detoxification, drug metabolism and 
host defence. 
A healthy adult human liver consists of four lobes including right, left, quadrate and 
caudate; however, based on vascular and ductal arrangements can be further 
functionally subdivided into nine segments (Kogure et al. 1999). Mouse and rat 
livers similarly comprise four lobes termed median, left, right and caudate, which are 
all further subdivided, except the left lobe (Kogure et al. 1999; Malarkey et al. 
2005).  
The blood supply of the liver is provided by the portal vein and the hepatic artery, 
which together with a bile duct represent the portal triad (on average a portal triad 
contains one to two arteries, one portal vein and one to two bile ducts). Highly 
nutritious blood from the portal vein drains from the splenic and gastrointestinal 
veins and carries 70% of the hepatic blood flow (40% of the oxygen), whereas the 
hepatic artery delivers the remaining 30% of higher oxygenated blood (60% of the 
oxygen) (Malarkey et al. 2005). Upon entry into the portal tract, arterial and venous 
blood mixes, enters the sinusoidal system through the terminal portal venules, flows 
towards the central veins (also referred to as hepatic venules) and exits through the 
hepatic vein and the inferior vena cava. Incomplete mixing of portal blood and blood 
flow alterations can lead to different interlobular responses during liver diseases such 
as hepatitis C virus (HCV)-derived cirrhosis and carcinogenesis (Solt et al. 1977; 
Richardson et al. 1986; Regev et al. 2002). Bile is secreted from hepatocytes, moves 
within bile canaliculi towards the portal tract, in the opposite direction of the blood 
flow in the liver, and is collected in intrahepatic bile ducts. The cell compartments at 
the biliary-hepatocytic interface located between the terminal bile ductules and the 




first hepatocytes of the hepatic plate are referred to as the Canals of Hering and have 
been suggested to harbour dormant liver stem cells (Sell 1990; Theise et al. 1999). 
Cellular components of the epithelial and mesenchymal lineage are organised in 
multiple repetitive units, which form the characteristic complex three-dimensional 
structure of the liver. Different concepts have been proposed to describe the smallest 
hepatic unit. The most common models are the liver lobule and the liver acinus. In 
1833 Kiernan described the classical hexagonal lobule as the smallest hepatic unit, 
which consists of a centric hepatic vein surrounded by portal tracts in the shape of a 
hexagon (Kierman 1833). Based on functional differences and dependent on the 
location within the lobule, Rappaport et al. introduced the liver acinus, which only 
focusses on the area between central veins (Rappaport et al. 1954). Thus the acinus 
defines a functional unit, which is divided into a periportal (zone 1), an intermediate 
(zone 2) and a pericentral area (zone 3). Based on the oxygen and nutritional gradient 
created by the incoming blood, there is a great functional heterogeneity from 
periportal towards pericentral hepatocytes (Gebhardt 1992). Characteristic functions 
of the periportal area include oxidative metabolism, gluconeogenesis, lipid and 
amino acid metabolism, bile formation and the synthesis of the plasma proteins 
albumin and fibrinogen, whereas the pericentral area is mainly responsible for 
glycolysis, fatty acid synthesis, ketogenesis, xenobiotic metabolism and 
detoxification (Jungermann and Kietzmann 1996; Malarkey et al. 2005). 
1.1.2 Adult hepatic cell types 
1.1.2.1 Hepatocytes 
Hepatocytes represent the main cell type in the liver by making up 80% of the 
volume and numerically accounting for 60% of all hepatic cells (Blouin et al. 1977). 
Their size ranges from 20 - 30 µm and the morphology resembles a characteristic 
cuboidal epithelial cell. Hepatocytes form a labyrinth-like structure consisting of one 
cell-thick plates (laminae) radiating out from the central vein, which also determines 
the sinusoidal architecture since their lumen is formed by neighbouring hepatic 
plates. Hepatocytes are polarised cells that face different adjacent compartments in 




the liver and show three characteristic membrane domains with specialised functions: 
the basolateral, lateral and apical domain (Treyer and Musch 2013). The basolateral 
surface or sinusoidal domain is exposed to the perisinusoidal space, also called the 
Space of Disse, which represents the extracellular space between hepatocytes and the 
sinusoidal endothelium. Microvilli structures on the surface of the basolateral domain 
facilitate the exchange of substances between the blood and hepatocytes (Grisham et 
al. 1975). The lateral surface or intercellular membrane domain anchors 
neighbouring hepatocytes by forming tight junctions, intermediate junctions and 
desmosomes, as well as gap junctions for communication (Treyer et al. 2013). The 
apical surface or canalicular domain secretes bile acid, and bile canaliculi are formed 
by the apical membranes of two opposing hepatocytes. Due to their high metabolic 
activity and numerous functions, hepatocytes contain a large number of 
mitochondria, free ribosomes, cytoskeleton elements, lysosomes and peroxisomes, as 
well as smooth and rough endoplasmic reticulum, and furthermore can be mono- or 
binucleated (di-, tetra- and octoploid), showing increased ploidy primarily towards 
the central area (Gandillet et al. 2003). 
1.1.2.2 Cholangiocytes 
Cholangiocytes or biliary epithelial cells line the lumen of bile ducts and represent 
approximately 3-5% of all hepatic cells. They form a branched three-dimensional 
network of intra- and extrahepatic bile ducts, termed the biliary tree, which drains 
secreted canalicular bile and mediates its transport from the Canals of Hering 
towards the intestine. During development, cholangiocytes from the intrahepatic 
biliary tree originate from bipotential hepatoblasts and thus share the same precursor 
cell with hepatocytes (Vestentoft et al. 2011). According to the diameter of their 
lumen, rodent intrahepatic bile ducts can be further subdivided into two groups, 
small and large ducts, which are lined by four to five small or 8-12 large 
cholangiocytes, respectively, with cell sizes ranging from 6-12 μm (Tabibian et al. 
2013). In addition to the function of bile transport, cholangiocytes also perform 
canalicular or primary bile modifications and concentration by coordinated 
membrane-transport of ions, solutes and water, mediated through numerous 
transporter proteins on their basolateral and apical surface (Franchitto et al. 2013; 




LaRusso et al. 1991; Alpini et al. 1988). Furthermore, it was shown in rats that 
connexin 43-gap junctions mediate hormonal-controlled intercellular communication 
(Bode et al. 2002). 
1.1.2.3 Liver Sinusoidal Endothelial Cells 
Combined blood entering through the hepatic artery and portal vein, streams between 
the hepatocyte plates towards the central vein. Blood flow is coordinated by hepatic 
sinusoids, which are lined by liver sinusoidal endothelial cells (LSECs) and act as a 
semi-accessible barrier between the blood and the extracellular Space of Disse, 
allowing bi-directional transfer of soluble and small substrates with hepatocytes 
(Wisse 1972). To facilitate this transport, LSECs have specialised characteristics, 
including the lack of a typical basement membrane and the existence of numerous 
transcellular pores termed fenestrations, which are clustered in sieve plates (Wisse et 
al. 1983; Svistounov et al. 2012). Consequently, their morphology, functions and 
phenotypes are significantly different from vascular endothelial cells in the liver and 
other organs. The availability of markers to label LSECs with specific antibodies is 
somewhat limited, as they also label other types of vascular endothelial cells. Widely 
used are markers such as von Willebrand factor (also called factor VIII) and platelet-
endothelial cell adhesion molecule 1, referred to as cluster of differentiation 31 
(CD31). Due to discrepancies in expression patterns in published studies, there is 
however much controversy regarding their respective expediency (Irving et al. 1984; 
Couvelard et al. 1993; Smedsrod et al. 1994). 
1.1.2.4 Kupffer cells 
Kupffer cells (KCs) were first described in 1876 by the anatomist Karl Wilhelm von 
Kupffer and named accordingly. They are defined as tissue-resident macrophages 
that reside in the hepatic sinusoids between LSECs, firmly attached to the sinusoid 
wall and play an important role in liver homeostasis and innate immunity (Smedsrod 
et al. 1994; Parker and Picut 2005). KCs account for approximately 15% of all 
hepatic cells and 30% of sinusoidal cells. The majority of KCs exist in the periportal 
area (43%) (Bouwens et al. 1986), facilitating the first contact to substances 




absorbed from the gastrointestinal tract and transported via the blood entering the 
hepatic vein. In addition, KCs are found in the intermediate (28%) and pericentral 
area (29%) of the lobule in rats (Bouwens et al. 1986), and importantly might be able 
to migrate within the sinusoids (MacPhee et al. 1992). Their main characteristics are 
scavenger and phagocytic functions, such as the elimination and detoxification of 
microorganisms, lipopolysaccharides, apoptotic cells, immune complexes and toxic 
agents from the blood (Parker et al. 2005). A previous study in rats found the 
distribution of KCs to be in a ratio of 4:3:2 from portal via intermediate towards 
central areas and showed functional heterogeneity depending on their position within 
the liver lobe (Sleyster and Knook 1982). Portal KCs were found to be larger and 
showed higher phagocytic and lysosomal enzyme activity than midzonal and central 
KCs (Sleyster et al. 1982). Initially the identification of KCs was based on their high 
peroxidase activity (Fahimi 1970; Widmann et al. 1972), however nowadays their 
phenotype can be characterised by immunodetection with markers such as CD68, 
F4/80 and CRIg (Brown et al. 2001; Elsegood et al. 2015). 
1.1.2.5 Hepatic Stellate Cells 
Hepatic stellate cells (HSCs), first described as “Sternzellen” (“star cells” in 
German) together with KCs by Kupffer in 1876, are located in the Space of Disse 
between LSECs and hepatocytes, and account for about 5% of all hepatic cells. The 
term hepatic stellate cell was standardised amongst researchers in 1996, as up to that 
date several different names were used in the literature including perisinusoidal cell, 
Ito cell, lipocyte, parasinusoidal cell, and fat-storing cell, causing confusion in the 
field (Friedman 2008a). In healthy livers, HSCs are quiescent and their main 
characteristic feature is the cytoplasmic storage of Vitamin A in lipid droplets (Wake 
1971). In rodents, desmin was described to represent a reliable marker for HSCs and 
distinguishes them from other fibroblast populations in the liver (Yokoi et al. 1984; 
Takase et al. 1988). The HSC population shows a high heterogeneity and plasticity. 
In response to liver injury, HSCs assume an activated state and severely change their 
morphology and phenotype by losing the lipid droplets and transforming into a 
myofibroblast-like cell type expressing α-smooth muscle actin (αSMA) (Schmitt-
Graff et al. 1991). These are the main producers of extracellular matrix (ECM) 




components and central players in ECM remodelling (Friedman 2008b), and hence 
fulfil an important role during fibrogenesis in chronic liver injuries. 
1.1.2.6 Pit cells 
Pit cells were first described in 1976 by Wisse et al. and named according to their 
high characteristic granules in the cytoplasm resembling fruit pits (Wisse et al. 
1976). They are located in the hepatic sinusoids firmly adhering to KCs and LSECs, 
and occasionally migrate along the sinusoid wall or penetrate the endothelial 
fenestrae mediated by microvilli or extending pseudopodia to facilitate contact to 
hepatocyte microvilli within the Space of Disse (Wisse et al. 1976; Kaneda and 
Wake 1983; Kaneda et al. 1984). Originally pit cells were identified as hepatic large 
granular lymphocytes with natural killer (NK) cell activity, however due to similar 
morphologies the pit cell population includes liver-associated NK cells and natural 
killer T cells (Nakatani et al. 2004). 
1.1.3 Liver tissue homeostasis under healthy conditions 
The origin and mechanism of newly generated hepatocytes during normal liver tissue 
homeostasis is still under debate. An early theory is termed “streaming liver” and 
claims that hepatocytes proliferate in portal areas with subsequent central-orientated 
migration and maturation while creating the distinct portal-to-central zonation with 
different metabolomics and gene expression patterns. (Zajicek et al. 1985; Arber et 
al. 1988). However, this model of normal tissue turnover has been disputed. Firstly, 
there is no evidence of a correlation between gradual maturation and cell function, 
and it was shown that lobular zonation is not dependent on the hepatocyte lineage 
maturation stage but rather on oxygen access and metabolic activities (Thurman and 
Kauffman 1985). Moreover, hepatocyte tracing studies revealed a contribution of all 
hepatocytes throughout the liver lobule by clonal proliferation (Bralet et al. 1994; 
Kennedy et al. 1995). 
More recently an albumin-driven lineage tracing study demonstrated the existence of 
new-born hepatocyte lineages emerging from prehepatocyte albumin-naïve cell 




populations in normal healthy livers (Iverson et al. 2011). A continuous supply of 
new hepatocytes was detected under steady-state conditions, which represented 
0.076% of all hepatocytes. As hepatocytes are proliferative, they give rise to several 
new hepatocytes. However, it is not known how many cell divisions they are capable 
of undergoing and whether they become senescent. The steady-state condition of 
new-born hepatocytes demonstrated by Iverson et al. indicates a finite self-renewing 
capacity of hepatocyte lineages and their senescence. 
A recent study by Wang and colleagues demonstrated the existence of an Axin2
+
 
stem cell/progenitor cell compartment adjacent to the central vein, which is active 
during normal healthy conditions and thus contributes to newly derived hepatocyte 
lineages (Wang et al. 2015). It was shown that this pericentral stem cell niche is 
maintained via Wnt signalling and is mediated by central vein endothelial cells. 
The current literature proposes that hepatocytes might not fuel the generation of new 
hepatocyte lineages by themselves. Instead there may be different cell sources of 
“prehepatocytes” contributing to tissue homeostasis. Whether they act in concert 
with each other or are mutually exclusive remains to be determined. 
1.2 Liver regeneration: tissue response in acute vs. chronic liver 
injury 
A unique characteristic of the liver is its great potential to regenerate in response to 
different injuries. There are two main mechanisms described in the literature, which 
mediate the regeneration process, depending on the type of injury. Acute liver injury 
caused by drug, toxin and acute viral exposure as well as resection, activates the 
hepatocyte-mediated regeneration cascade. However, following severe or chronic 
liver injury, residual hepatocytes may no longer meet the tissue demand due to cell 
cycle arrest and senescence, and consequently a progenitor cell compartment takes 
over and facilitates the replacement of damaged hepatocytes via liver progenitor cell 
(LPC)-mediated regeneration.  
Hepatocyte-mediated liver regeneration has mainly been studied after partial 
hepatectomy (PH). The protocol used in rats, where two thirds of the liver are 
resected (Higgins 1931), had to be adjusted for safe performance in mice (Greene 




and Puder 2003) due to induced necrosis after removal of the left and median lobes 
(Fausto et al. 2006). However, in both species a PH consistently leads to the 
expansion of the remaining lobes until the original mass is restored, which is 
accomplished within five to seven days. The restoration process is mediated by a 
sequential replication of the residual liver cells including hepatocytes, which 
represent one of the few fully differentiated cell types capable of performing DNA 
replication and cell proliferation (Inoue et al. 2006). However, differences in 
hepatocyte proliferation capabilities were reported to be dependent on the location 
within the liver acinus, showing initial replication in periportal areas and lower 
activity in central areas (Rabes 1976; Gebhardt 1988). It is commonly accepted that 
hepatocyte compensation is self-regulated by the metabolic needs and ends when the 
appropriate liver-body-weight ratio is reached. This regeneration process is regulated 
by a complex signalling network including cytokines, growth factors and metabolic 
pathways, which operate simultaneously and/or sequentially (Fausto et al. 2006; 
Riehle et al. 2011). Kupffer cells represent at least one initiator of hepatocyte 
regeneration, since they activate the inflammatory cascade mediated by tumour 
necrosis factor (TNF)-induced NF-κB signalling and subsequent interleukin 6 (IL6) 
secretion (Yamada et al. 1997; Cressman et al. 1996). Downstream signalling in 
hepatocytes causes nuclear translocation of signal transducer and activator of 
transcription 3 (STAT3), and promotes cell proliferation in concert with several 
growth factors, in particular members of the epidermal growth factor (EGF) family 
such as EGF (Francavilla et al. 1986; Raper et al. 1987), transforming growth factor 
(TGF) α (Webber et al. 1993) and heparin binding EGF-like growth factor (Kiso et 
al. 2003), as well as hepatocyte growth factor (HGF) (Strain et al. 1991; Inoue et al. 
2006; Natarajan et al. 2007) and TNF (Akerman et al. 1992; Webber et al. 1998). It 
was shown that full mitogen function of HGF, TGFα and EGF during acute injury is 
achieved after initial stimulation of hepatocytes with factors including TNF, a 
process called “hepatocyte priming” (Webber et al. 1994; Webber et al. 1998). Since 
HGF is bound to the ECM and requires release before performing mitogen activity 
(Schuppan et al. 1998) and matrix remodelling is associated with liver regeneration, 
it is not surprising that matrix metalloproteinases (MMPs) play an important role 
during hepatocyte proliferation (Kim et al. 2000; Olle et al. 2006; Riehle et al. 
2011). During the end stage of liver repair these growth-stimulating processes 
eventually have to be abolished. Suppressor of cytokine signalling 3 is an important 




player as it inhibits STAT3 signalling via a negative feedback loop during IL6 signal 
transduction, and thus helps to mediate the end of hepatocyte compensatory 
proliferation (Campbell et al. 2001; Fausto et al. 2006). 
On the other hand, activation of the LPC compartment is associated with chronic 
liver injuries such as hepatitis B virus (HBV) and HCV infections, alcoholic liver 
disease (ALD), non-alcoholic fatty liver disease (NAFLD) and haemochromatosis. It 
was shown that inflammatory cytokines and growth factors play a key role in the 
LPC response (Knight et al. 2005b; Bird et al. 2008; Riehle et al. 2011). Several in 
vitro and in vivo studies have reported the relevance of numerous signalling 
molecules including TNF superfamily members such as TNF (Knight et al. 2000), 
lymphotoxin (LT) α (Knight and Yeoh 2005c), LTβ (Akhurst et al. 2005) and TNF-
like weak inducer of apoptosis (TWEAK) (Tirnitz-Parker et al. 2010), as well as 
interferon γ (IFNγ) (Akhurst et al. 2005), TGFβ (Nguyen et al. 2007), HGF 
(Ishikawa et al. 2012) and fibroblast growth factor (FGF) (Kaneko et al. 2015). 
Within this complex signalling network, the mitogens TWEAK and FGF, in 
particular, represent molecules which are active in the primary induction phase of 
LPCs since their expression was sufficient to induce a LPC response in uninjured 
livers (Jakubowski et al. 2005; Takase et al. 2013). Besides its proliferative effect on 
LPCs, HGF signalling through its receptor c-Met is also involved in LPC migration 
and parenchymal invasion (Suarez-Causado et al. 2015). Further details on the 
biology of LPCs are discussed in the following paragraphs. 
During the process of regeneration, hepatocytes and LPCs do not act in a mutually 
exclusive manner and have been reported to function simultaneously (Dabeva and 
Shafritz 1993; Thorgeirsson 1996; Ochoa et al. 2010), which is consistent with the 
fact that several factors act as growth factors for both cell types. A human study by 
Katoonizadeh et al. showed that LPC activation occurs in response to PH when at 
least 50% of hepatocytes are lost and the remaining hepatocytes show decreased 
proliferation activity (Katoonizadeh et al. 2006). However, dependent on the severity 
of the injury and the degree of hepatocyte inhibition, the liver favours one of the two 
pathways. Even though several signalling molecules have an impact on both 
hepatocytes and LPCs, opposing effects may result from different responses to 
specific cytokines, mediated by divergent downstream pathways. Candidates which 
promote opposing effects and thus potentially mediate the switch from hepatocyte- 




towards LPC-mediated regeneration, include TGFβ and IFNγ. TGFβ signalling is 
induced in chronic liver disease (CLD) (Dooley and ten Dijke 2012) and is capable 
of inhibiting proliferation in both cell types (Moustakas and Kardassis 1998; 
Thenappan et al. 2010). However lower inhibitory activity in LPCs was 
demonstrated to be potentially due to the expression of the TGFβ inhibitor Sma- and 
Mad-related protein 6 (Nguyen et al. 2007). Moreover in hepatocytes, TGFβ 
signalling was linked to dedifferentiation and the treatment of LPCs in vitro resulted 
in tumour-initiating potential (Wu et al. 2012a), which further highlights different 
responses in the two cell types. Similar results were obtained when investigating the 
role of IFNγ signalling, which is involved in promoting the LPC response during 
chronic injury (Knight et al. 2007b). In vitro studies showed an inhibitory effect of 
IFNγ signalling on TNF-stimulated hepatocyte proliferation mediated by nitric oxide 
(NO) formation, whereas LPC proliferation was not affected due to a lack in NO 
production (Brooling et al. 2005). Furthermore, data generated with the LPC line 
PIL-2 even suggest a pro-proliferative effect of IFNγ via STAT3 signalling 
activation (Akhurst et al. 2005). 
1.3 Liver progenitor cell-mediated regeneration 
1.3.1 Discovery and characteristics of liver progenitor cells 
In contrast to the haematopoietic system, the somatic stem cells in the liver have not 
been isolated or even identified yet (Reya et al. 2001; Spangrude et al. 1988) and 
thus only a potential progenitor cell population has been extensively studied up-to-
date. In rodents, LPCs were originally identified by Kinosita in rats treated with the 
azo dye and former food additive “Butter Yellow” (Kinosita 1937) and later 
introduced by Farber as “ovoid cells”, describing their cytologic appearance 
following treatment with carcinogenic agents (Farber 1956). Since then a variety of 
different terminologies have been used to describe this extremely heterogeneous cell 
population, including hepatic stem-like/progenitor cells, oval cells (mainly used in 
rodent models) or transit-amplifying ductular cells. In addition, they are described as 
a component of so-called ductular reactions (DRs) (mainly used in human 
pathologies, detailed further below). They are defined as small cells (7-10 μm in 




diameter) featuring a high nuclear-to-cytoplasmic ratio, a small ovoid nucleus, a 
basophilic character, and variably express both biliary and hepatocytic as well as 
haematopoietic markers (see Table 1.1 and Table 1.2). Common markers used in the 
literature to identify LPCs are cytokeratin (CK) 7, CK19, CD24, CD133, epithelial 
cell adhesion molecule (EpCAM), oval cell marker (MIC1-1C3), and SRY (sex 
determining region Y)-related HMG (high mobility group) box 9 (Sox9) (Dorrell et 
al. 2008; Dorrell et al. 2011; Okabe et al. 2009; Qiu et al. 2011; Sackett et al. 2009; 
Schievenbusch et al. 2012; Shin et al. 2011; Suzuki et al. 2008; Lu et al. 2015; Kim 
et al. 2014). These markers do not differentiate between cholangiocytes and LPCs, 
however a study by Okabe et al. proposed tumour-associated calcium signal 
transducer 2 (Trop2) to be a marker that distinguishes between activated proliferative 
LPCs and cholangiocytes as well as potential dormant LPCs during liver injury 
response. Trop2 expression was detected in EpCAM-positive LPCs following a 3,5-
diethoxycarbonyl-1,4-dihydro-collidine (DDC) diet but not in normal mouse livers 
(Okabe et al. 2009) indicating its potential value as a specific LPC marker. However, 
its exclusive expression profile has not been confirmed in other experimental models. 
1.3.2 Origin of liver progenitor cells 
The origin of LPCs remains highly controversial. The multi-lineage phenotype of 
LPCs provoked the debate of their cellular origin and many theories were proposed. 
Some studies were based on marker co-expression and the fact that LPCs express 
common cell surface markers, which they share with haematopoietic stem cells, such 
as CD34, c-Kit, stem cell antigen-1 (Sca-1) and Thy-1 (CD90), suggesting that they 
might originate from the bone marrow (Petersen et al. 1998; Petersen et al. 1999; 
Petersen et al. 2003). 





Mouse and Rat 
 
Marker LPC Hepatocyte Cholangiocyte Model Reference 





(Petersen et al. 2003; Ueberham 
et al. 2007; Tirnitz-Parker et al. 
2007; Tonkin et al. 2008; Endo 
et al. 2012; Schievenbusch et 
al. 2012) 
AFP + fetal - 
AAF/PH, 
DEN, CDE 
(Sell 1978; Evarts et al. 1987; 
Smith et al. 1996; Jelnes et al. 
2007) 
Alb + + - CDE, AAF (Sell 1978; Tian et al. 1997) 
CD13 + - ?  (Kamiya et al. 2009) 
CD24 + - + 
AAF/PH, 
DDC 
(Yovchev et al. 2007; Qiu et al. 
2011; Schievenbusch et al. 
2012) 
CD34 + - + 
AAF/PH, 
DDC 
(Omori et al. 1997; Petersen et 
al. 2003) 
CD44 
low - ? AAF/PH (Ueberham et al. 2007) 
+ (intermediate state) - D-gal (Kon et al. 2006)Kon 2006 
CD133 + - + 
AAF/PH, 
DDC 
(Rountree et al. 2007; Suzuki et 
al. 2008; Kamiya et al. 2009)  
CK7 + - + AAF/PH 
(Sarraf et al. 1994; Paku et al. 
2005; Clouston et al. 2005) 
CK8 + + (+) AAF/PH 
(Sarraf et al. 1994; Sasaki et al. 
2008) 
CK18 + low (+) AAF/PH 
(Sarraf et al. 1994; Golding et 
al. 1995) 




(Sarraf et al. 1994; Petersen et 
al. 1998; Paku et al. 2005; 
Okabe et al. 2009) 
c-Kit + - + 
AAF/PH, 
CDE, D-gal 
(Fujio et al. 1994; Fujio et al. 
1996; Knight et al. 2008) 
c-Met + - + AAF/PH (Hu et al. 1993) 
Cx43 + - + AAF/PH 
(Zhang and Thorgeirsson 1994; 
Paku et al. 2004; Yovchev et al. 
2007) 




(Jensen et al. 2004; Jelnes et al. 
2007) 
E-cadherin +/high -/low +/high CDE 
(Ueberham et al. 2007; Tirnitz-
Parker et al. 2007; Van Hul et 
al. 2009) 





(Yovchev et al. 2007; Okabe et 
al. 2009; Endo et al. 2012; 
Schievenbusch et al. 2012) 
Foxl1 + - + 
DDC, CDE, 
BDL 
(Sackett et al. 2009; Shin et al. 
2011) 




(Petersen et al. 1998; Holic et 
al. 2000) 
Integrin αvβ6 + - + 
MDR2 
deletion 
(Peng et al. 2015) 
Lgr5 + - - CCl4 (Huch et al. 2013) 
MIC1-1C3 + - + DDC 
(Dorrell et al. 2008; Dorrell et 
al. 2011) 
 
Table 1.1: Adult LPC marker expression in different cell lineages in liver injury-induced and 
non-injured settings. To be continued on following page. 





Mouse and Rat 
 
Marker LPC Hepatocyte Cholangiocyte Model Reference 
M2PK + fetal + 
AAF/PH, 
CDE 
(Tee et al. 1994; Smith et al. 
1996; Jelnes et al. 2007; 
Tirnitz-Parker et al. 2007) 
Nope + - low DDC (Schievenbusch et al. 2012) 





(Hixson and Allison 1985; 
Petersen et al. 1998) 
OPN + - + 
DDC, CDE, 
CCl4 
(Carpentier et al. 2011; 
Espanol-Suner et al. 2012) 
Sox9 + - + DDC, CDE 
(Carpentier et al. 2011; 
Furuyama et al. 2011) 





(Yang et al. 1993; Petersen et 
al. 1998; Paku et al. 2004) 
π-GST + fetal - CDE 
(Tee et al. 1994; Smith et al. 
1996; Lowes et al. 1999; 
Oliva et al. 2010) 
Sca-1 + - - DDC (Petersen et al. 2003) 




(Petersen et al. 1998; Petersen 
et al. 2003) 
Trop2 + - - DDC, CDE 
(Okabe et al. 2009; 
Carpentier et al. 2011) 
 
Progenitor cell compartments in non-injured livers 
 
CD49f+CD13+CD133+  (Kamiya et al. 2009) 
MIC1-1C3+CD133+  (Dorrell et al. 2011) 
EpCAM  (Okabe et al. 2009) 
 
Table 1.1: Adult LPC marker expression in different cell lineages in liver injury-induced and 
non-injured settings. +, positive; -, negative; (+), occasionally expressed; “low” denotes weakly 
expressed; “high” denotes highly expressed; AAF, 2-acetylaminofluorene; PH, partial hepatectomy; 
CDE, choline deficiency and ethionine supplementation; DDC, 3,5-diethoxycarbonyl-1,4-
dihydrocollidine; DDB1, damaged DNA binding protein 1; D-gal, D-galactosamine; DEN, 
diethylnitrosamine; MDR2, multidrug resistance protein 2. 







Marker LPC Hepatocyte Cholangiocyte Disease Reference 
AFP + - - 
Acetaminophen-induced 
necrosis, acute necrotising 
hepatitis 
(Theise et al. 1999; 
Spee et al. 2010) 
CD90 + - - HCV 
(Villano et al. 2014; 
Li et al. 2014) 
CD109 + low low  (Li et al. 2014) 
CD133 + - (+) 
Acute necrotising hepatitis, 
HBV, HCV, primary biliary 
cirrhosis 
(Porretti et al. 2010; 
Spee et al. 2010) 
CK7 + - + 
Alcoholic hepatitis, acute 
necrotising hepatitis, HCV, 
pNAFLD, primary biliary 
cirrhosis 
(Spee et al. 2010; 
Nobili et al. 2012; 
Sancho-Bru et al. 
2012; Villano et al. 
2014) 
CK8 + low (-)  (Li et al. 2014) 
CK18 + low (-)  (Li et al. 2014) 
CK19 + - + 
Acetaminophen-induced 
necrosis, ALD, genetic 
hemochromatosis, HBV, 
HCV 
(Lowes et al. 1999; 
Theise et al. 1999; Li 
et al. 2014; Villano et 
al. 2014) 
c-Kit + - +/- 
Acetaminophen-induced 
necrosis, acute liver failure, 
extrahepatic biliary atresia 
(Cirrhosis) 
(Baumann et al. 1999; 
Theise et al. 1999; Li 
et al. 2014) 
EpCAM + - + 
Alcoholic hepatitis, HBV, 
HCV 
(Porretti et al. 2010; 
Sancho-Bru et al. 
2012; Villano et al. 
2014) 
Jagged 1 + - (+) 
Acute necrotising hepatitis, 
HCV, primary Biliary 
cirrhosis 
(Spee et al. 2010) 
M2PK + (-) - 
Genetic hemochromatosis, 
ALD, HCV 
(Lowes et al. 1999) 
NCAM + - (-) 
Acute necrotising hepatitis, 
HBV, HCV, primary biliary 
cirrhosis 
(Porretti et al. 2010; 
Spee et al. 2010) 
Oval-6 + - -  (Li et al. 2014) 
 
Table 1.2: Adult human LPC marker expression in different cell lineages in liver injury and 
non-injured settings. +, positive; -, negative; (+), occasionally expressed; “low” denotes weakly 
expressed; ALD, alcoholic liver disease; BDL, bile duct ligation; pNAFLD, paediatric non-alcoholic 
fatty liver disease; HBV, hepatitis B virus infection; HCV, hepatitis C virus infection. 




However, it was later shown in a cell transplantation model that bone marrow-
derived hepatocytes were a result of cell fusion rather than transdifferentiation 
(Wang et al. 2003). Another study identified a LPC population that expresses several 
mesenchymal markers such as vimentin, mesothelin, bone morphogenic protein and 
TWEAK receptor (fibroblast growth factor-inducible 14, Fn14) (Yovchev et al. 
2008) indicating a mixed epithelial/mesenchymal phenotype. 
Since their proliferation is always first seen in periportal hepatic regions, the general 
view has been that they are the progeny of a yet to be identified liver-resident stem 
cell, residing in the Canals of Hering (Lenzi et al. 1992). More evidence for their role 
as progenitor cell origin was provided by three-dimensional reconstructions in 
healthy adult tissue and following massive hepatic necrosis secondary to 
acetaminophen toxicity, where it was demonstrated that LPC proliferation was 
topographically identified in the Canals of Hering structures (Theise et al. 1999). 
Label retention assays on the basis of bromodeoxyuridine incorporation equally 
identified the Canals of Hering and in addition intraductal cholangiocytes, periductal 
“null cells” (lacking expression of hepatobiliary markers) and the first hepatocytes of 
the hepatic acinus as potential functional stem cell niche locations, and thus 
suggested a flexible regeneration system with more than one stem cell niche 
(Kuwahara et al. 2008). Additionally, a cell lineage tracing study, following Sox9 
expression, demonstrated that embryonic ductal plate cells give rise to adult LPCs 
and represent at least one of the precursor cell types (Furuyama et al. 2011; 
Carpentier et al. 2011). 
A recent study using a hepatocyte-chimeric lineage tracing system followed by 
extensive RNA-sequencing and ultrastructural analysis suggested that mature, fully 
differentiated hepatocytes can contribute to the LPC pool by undergoing reversible 
metaplasia to a biliary-like progenitor state during 3,5-diethoxycarbonyl-1-4-
dihydrocollidine (DDC)-induced liver injury (Tarlow et al. 2014b). Kordes and 
colleagues demonstrated through HSC transplantation experiments in two chronic 
liver injury models that HSCs were able to contribute to the regeneration process by 
transdifferentiation into hepatocytes and cholangiocytes and may therefore represent 
another candidate cell contributing to the LPC population under certain experimental 
conditions (Kordes et al. 2014). Another lineage tracing study that followed the fate 
and regenerative capacity of hepatocyte nuclear factor 1 β-positive biliary cells 




demonstrated that this population did not contribute to the generation of new 
hepatocytes in healthy liver or after acute injury. However these cells can 
differentiate into hepatocytes in certain chronic injury regimes, such as shown using 
the choline-deficient, ethionine-supplemented (CDE) dietary mouse model (Rodrigo-
Torres et al. 2014), via an intermediate LPC phenotype. 
Taken together, these data suggest that the adult liver may retain a certain level of 
plasticity and the ability to recruit multiple distinct cellular sources for LPC 
generation (Fig. 1.1). The term “LPC” could lead to the false assumption of a 
potential stem cell origin, which has not been established yet. In this thesis, the term 
LPC will be used without evaluating the source of this cell population induced during 
CLD. 
1.3.3 Function of liver progenitor cells during chronic liver injury 
LPCs, defined by their immature stem cell-like marker expression profile, have been 
shown to differentiate bipotentially into biliary cells and hepatocytes (Forster et al. 
2011; Sackett et al. 2009; Shin et al. 2011; Suzuki et al. 2008; Tirnitz-Parker et al. 
2007) and in some models have demonstrated multipotentiality by differentiation 
into pancreatic and intestinal lineages (Leite et al. 2007; Tatematsu et al. 1985; Yang 
et al. 2002). 
However, the actual regenerative capacity of LPCs has been highly debated. A recent 
genetic lineage tracing study used yellow fluorescent protein-osteopontin (OPN)-
marked cholangiocytes and LPCs to study their role during (i) PH, (ii) carbon 
tetrachloride (CCl4)-induced acute injury, or (iii) chronic injury following 
administration of either a CDE or DDC diet (Espanol-Suner et al. 2012). This study 
revealed that OPN-expressing LPCs only contributed significantly to hepatocellular 
regeneration in the CDE model of chronic liver injury, highlighting injury context 
specificity. Further evidence that LPCs might play an important role during liver 
mass reconstitution comes from experiments using a reporter mouse for the LPC 
marker forkhead helix-box L1 (Foxl1), establishing that Foxl1
+
 LPCs and their 
descendants are critically required for hepatocyte generation during recovery from 
CDE-induced injury (Shin et al. 2015). 








Fig. 1.1: The potential origins and differentiation capabilities of liver progenitor cells. LPCs have 
been suggested to originate from dormant precursors in the Canals of Hering (CoH), the 
dedifferentiation of biliary epithelial cells (BEC) or hepatocytes (Hep) or the metaplastic contribution 
of hepatic stellate cells (HSC). Upon appropriate stimulation, they can differentiate into 
cholangiocytes and hepatocytes, possibly via transitional phenotypes (reactive biliary cells and 
intermediate hepatocytes, respectively), and have been suggested as precursor cells for 
cholangiocarcinoma (CC) and hepatocellular carcinoma (HCC). The background photomicrograph 
depicts a primary cell culture of LPCs isolated from a chronically injured, CDE-treated mouse liver. 




Additionally Huch and colleagues demonstrated that single cells positive for leucine-
rich repeat-containing G protein-coupled receptor 5 (Lgr5) can be expanded as 
epithelial three-dimensional organoids in vitro, and can be differentiated towards 
hepatocytes in vitro and form new hepatocytes upon transplantation into CCl4-
retrorsine-treated mice (Huch et al. 2015). 
Tarlow et al. reported conflicting results by showing that LPCs labelled via 
expression of Sox9 only rarely (<1%) produced new hepatocytes in the CDE model 
(Tarlow et al. 2014a). However, it should be noted that this study used 
supplementation with only 0.1% ethionine in the drinking water, as opposed to the 
more common concentration of 0.15% also used by Shin and colleagues (Shin et al. 
2015), highlighting the fact that observed disparities might be the result of 
differences in the severity of induced liver injury. 
A very recent study defined a population of highly expandable, clonogenic cells 
negatively sorted for haematopoietic (CD45), endothelial (CD31) and erythroid 







, as capable of efficiently repopulating the liver 
bipotentially. This was observed following repeated rounds of induced hepatocyte 
senescence in mice lacking functional E3 ubiquitin-protein ligase Mdm2 in 
hepatocytes (Lu et al. 2015). The discrepancies and contradicting results between 
studies probably stem from a lack of uniformity with regards to the animal model 
used, the degree of evoked liver injury and differences in the underlying injury and 
repair mechanisms. However, overall it shows a high degree of plasticity in the liver 
and LPC-mediated regeneration (see Fig. 1.1). 
1.3.4 Isolation strategies for liver progenitor cells 
Primary cell culture is of considerable value for LPC research as these cells most 
closely mimic their in vivo status whilst facilitating the study and direct manipulation 
of cell proliferation, lineage commitment and differentiation. Since LPCs are hardly 
detectable in healthy liver, most isolation procedures involve an induction protocol, 
followed by a series of standard isolation steps including tissue perfusion, digestion 




and fluorescence-activated cell sorting (FACS) or cell centrifugation and 
fractionation for further purification. 
To establish a mixed culture containing a variety of heterogeneous LPC phenotypes, 
centrifugal elutriation based on cell size and density (Yaswen et al. 1984) can be 
used to separate LPC populations from other liver cell fractions, followed by growth 
in LPC-promoting culture conditions (Tirnitz-Parker et al. 2007). The generation of 
clonogenic cell lines for single cell tracing is required to thoroughly characterise 
these different populations. However, the resultant LPC subpopulation as well as cell 
quantity, viability and features of LPCs maintained in culture, very much depends on 
the method of isolation, the surface coating of the culture dish and the combination 
and concentration of growth factors in the culture medium. These factors vary 
considerably amongst laboratories, making it difficult to interpret in vitro results 
obtained by different groups, and it is clear that reliable, standardised protocols are 
urgently required.  
Importantly, the term LPC primarily describes a cell’s bi-lineage marker expression 
and ability to differentiate into cholangiocytes and hepatocytes in vitro or in vivo and 
does not describe a specific cell origin, cell ontogenesis or predefined lineage fate. In 
addition, LPCs may continuously change their phenotype, according to their transient 
proliferation and differentiation status. Consequently the LPC compartment is 
composed of heterogeneous cell populations including immature, intermediate and 
more mature or differentiated phenotypes and, so far, no marker is available that is 
specific for LPCs and able to discriminate between LPCs and other cell types sharing 
certain markers, such as cholangiocytes, hepatocytes and haematopoietic stem cells 
(see Table 1.1 for published LPC expression profiles). Thus, a combination of 
different markers is necessary to identify and isolate specific LPCs using FACS. 
1.3.5 Animal models to study liver progenitor cells 
Rodent models are commonly used to study CLD and associated processes as rats 
and mice generally display high levels of genetic similarity to humans, while the ever 
increasing availability of genetically manipulated mice makes them powerful tools 
for the mechanistic evaluation of disease development and progression. They are 




easy to handle due to their size, easy to breed in captivity and have a relatively short 
gestational period and life span, allowing cost effective analyses. Nevertheless, no 
model can be a complete replica of the corresponding human liver disease due to 
differences in the immune system and metabolic rates during tissue homeostasis as 
well as the metabolic response to injury stimuli (Liu et al. 2013b). Importantly, 
remarkable heterogeneity with respect to phenotypic disparity has been displayed by 
LPCs in different models, warranting careful selection and interpretation. Most of the 
models described below were initially developed to follow hepatocellular carcinoma 
development and only later adapted to study induction and subsequent biology of 
LPCs. 
1.3.5.1 The D-galactosamine model 
The non-carcinogenic agent D-galactosamine has been routinely used to induce 
LPCs in rats. It is metabolised by centrilobular hepatocytes, where it blocks RNA 
synthesis, leading to an inhibition of protein synthesis by trapping uridine-
nucleotides and uridine diphosphate glucose, and subsequently to the development of 
necrosis (Farber and El-Mofty 1975). Activation of LPC-like non-parenchymal cells 
occurs in the periportal area due to impaired hepatocyte proliferation within 48 h of 
administration of a single dose of D-galactosamine (70 mg/100 g body weight), 
followed by expansion into the parenchyma forming a network of cells expressing γ-
glutamyl transpeptidase (Dabeva et al. 1993). D-galactosamine was shown to induce 
the proliferation of LPCs and small hepatocytes (only up to 16 µm in diameter) that 
are positive for the fetal form of α-fetoprotein (AFP), which importantly does not 
seem to be induced in mouse models featuring LPC proliferation (Lemire et al. 
1991). 
1.3.5.2 The Solt-Farber Model and the 2-AAF/PH regimen 
This model, which is commonly used in rats and only rarely in mice, is composed of 
three stages of disease/LPC induction - (i) injection of the ethylating 
hepatocarcinogen diethylnitrosamine (DEN), which acts as disease initiator, (ii) 
administration of 0.02% 2-acetylaminofluorene (2-AAF) two weeks later and (iii) 




PH, as a growth stimulus, one week into 2-AAF feeding (Solt and Farber 1976). This 
regimen is frequently modified by omission of the DEN initiation step and 2-AAF is 
administered four days prior and after PH. Both models induce proliferation of 
ductular or periductular LPCs, which accelerates when 2-AAF feeding is terminated, 
indicating that not only hepatocytes but also LPCs are growth-inhibited by 2-AAF, 
although to a lesser extent. LPCs tend to differentiate more efficiently into 
hepatocytes at low 2-AAF doses, whereas they undergo apoptosis at higher dosages 
(Alison et al. 1997). As a consequence, the rate of hepatocytic LPC differentiation 
can be controlled through variation of the 2-AAF dose (Paku et al. 2004). 
1.3.5.3 The DDC diet model 
DDC is a potent xenobiotic hepatotoxin that stimulates robust biliary and LPC 
proliferation, while inducing mitochondrial stress, hepatocyte ballooning, apoptosis, 
the formation of cytoplasmic aggregates termed Mallory-Denk bodies that resemble 
hepatocyte inclusion bodies observed in human alcoholic and non-alcoholic 
steatohepatitis (NASH), and hepatomegaly (Preisegger et al. 1999; Zatloukal et al. 
2007). Feeding of 0.1% DD 
C in chow leads to a DR involving CK19
+
 cells and significantly increased biliary 
secretion within the first week, which is followed by segmental bile duct obstructions 
through deposition of porphyrin pigment plugs in the lumina of small bile ducts - a 
distinct histological feature of this cholestatic liver injury model (see Fig. 1.4.5). At 
later disease stages, activated periductal myofibroblasts cause progressive biliary 
liver fibrosis with portal-portal septa, resembling human sclerosing cholangitis 
(Fickert et al. 2007). Interestingly, this model only results in activation of LPC 
proliferation in mice and not in rats (Jelnes et al. 2007) and the liver phenotype, in 
particular the extent of hepatomegaly and pigment deposition induced by DDC 
feeding, largely depends on the genetic background of the mouse strain used in the 
model (Hanada et al. 2008). 
1.3.5.4 The CDE diet model 
Dietary deficiency of the lipotrope choline combined with 0.05 or 0.1% of the 
methionine-agonist and hepatocarcinogen ethionine was initially developed as a 




chronic liver injury model in rats, where it produces alterations in phospholipid 
metabolism, fatty liver and substantial numbers of proliferating AFP
+
 LPCs by three 
weeks (Shinozuka et al. 1978). Due to its high murine morbidity and mortality, an 
alternative protocol was later developed for use in mice that involved feeding of a 
choline-deficient diet with separate administration of 0.15% of ethionine dissolved in 
the drinking water (Akhurst et al. 2001). The CDE diet reliably induces steatosis, an 
inflammatory response, proliferation of hepatocytic and biliary LPCs (see Fig. 1.4.5), 
portal fibrosis and eventually, hepatocellular carcinoma after 10-12 months (Knight 
et al. 2008; Tirnitz-Parker et al. 2007). 
1.3.5.5 The thioacetamide (TAA) supplementation model 
Prolonged administration of TAA, either via intraperitoneal injection at 
concentrations of 150-200 mg/kg body weight three times a week, or given orally in 
the drinking water at 200-300 mg/L, is a well-established rodent model of 
hepatotoxicity and cirrhosis akin to human cirrhosis (Liedtke et al. 2013). TAA is a 
thiono-sulfur-containing compound that is converted by microsomal flavin-adenine 
dinucleotide-containing monooxygenase as well as the P450 cytochrome enzyme 
CYP2E1 through reduction of dioxygen to superoxide anion and subsequent catalysis 
to hydrogen peroxide, which is responsible for the observed oxidative stress-induced 
liver injury, lipid peroxidation and centrilobular necrosis (Low et al. 2004). TAA 
administration has been used to induce chronic inflammation, LPC proliferation (see 
Fig. 1.4.5), fibrosis, cirrhosis, cholangiocarcinoma (CC) as well as hepatocellular 
carcinoma (HCC) (Boulter et al. 2015; Sakurai et al. 2013). 
1.4 Liver progenitor cells in human chronic liver disease 
Most human CLDs are associated with the proliferation of LPCs, either as single 
cells or strings of cells or as part of DRs. The latter are seen in many acute and CLDs 
and are commonly composed of a diversity of cellular components, including 
activated or reactive biliary epithelial cells and LPCs - providing the ductular 
component of the name - as well as mesenchymal, endothelial, neural, 
haematopoietic and inflammatory cells. These cellular changes go hand-in-hand with 
ECM modifications and depositions and there is an enormous range of patterns seen 




clinically. The time of appearance after injury induction, the morphology and the 
relative proportion of DR (cellular) components depend on the aetiology, severity of 
underlying stimuli and the respective disease progression state (for reviews see 
(Gouw et al. 2011; Williams et al. 2014)). A study by Lunz and colleagues in a 
mouse model of decompensated biliary cirrhosis demonstrated that DRs and LPC 
proliferation are induced when mitochondria-rich hepatocytes are targeted by 
oxidative stress and undergo replicative arrest through upregulation of the cyclin-
dependent kinase inhibitor p21 (Lunz et al. 2005). Oxidative stress plays a major role 
during ALD and NAFLD, which alongside chronic hepatitis represent the most 
prevalent risk factors for the development of hepatocellular carcinoma in the Western 
World. All of these conditions feature DRs and LPC proliferation and the magnitude 
of this response directly correlates with the progression of fibrosis and the severity of 
the underlying disease (Clouston et al. 2005; Lowes et al. 1999; Roskams et al. 
2003b). In addition, continuous iron loading of hepatocytes leading to impaired 
hepatocyte replication in hereditary haemochromatosis has been linked to LPC 
proliferation and the DR, with both the presence of the DR and portal inflammation 
strongly associated with hepatic fibrosis progression (Lowes et al. 1999; Tirnitz-
Parker et al. 2013; Wood et al. 2014). A recent retrospective cohort study on HCV-
infected patients demonstrated that inflammatory, fibrogenic and LPC-associated 
responses are intricately linked and co-regulated during disease progression as well 
as during HCV recurrence after orthotopic liver transplantation (Prakoso et al. 2014). 
1.5 Liver progenitor cells and the extracellular matrix  
The ECM represents an important component of the LPC niche. This structural 
network contains different types of collagens, proteoglycans and glycoproteins such 
as laminin and plays an essential role in the regulation of LPC proliferation, 
migration and differentiation (Katoonizadeh and Poustchi 2014). In healthy livers 
and chronic liver injury models, ductular structures and LPCs are surrounded by the 
ECM component laminin which promotes LPC and biliary gene expression and thus 
supports a progenitor phenotype, whereas hepatocyte-specific gene expression is 
inhibited (Lorenzini et al. 2010). With the use of a AAF/PH-induced hepatic injury 
model, Paku and colleagues demonstrated in rats that LPC-mediated regeneration 
and hepatic differentiation is associated with downregulation of laminin-receptor 




integrin α6 and subsequent loss of contact with this basement membrane component 
(Paku et al. 2004). Furthermore, in vitro studies have shown that collagen I and IV, 
and fibronectin on the other hand had no impact on LPC and biliary gene expression, 
however fibronectin drove gene expression of factors regulating the early hepatocyte 
lineage such as CCAAT/enhancer-binding protein α (C/EBP-α) (Lorenzini et al. 
2010). Thus, the composition of the surrounding ECM and its interactions with LPCs 
play an important role during CLD regeneration by regulating the LPC fate. 
1.6 Liver progenitor cells and hepatic fibrosis 
Matrix remodelling is a key mechanism during wound healing and tissue 
regeneration in CLD. However, an uncontrolled and inappropriate process can lead 
to complications such cirrhosis and HCC. Remodelling of the ECM in response to 
tissue injury is mediated by activated HSCs and portal fibroblasts, which 
transdifferentiate into collagen-producing myofibroblasts. The transformation from a 
quiescent state to an activated profibrogenic myofibroblast is mediated by growth 
factors and cytokines produced by other resident and infiltrating cells in response to 
tissue injury (Bataller and Brenner 2005; Ramm 2009). A variety of studies have 
proposed that HSCs are influenced by their hepatic paracrine environment (Dwyer et 
al. 2014; Tirnitz-Parker et al. 2014; Williams et al. 2014), mediated by the local 
production of soluble mediators as well as by direct cell-cell contact with LPCs, 
inflammatory cells and other parenchymal cells (Ramm et al. 2009; Ruddell et al. 
2009; Tirnitz-Parker et al. 2010). 
As mentioned earlier, the LPC phenotype and their expansion is closely related to 
ECM remodelling. Parenchymal infiltration of LPCs occurs in close temporal and 
spatial association with activated HSCs, which support the cell migration process by 
matrix degradation and the maintenance of the liver architecture by forming a 
collagen-scaffold structure (Tirnitz-Parker et al. 2012). Several studies demonstrated 
a co-dependent relationship between the two cell populations. The lack of T helper 
type 1 immune signalling in mice caused a significantly reduced LPC response as 
well as a decrease in fibrosis when exposed to a CDE diet (Knight et al. 2007a). On 
the other hand, mice receiving IFNγ administration in combination with CDE 
treatment showed an increased LPC response and a simultaneous acceleration of 




HSC activation and fibrogenesis (Knight et al. 2007b). Moreover, Patsenker and 
colleagues demonstrated that integrin αvβ6 is induced in CK19
+
 proliferating bile 
duct epithelial cells (and possibly LPCs) in bile duct-ligated rats and that its 
inhibition significantly impedes fibrosis progression (Patsenker et al. 2008). 
It has been proposed that communication between HSCs and LPCs may be mediated 
via direct cell-cell contact (Ruddell et al. 2009; Tirnitz-Parker et al. 2014). One 
potential coordinating pathway that may control fibrogenesis is LTβ signalling. This 
pathway is upregulated in CLD caused by CDE treatment and bile duct ligation in 
rodents (Akhurst et al. 2005; Knight et al. 2005a; Lee et al. 2005), and in HCV 
patients (Lowes et al. 2003), showing correlating LTβ mRNA and fibrosis levels. 
Mice lacking LTβ receptor (LTβR) showed reduced LPC and activated HSC 
numbers, as well as decreased hepatic fibrosis in response to CDE treatment 
(Akhurst et al. 2005; Ruddell et al. 2009). More evidence for the potential cross-talk 
between LTβ
+
 LPCs and LTβR
+
 HSCs was provided by Ruddell and colleages 
(Ruddell et al. 2009). Their study demonstrated a LTβ-induced expression of 
chemotaxis-associated factors in HSCs (intercellular adhesion molecule 1 (ICAM-1) 
and regulated upon activation, normal T cell expressed and secreted (RANTES)), 
suggesting that paracrine LTβ/LTβR signalling plays a role in recruiting LPCs, HSCs 
and leukocytes, which are essential cellular players during liver regeneration. 
Even though there is a strong correlation between LPC-mediated regeneration, HSC 
activation and fibrosis, as well as a potential direct interaction between the two cell 
populations during fibrogenesis, the question of the successive order of activation 
still remains. In CDE-fed mice, it was demonstrated that HSC activation and ECM 
deposition represent initial steps before parenchymal infiltration of LPCs, as these 
events happen in the early injury phase prior to an evident LPC response (Van Hul et 
al. 2009). Hence, this study suggests that HSCs may be activated first and then 
regulate the LPC response by establishing the required niche. However, another 
accepted theory is that LPC expansion and the DR are contemporaneous key drivers 
of periportal fibrosis (Clouston et al. 2005). These opposing patterns are not 
mutually exclusive and the order of events may depend on the injury cause, the 
hepatic target area and the induced signalling pathways. Williams et al. suggested 
that both the cellular heterogeneity and polarity of the DR allow for the promotion of 




different responses with regards to LPC biology and collagen deposition (Williams et 
al. 2014). 
One pathway which may influence both LPC proliferation and fibrogenesis is 
TWEAK/Fn14 signalling. A study in primary cell isolates from CDE-injured livers 
observed that LPCs and a subpopulation of activated HSCs express Fn14, the 
cognate receptor for TWEAK (Tirnitz-Parker et al. 2010). While it is well-
established that TWEAK represents a mitogen for LPCs, the knowledge of its effects 
on HSC biology is still limited. Tirnitz-Parker et al. first demonstrated a potential 
link between TWEAK-regulated LPC and fibrogenic responses in Fn14-deficient 
mice subjected to a CDE diet, showing decreased LPC proliferation in addition to 
reduced tissue inhibitor of metalloproteinases (TIMP) 1 and 2 mRNA expression and 
alleviated collagen deposition (Tirnitz-Parker et al. 2010). More recently, Kuramitsu 
and colleagues performed a 70% PH prior to injecting recombinant TWEAK in mice, 
which resulted in increased numbers of A6
+
 duct-like structures and LPCs, and 
simultaneously upregulated expression levels of fibrosis-enhancing mediators after 
five days. On the other hand, mice receiving a neutralising TWEAK antibody 
showed significant inhibition of the LPC response and associated fibrogenic factors 
(Kuramitsu et al. 2013). Taken together this further suggests a functional 
contribution of LPCs during hepatic wound healing by modulating the profibrogenic 
response. However, the underlying mechanism remains elusive. Indeed, fibrosis 
inhibition following TWEAK pathway manipulation could mean that either TWEAK 
acts directly on HSCs, or TWEAK-induced LPC expansion may indirectly control 
fibrogenesis via LPC/HSC cross-talk, i.e. via Notch or LTβ signalling (Tirnitz-Parker 
et al. 2014). Even though investigations on TWEAK signalling in other organs 
suggested a direct effect on the active state of myofibroblasts and collagen 
production, there is no evidence of similar effects in liver disease to date (Dohi and 
Burkly 2012; Novoyatleva et al. 2013). 




1.7 Liver cancer and liver progenitor cells 
1.7.1 Liver cancer and its risk factors 
Liver cancer is one of the most common solid cancers worldwide and the global 
incidence, disease burden and mortality rate are steadily increasing. HCC embodies 
its major subtype (Jemal et al. 2011), accounting for up to 90% of all liver cancers, 
with major risk factors being represented by chronic HBV and HCV infection, 
continuous excessive alcohol consumption, NAFLD and other metabolic disorders 
(Llovet et al. 2015). A study by Paradis and colleagues established that in patients 
with metabolic syndrome as the only risk factor HCC may develop from malignant 
transformation of pre-existing liver cell adenomas in the absence of significant liver 
fibrosis and cirrhosis (Paradis et al. 2009). Due to the increasing prevalence of 
obesity and type 2 diabetes worldwide, which significantly predispose to the 
development of metabolic fatty liver disorders, NAFLD has been of particular 
concern. Currently, surgical resection, radio-frequency ablation, orthotopic liver 
transplantion, transcatheter arterial chemoembolisation (TACE) and administration 
of the small molecule tyrosine kinase inhibitor sorafenib are the treatments of choice 
for HCC (Llovet et al. 2015).  
The second most common primary liver cancer, CC, accounts for 10-25% of primary 
hepatobiliary malignancies worldwide, with the greatest incidence being recorded in 
Southeast Asian regions, due to higher prevalence of risk factors such as parasitic 
infections with the hepatobiliary flukes Opisthorchis viverrini and Clonorchis 
sinensis as well as hepatolithiasis (gall stones). In the Western World, the most 
common CC risk factor is primary sclerosing cholangitis, with other less-established 
risk factors including inflammatory bowel disease, HBV and HCV infection, 
cirrhosis, chronic alcohol consumption, diabetes and obesity (Tyson and El-Serag 
2011). While the global CC incidence has been rising rapidly, this malignancy 
remains untreatable due to its multifocal nature and chemoresistant profile, 
signifying a very poor prognosis and survival rate of only 5-10% at five years post-
diagnosis (Shaib and El-Serag 2004). 




Cancer in general is caused by sequential gene mutations leading to either sequence 
alterations or changes in the epigenetic signature of regulators including oncogenes 
and tumour suppressor genes (Hahn et al. 1999; Hahn and Weinberg 2002). The 
most affected genes play key roles in cell cycle control mechanisms, cell 
proliferation, self-renewal and differentiation. Both HCC and CC develop from focal 
precursor lesions, reflecting the multistep process of hepatic carcinogenesis 
(Libbrecht et al. 2005). 
1.7.2 Tumour microenvironment and the role of cytokines in hepatocellular 
carcinoma 
Alterations in the stromal cell composition and the stromal compounds play a key 
role in orchestrating tumour growth, invasion and metastasis in HCC. The cellular 
compounds of the microenvironment consist of carcinoma-associated fibroblasts, 
HSCs, tumour-associated macrophages (TAMs) and tumour-associated endothelial 
cells that are wrapped around pericytes (vascular smooth muscle cells). The stromal 
cell composition, the ECM (Yang et al. 2011), and the cellular cross-talk are changed 
in the tumour environment (Coulouarn et al. 2012; Wu et al. 2012b). There is 
evidence that the local inflammatory microenvironment plays a key role in 
orchestrating cancer development (Budhu and Wang 2006). Several cytokines and 
their associated signalling pathways have been linked to HCC as well as to LPC 
proliferation. Elevated expression levels of LTα, LTβ, TNF, and their receptors 
LTβR and TNFR1, respectively, have been detected in HCC and tumour formation 
was shown to be mediated through factors such as nuclear factor (NF)-κB signalling 
(Haybaeck et al. 2009). TNF is expressed in inflammatory cells during CDE diet-
induced chronic liver injury and is required for LPC proliferation. Impaired TNF 
signalling through TNFR1 was shown to inhibit LPC proliferation and reduce tumour 
development (Knight et al. 2000). Additional studies in chronically injured livers 
targeting inflammatory signalling such as mediated by LTβ showed a subsequent 
decrease in tumour development (Haybaeck et al. 2009). NF-κB and STAT3 
signalling play major roles in liver inflammation and HCC by regulating genes 
involved in cell survival, proliferation, invasion and angiogenesis which promote 
tumour progression upon activation (Nakagawa and Maeda 2012). However, 




cytokine expression levels greatly vary between different studies and may depend on 
the nature of the underlying pathology and its progression. Consequently, the 
signalling networks are not completely understood and require further investigations. 
1.7.3 Hepatocarcinogenesis: dedifferentiation theory versus maturation arrest 
theory 
Considering cell transformation is caused by accumulated gene mutations (Hahn et 
al. 1999; Hahn et al. 2002), long-living cells such as stem cells and highly 
proliferating cells such as transit amplifying progenitor cells are likely targets for 
transformation. In addition to LPCs, hepatocytes represent the other major target 
population for cell transformation in HCC; a hypothesis which is based on the 
dedifferentiation theory versus the maturation arrest theory (Roskams 2006). 
According to the dedifferentiation theory, hepatocytes undergo clonal proliferation 
during carcinogenesis, dedifferentiate and gain a high proliferative capacity due to a 
newly acquired immature phenotype (Bralet et al. 1996). Fan et al. demonstrated 
Notch-mediated reprogramming of fully differentiated hepatocytes into CC 
precursors via atypical biliary cells (Fan et al. 2012). In addition, Dubois-Pot-
Schneider and colleagues ‘retrodifferentiated’ hepatocyte-like cells, derived from 
HCV-induced HCC, into bipotential LPCs through crosstalk of TGFβ1, TNF and 
IL6, proposing that the proinflammatory microenvironment frequently associated 
with most CLDs may trigger this pathogenic mechanism (Dubois-Pot-Schneider et 
al. 2014). 
On the other hand the maturation arrest theory is based on a combination of 
proliferation and blocked ontogeny in progenitor cells (Potter 1978). In the case of 
malignant LPC transformation during carcinogenesis, terminal differentiation is 
suppressed and an accumulation of maturation-arrested cells occurs due to a lack of 
apoptosis, making them prone to genetic alterations. Many laboratories worldwide 
support a precursor-product relationship between LPCs and HCCs, which is 
discussed more in detail in the following paragraph. 




1.7.4 Liver progenitor cells as candidates for the cell of origin during 
hepatocarcinogenesis 
Phenotypical tumour features give a hint for the cell of origin in HCCs, as most 
tumours still share characteristics with their precursor cell. Several studies based on 
immunohistochemical analysis of HCCs detected the expression of LPC markers 
such as CK7, CK19, oval cell marker (OV)-6 and EpCAM (Hixson et al. 2000; 
Libbrecht et al. 2000b) with CK19 positivity denoting a particularly poor prognosis 
for HCC patients (Durnez et al. 2006; Roskams 2006). 
A prospective study of 242 HCC samples, including resection as well as biopsy 
material, confirmed the prognostic value of CK19 in a Caucasian cohort, regardless 
of the underlying aetiology. The data revealed that HCC cells with a CK19
+
 LPC-
like phenotype featured higher invasive or metastatic capacity and chemoresistant 
properties than CK19
-
 counterparts (Govaere et al. 2014). Consistent with results 
demonstrating that proliferating, immature LPCs are generally surrounded by the 
glycoprotein laminin (Lorenzini et al. 2010), Govaere and collegues also showed a 
strong correlation of cytoplasmic laminin and CK19 expression in more aggressive 
HCCs, suggesting that laminin secretion by CK19
+
 tumour cells might represent an 
effective autocrine mechanism to maintain stemness (Govaere et al. 2014).  
Based on immunohistochemical and microarray studies using several HCCs, 
different subtypes can be clustered according to their expression profiles (Andrisani 
et al. 2011). Yamashita and colleagues classified HCCs based on their expression 
levels of EpCAM and AFP and proposed that different stages of hepatic cell lineages 
may be involved in the transformation process: (i) hepatic stem-cell like HCC, (ii) 
bile duct epithelium-like HCC, (iii) hepatocytic LPC-like HCC and (iv) hepatocyte-
like HCC, where (i) and (iii) were associated with a particularly poor prognosis. 
They further demonstrated that EpCAM
+
 HCCs downregulate hepatocyte-specific 
genes, whilst upregulating the Wnt/β-catenin pathway (Yamashita et al. 2008). This 
profile has been implicated in the maintenance of stemness and stem cell self-
renewal and was demonstrated to represent a major regulator of the LPC response in 
rodents (Apte et al. 2008). Furthermore a study by Lee et al. analysed the gene 
expression pattern of HCC in mice and human models and proposed a link between 




poor prognosis and LPC marker expression by integrating expression profiles of fetal 
hepatoblasts and adult hepatocytes (Lee et al. 2006). 
A study by He et al. based on cell isolation and functional characterisation further 
supports the hypothesis of a precursor-product relationship between LPCs and HCC. 
They identified a progenitor cell in premalignant dysplastic foci in HCC and showed 
that isolated HCC progenitor cell aggregates were able to progress to cancer when 
exposed to a tumorigenic microenvironment induced by chronic liver damage and 
compensatory proliferation. A comparison to LPCs revealed similarities in the gene 
expression pattern and some cells were positive for markers shared by LPCs such as 
CK19, A6, EpCAM and Sox9 (He et al. 2013). 
Immunohistochemical phenotyping of cirrhotic human livers revealed that at least 
half of the earliest premalignant precursor lesions or small dysplastic foci consist of 
immature LPC phenotypes and intermediate hepatocytes, consistent with a 
progenitor cell origin (Roskams 2006). Moreover, studies targeting LPC proliferation 
in chronically injured livers correlate LPC inhibition with reduced tumour 
development (Davies et al. 2006; Knight et al. 2008; Knight et al. 2000; Lee et al. 
2010b; Lee et al. 2010a) potentially linking LPC activation and proliferation with 
HCC development. Importantly, various studies have demonstrated that only a few 
mutations are necessary for the transformation of LPCs. For instance, the loss of the 
tumour suppressor gene p53 enables LPCs to immortalise in culture and to form 
poorly differentiated HCCs after transplantation into nude mice (Dumble et al. 2002; 
Suzuki et al. 2008), demonstrating that dysregulated LPCs may play an important 
role in early steps of carcinogenesis. Finally, the existence of tumours of a combined 
hepatocellular-cholangiocarcinoma (HCC-CC) phenotype with characteristics of 
both hepatocytes and cholangiocytes further suggests the bipotential LPC as a 
potential tumour-initiating cell (Theise et al. 2003; Cai et al. 2012; Robrechts et al. 
1998). 
More recently a cell lineage tracing study tracking CK19 expression revealed the 
existence of cholangiocyte lineage tumours following TAA-induced CLD (Guest et 
al. 2014). Consequently, cholangiocytes and/ or LPCs represent one cell of origin in 
intrahepatic CC. These results stand in contrast to an earlier study proposing that the 
appearance of these tumours relies exclusively on the dedifferentiation process of 




mature hepatocytes, induced by Notch and AKT signalling activation (Sekiya and 
Suzuki 2012). 
1.8 Cancer stem cells in the liver 
1.8.1 Cancer stem cell theory 
The cancer stem cell (CSC) theory was proposed decades ago, based on the 
haematopoietic cancer acute myeloid leukaemia (Bonnet and Dick 1997; Lapidot et 
al. 1994). Several studies have addressed this hypothesis and the existence of CSCs 
has later also been proposed in solid tumours, such as HCC (Visvader and Lindeman 
2008; Chiba et al. 2009). There is an overall agreement that tumours are composed 
of heterogeneous cell populations and the hierarchical hypothesis postulates the 
existence of a small subpopulation of stem-like cells (Reya et al. 2001). They share 
phenotypic characteristics with tissue-specific multipotential stem cells as well as 
general features such as self-renewing capacity and low proliferation activity. Their 
differentiation potential enables the formation of a hierarchical tumour structure and 
thus the promotion of tumour growth (Liu et al. 2013a). The hierarchical hypothesis 
is supported by the fact that radiation therapy and chemotherapy only target the 
major tumour cell population featuring a highly active cell cycle progression and 
very often cannot cure the disease completely. The resistance of a cancer 
subpopulation, such as CSCs, could be explained by differentially expressed 
signalling pathways active in stem cells as compared to mature, differentiated cells 
(Boniver and Herfs 2011).  
A widely used strategy to investigate the tumorigenic potential of cells to identify 
CSC populations in different cancer subtypes is their transplantation into 
immunodeficient mice and the subsequent monitoring of tumour development. Using 
this method, several isolated cell subpopulations from cancer tissues or cancer cell 
lines (including HCC) have been referred to as CSCs according to their properties 
(Chiba et al. 2006; Zhu et al. 2010). Recently an orthotopic tumour model as 
alternative approach to subcutaneous injection has been described, which allows 
studying the tumour-initiating potential under pathologic host microenvironments 




(Reiberger et al. 2015). As all of these studies are based on tumour cell isolation and 
transplantation, they do not represent tumour development in its native environment. 
However, further support for the CSC theory in solid tumours came from studies that 
identified CSCs in vivo using lineage tracing experiments that genetically labelled 
individual tumour cells (Chen et al. 2012; Driessens et al. 2012; Schepers et al. 
2012). Here, recurrence after tumour treatment has been attributed to clonal cell 
origins most likely represented by CSCs. 
There is a discrepancy in the literature about the term “cancer stem cell” and it has 
been debated whether it may be more appropriate to name this cell population 
“tumour-initiating cells”. Tumours most likely arise from a single progenitor cell 
with enhanced growth and survival capabilities due to genetic and epigenetic changes 
(Hahn et al. 2002; Marquardt et al. 2010). Thus, the definition CSC in that context is 
not necessarily valid as they do not maintain and renew already established tumours 
(Visvader et al. 2008) but following mutations in response to selective pressure may 
establish premalignant lesions. However regardless of any terminology disputes, the 
“stem-like” characteristics and functions remain the same in this cell population. The 
term CSC is used throughout this thesis. 
1.8.2 Cancer stem cells in hepatocellular carcinoma and a potential link to LPCs 
In HCC, high levels of metastasis, recurrence as well as mortality after treatment of 
the primary tumour have been reported, suggesting the potential involvement of 
CSCs. Support for the existence of a potential liver CSC has been provided by 
Mishra and colleagues who reported alterations in signalling pathways that are 
known to regulate stem cell maintenance and self-renewing in HCC, such as altered 
Wnt, sonic hedgehog homologue and Notch pathways (Mishra et al. 2009). This 
suggests a key role for CSCs in promoting tumour development and inducing 
molecular changes in HCCs. It was also shown that poor HCC prognosis is 
associated with LPC marker expression and an immature phenotype (Lee et al. 
2006). Moreover CK19 expression in HCCs was linked to postoperative recurrence 
and metastasis (Ding et al. 2004; Uenishi et al. 2003). This further supports the 
theory that CSCs exist and originate from less differentiated cells, such as LPCs, 
capable of forming a more aggressive hierarchical tumour structure. 




In addition to the concept of LPCs playing a role during carcinogenesis as a potential 
cell of origin, it has been debated if they might even represent CSCs. As mentioned 
above, poor prognosis and recurrence is highly associated with tumours featuring a 
LPC phenotype. Moreover, Zhang and colleagues identified LPC characteristics in a 
cell population obtained from human resected non-tumorous tissue samples adjacent 
to HCC. The authors confirmed their tumorigenic potential in vitro and in vivo using 
an anchorage-independent growth assay (soft agar assay) and transplantation into 
immunodeficient mice (Zhang et al. 2010a). This population might represent 
dormant tumour-initiating cells in the tumour-surrounding tissue, which are 
responsible for a high rate of recurrence in HCC patients. Further support is provided 
by a study from Cai et al. who showed a strong correlation between background LPC 
proliferation, as part of the non-tumour DR, and tumour recurrence (Cai et al. 2012). 
The Wnt/β-catenin signalling pathway is generally involved in normal stem cell 
regulation including self-renewing, cell growth, development and differentiation but 
has also been associated with the process of carcinogenesis (Nusse 2008; Polakis 
2012). In HCC, OV-6
+
 cells represent a subpopulation of less differentiated 
progenitor-like cells with active Wnt/β-catenin signalling. This subpopulation was 
increased following Wnt pathway activation and decreased after inhibition of β-
catenin signalling, and has been referred to as CSCs, due to their high tumorigenic 
potential in vivo and a remarkable resistance to chemotherapy (Yang et al. 2008a). 
Moreover, it was shown that Notch-induced hepatocarcinogenesis in mice is 
accompanied by panCK
+ 
progenitor cell expansion and Notch target gene activation 
including insulin-like growth factor 2 (Igf2) and Sox9 (Villanueva et al. 2012). IGF2 
is a critical player in Nanog-mediated self-renewal of CSCs (Shan 2012 Hepatology) 
and Sox9 expression is associated with regulation of the progenitor cell fate 
(Furuyama et al. 2011). These findings suggest that Notch signalling might drive 
LPC-mediated development into HCC via LPC expansion or dedifferentiation. 
1.8.3 Identification of liver CSCs 
In general, there are two different applications to identify and isolate CSCs from 
cancer tissues or cell lines: (i) the functional approach takes advantage of the CSC 
characteristics and (ii) isolation strategies include the side population (SP) assay, 




which is based on the exclusion of Hoechst dye (Chiba et al. 2006; Haraguchi et al. 
2006; Shi et al. 2008), and the aldehyde dehydrogenase activity assay (Ma et al. 
2008a). The so-called SP only represents a small subpopulation of cells featuring 
high proliferative as well as tumour-initiating potential compared to non-SP cells. 
The majority of SP cells display characteristics of LPCs and upon transplantation are 
able to provide the heterogeneity of the cancer structure. Importantly, dissociation of 
SP-derived tumours and separation into SP and non-SP cells emphasises their 
plasticity and CSC phenotype (Chiba et al. 2006). 
The antigenic approach is based on the immunogenic properties of a CSC and relies 
on the detection of cell markers. Ideally, a combination of different markers is used 
to define a more “homogeneous” CSC population (Marquardt et al. 2010). In the 
literature surface markers such as EpCAM, CD13, CD24, CD44, CD47, CD90, 
CD133 and OV-6 are used for the identification as well as isolation of HCC CSCs in 
primary tumours and cell lines (Ma et al. 2007; Yamashita et al. 2009; Yang et al. 
2008b; Haraguchi et al. 2010; Lee et al. 2011; Lee et al. 2014a). These markers are 
not specific for CSCs but are also expressed on other cell types in the liver including 
LPCs, biliary cells or cells from the haematopoietic lineage, which again highlights 
the importance of using different markers simultaneously. 
Evidence for a great heterogeneity within the CSC population comes from a study by 
Yamashita and colleagues. They reported the existence of cell populations 
independently expressing CD90 and EpCAM in primary HCCs. The analysis of their 
gene expression profile suggested that the CD90
+
 cell population shares 
characteristics with vascular endothelial cells and EpCAM
+
 cells have features of 
epithelial cells. Moreover, EpCAM
+
 HCC has been demonstrated to be associated 
with poorly differentiated morphology and high serum levels of AFP, whereas 
CD90
+
 HCC was related to a high rate of distant metastasis (Yamashita et al. 2013). 





populations with distinct properties. Additionally, this study 





results in enhanced motility of EpCAM
+
 CSCs. 




1.8.3.1 Cancer stem cell markers 
CD133 
Suetsugu and colleagues used the HCC cell line Huh-7 to introduce the CD133
+
 
subpopulation as a putative pool of CSCs. These cells featured a high proliferative 
potential in vitro and were able to form tumours after subcutaneous injection into 
immunodeficient mice, showing stem-like characteristics such as self-renewing and 
differentiation capacity (Suetsugu et al. 2006; Kohga et al. 2010). A less 
differentiated phenotype of the CD133
+
 subpopulation has been indicated by 
increased AFP expression levels and decreased levels of mature hepatocyte markers 
(Suetsugu et al. 2006). Similar results were obtained with CD133
+
 cells isolated from 
the HCC cell line SMMC-7721 demonstrating a high clonogenicity in vitro and 
tumorigenic potential in vivo (Yin et al. 2007). Moreover, analogous properties to 
normal stem/progenitor cells such as the expression of “stemness” genes, the ability 
to self-renew, the potential to differentiate into non-hepatocyte lineages and a 
resistance to chemotherapeutic agents as well to radiotherapy have been detected in 
CD133-expressing cells (Ma et al. 2007; Ma et al. 2008b; Piao et al. 2012). The 
relevance of therapeutic intervention targeting the CD133
+
 cell population has been 
demonstrated to be beneficial, since an anti-human CD133 antibody (AC133) 
conjugate linked to the cytotoxic drug monomethyl auristatin F showed a significant 
delay in tumour xenograft development in immunodeficient mice (Smith et al. 2008). 
The number of cells expressing CD133 differed from 1% up to 90% within several 
HCC cell lineages, whereas stem cells are thought to only represent a minor 
subpopulation (Ma et al. 2008a; Zhu et al. 2010). Consequently, even though they 
are highly enriched for tumour-initiating cells, CD133
+
 cells might be composed of 
heterogeneous subpopulations with different tumorigenic potentials and thus single 
CD133 marker expression is insufficient to identify the CSC population in HCC. 
 
EpCAM 
A gene expression analysis by Kim and colleagues introduced EpCAM as a potential 
early biomarker of HCC due to significantly increased expression levels in 
preneoplastic tissue from CLD patients as well as in a subset of HCC specimens 




(Kim et al. 2004). Furthermore, isolation and clonal analysis of the EpCAM
+
 
subpopulation in HCC cell lines demonstrated their CSC characteristics such as 
enhanced sphere formation, self-renewing and differentiation capacity in vitro as 
well as a high tumour-initiating potential in vivo (Yamashita et al. 2009; Kimura et 
al. 2010). Moreover, based on the expression profile and immunohistochemical 
analysis of HCC tissues, two subtypes were classified; (i) EpCAM
+
 HCCs shared 
features with LPCs such as CK19, c-Kit and EpCAM expression as well as active 
Wnt signalling, and correlated to a poor prognosis when co-expressing AFP, whereas 
(ii) EpCAM
-
 HCCs showed characteristics of mature hepatocytes (Yamashita et al. 
2008). A study by Yamashita et al. suggested that EpCAM is a downstream target of 
the Wnt/β-catenin signalling pathway, as EpCAM expressing cells were increased 
after signal activation, whereas a decreased tumorigenic potential has been observed 
after blockage of the pathway (Yamashita et al. 2007). 
 
CD90 
CD90 expression has been demonstrated to discriminate CSCs form the bulk of 
tumour cells. CD90
+
 HCC cells isolated from cell lines as well as from tumour tissue 
were able to form tumour nodules in immunodeficient mice after transplantation and 
thus featured tumorigenic capacity (Yang et al. 2008c). Furthermore, the CD90
+
 
subpopulation has been identified in 91.6% of blood samples from HCC patients 
showing the same characteristics (Yang et al. 2008b) suggesting a reason for the 
poor prognosis in HCC. Isolated CD90
+
 CSCs from human HCC displayed enhanced 
expression of genes contributing in inflammation, drug resistance, and lipid 
metabolism (Ho et al. 2012). 
 
CD44 
A knockout study with the HCC cell line SNU-449 revealed that CD44 inhibition 
was associated with a decreased tumorigenic potential and invasiveness as well as 
increased apoptosis, necrosis and chemosensitivity to doxorubicin, supposedly 
mediated through reduced levels of the anti-apoptotic proteins B cell lymphoma 2 
and multi drug resistance gene 1 (Xie et al. 2008). CD44 expression alone is not 




sufficient to discriminate the CSC population in HCC. However, it acts as a marker 
that defines a more aggressive subpopulation when co-expressed with other CSC 





 subpopulations represents a more aggressive phenotype of circulating 
CSCs (Yang et al. 2008b). Furthermore, the CD44-positive subpopulation in CD133-
expressing HCC cells defined a cell population featuring higher tumorigenic 
potential, preferential expression of “stemness” genes and greater resistance to 




 counterparts(Zhu et al. 
2010). This may explain an aggressive tumour growth and even the potential of 
metastasis in HCC, as CD44 is a cell adhesion molecule contributing to tumour cell 
invasion, migration and resistance to apoptosis (Lara-Pezzi et al. 2001; Park et al. 
2012).




1.9 Study Aims 
 
The first aim was to characterise and compare two commonly used murine CLD 
models, CDE and TAA, over a period of six weeks to follow stages of injury 
induction, establishment and maintenance. Disease parameters such as hepatocyte 
damage, hepatic fat loading, oxidative stress, inflammation, fibrosis and the LPC 
response were to be investigated to analyse their dynamics and lobular appearance 
and potentially correlate them with distinct injury patterns. 
The second aim was to thoroughly characterise the CDE- and TAA-induced LPC 
response in the six-week time course by immunofluorescent assessment of cell 
proliferation and the expression pattern of common LPC markers. 
The third aim was to investigate the response dynamics induced by CDE and TAA 
long-term treatment, over a period of 7 months, and to analyse model-specific injury 
patterns during CLD progression and carcinogenesis. This includes the 
comprehensive analysis of induced tumours and the examination of disease 
parameters in the surrounding tissue including the inflammatory, fibrogenic and LPC 
responses. 
The fourth aim was to examine the relationship between the LPC response and HCC 
development in humans by characterising the magnitude and distribution of CK7+ 











Materials and Methods 
 





2.1.1 Laboratory Chemicals 
All general laboratory chemicals were of analytical research grade or equivalent and 
were obtained from a range of commercial manufacturers. Supplier information is 
provided for specialty reagents. 
2.1.2 Solutions and Buffers 
Water (H2O) 
All general solutions and buffers were prepared with double-deionised H2O (ddH2O) 
generated with a purification system (Aquatec, VIC, Australia). The ddH2O quality 
was monitored with the Hydro-Check Systems 414R, Resistivity Monitor-Controller 
(Hydro-Check Systems, Inc., CA, USA). For molecular techniques involving RNA 
and for the preparation of real-time polymerase chain reactions (RT-PCR), 
UltraPure
TM
 DNase/RNase-free water (Life Technologies, VIC, Australia) was 
utilised. 
Acetate Citrate Buffer (hydroxyproline assay) 
0.88 M sodium acetate tri-hydrate, 0.24 M citric acid, 0.2 M acetic acid, 0.85 M 
NaOH; adjusted to pH 6.5 and stored at RT. 
Acetone-Methanol Fixative (fixation of frozen tissue sections) 
A 1:1 (v/v) ratio of acetone and methanol was prepared and stored at -20°C prior to 
use. 
Alanine transaminase (ALT) Colour Reagent (ALT assay) 
For the preparation of 1 mM 2,4-dinitrophenylhydrazine in 1 M HCl, 20 mg of 2,4-
dinitrophenylhydrazine were dissolved in 20 ml of 5 M HCl and adjusted to a total 
volume of 100 ml with ddH2O. 




ALT Substrate Solution (ALT assay) 
0.2 M DL-alanine, 1.8 mM α-ketoglutarate in PBS, adjusted to pH 7.5 and stored at 
4°C. 
Chloramine-T Solution (hydroxyproline assay) 
The solution was prepared by adding 127 mg of chloramine-T to 2 ml of 50% n-
propanol, and then added up to a total volume of 10 ml using Acetate Citrate Buffer. 
The solution was prepared freshly prior to use. 
Citrate Buffer (antigen retrieval) 
A 10x stock solution of 100 mM citrate was prepared, adjusted to pH 6 and stored at 
RT. Prior to use, the stock solution was diluted 1:10 in ddH2O. 
EDTA Buffer (antigen retrieval) 
A 10x stock solution of 1 M EDTA was prepared, adjusted to pH 8 and stored at RT. 
The stock solution was diluted 1:1000 in ddH2O prior to use. 
Ehrlich’s Reagent - DMAB Solution (hydroxyproline assay) 
The solution was prepared by dissolving 1.5 g of 4-dimethylaminobenzaldehyde 
(DMAB) in a 2:1 (v/v) n-propanol/perchloric acid mix. 
Gelatine Mounting Medium (Oil Red O staining) 
A gelatine-based aqueous mounting medium was prepared by dissolving 1 g of 
gelatine (Coles Brand, WA, Australia) in 6 ml of ddH2O while heating. Then 7 ml of 
glycerol was added and the glycerine jelly was stored at RT. Prior to use, the 
Gelatine Mounting Medium was heated until molten. 
0.5% Oil Red O Solution (Oil Red O staining) 
A small volume of propylene glycol was added to 0.5 g of Oil Red O (Sigma-
Aldrich, NSW, Australia) and mixed well. A total volume of 100 ml was gradually 
adjusted with propylene glycol while stirring and heating the solution up to 95-
100°C. The warm solution was filtered through a Whatman
®
 coarse filter paper (GE 




Healthcare Life Sciences, NSW, Australia), settled overnight at RT prior to use and 
long-term stored at RT. 
 
4% PFA Fixative (fixation of frozen tissue sections) 
A 4% paraformaldehyde (PFA) solution was prepared by dissolving 10 g PFA 
(Sigma-Aldrich, NSW, Australia) in 250 ml PBS while heating at 60°C, and stored at 
-20°C. 
Phosphate Buffered Saline (PBS) 
137 mM NaCl, 2.7 mM KCl, 4.3 mM Na2HPO4, 1.47 mM KH2PO4, adjusted to pH 
7.4, sterilised by autoclaving and stored at RT. 
Silver Solution (reticulin staining) 
While continuously stirring, ammonium hydroxide was added drop by drop into 5 ml 
of 10% aqueous silver nitrate solution until the precipitate was fully dissolved. Then 
5 ml of 3% aqueous sodium hydroxide solution was added and the precipitate was re-
dissolved with ammonium hydroxide. The solution was filled up to a total volume of 
50 ml using ddH2O and filtered through a Whatman
®
 coarse filter paper (GE 
Healthcare Life Sciences) when new precipitate was formed. 
Tris-EDTA Buffer (antigen retrieval) 
A 10x stock solution of 100 mM Tris and 10 mM EDTA was prepared, adjusted to 
pH 9 and stored at RT. The stock solution was diluted 1:10 in ddH2O prior to use. 
2.1.3 Oligonucleotide Primer  
Forward and reverse sequences, annealing/extension (A/E) temperatures of 
oligonucleotide primers (Sigma-Aldrich, NSW, Australia) as well as product 
information of QuantiTect Primer Assays (Qiagen, VIC, Australia) utilised in this 
thesis are listed in Table 2.1. 





Primary and secondary antibodies used in this thesis and their optimised 





Primer sequences (5’ to 3’) A/E 
(⁰C) 
QuantiTect Primer Assay 
Gapdh Fwd: AAGGTCGGTGTGAACGGATTTGG 
Rev: CGTTGAATTTGCCGTGAGTGGAG 
68  
Mmp9 Fwd: CTGGACAGCCAGACACTAAAG 
Rev: CTCGCGGCAAGTCTTCAGAG 
62  
Nqo1 Fwd: TATCCTTCCGAGTCATCTCTAGCA 
Rev: TCTGCAGCTTCCAGCTTCTTG 
63  
Nrf1 Fwd: AGCACGGAGTGACCCAAAC 
Rev: TGTACGTGGCTACATGGACCT 
60  
Rn18S Fwd: CGGCTACCACATCCAAGGAA 
Rev: GCTGGAATTACCGCGGCT 
60  
Tgfβ Fwd: GCGGACTACTATGCTAAAGAGG 
Rev: GTAGAGTTCCACATGTTGCTCC 
55  
Timp1 Fwd: ATTCAAGGCTGTGGGAAATG 
Rev: CTCAGAGTACGCCAGGGAAC 
62  
Txn Fwd: GCCAAAATGGTGAAGCTGAT 
Rev: TGATCATTTTGCAAGGTCCA 
60  
Col1α1  60 QT00162204 
Hgf  60 QT00158046 
Ifnγ  60 QT01038821 
Il6  60 QT00098875 
Ltβ  60 QT00107443 
Mmp2  60 QT00116116 
Taf4α  60 QT01060661 
Timp2  60 QT00138558 
Tnf  60 QT00104006 
Tweak  60 QT01743252 





Epitope Host Species Reactivity Clone Dilution Conjugate Fixation Antigen Retrieval Supplier details 
Primary Antibody 
A6 rat mu  1/200  Ac-Me  Gift from Dr. Factor, National Cancer 
Institute, Bethesda, MD, USA 
CD11b rat mu M1/70 1/400  Ac-Me  eBioscience, CA, USA 
CD31 rat mu MEC13.3 1/100 Alexa Fluor 
594 
Ac-Me  BioLegend, CA, USA 
CD31 rat mu MEC13.3 1/200  Ac-Me  BioLegend, CA, USA 
CD34 rat mu RAM34 1/200  Ac-Me  eBioscience, CA, USA 
CD44 rat hu, mu IM7 1/400  Ac-Me  eBioscience, CA, USA 
CD45 rat mu 30-F11 1/30 IHC, 
1/200 IF 
 Ac-Me Dako GV805 BD, NSW, Australia 
CD90 rat mu IBL-6/23 1/300  Ac-Me  Abcam, VIC, Australia 
CD133 rat hu, mu, rat 13A4 1/200  Ac-Me  eBioscience, CA, USA 
CK7 rabbit hu, mu, rat EPR17078 1/4000   Tris-EDTA Abcam, VIC, Australia 
CK7 mu hu OV-TL 12/30 1/50   Tris-EDTA Dako, NSW, Australia 
CK19 rat mu  1/200 Fr-IF, 
1/100 IHC 
 Ac-Me Proteinase K TROMA-III, Developmental Studies 
Hybridoma Bank, IA, USA 
CPS1 rabbit hu, mu  1/1000   Dako GV805 Abcam, VIC, Australia 
E-cadherin rabbit hu, mu 24E10 1/200  Ac-Me  Cell Signaling, MA, USA 
EpCAM rabbit hu, mu,rat  1/200  Ac-Me  Abcam, VIC, Australia 
EpCAM mu hu Ber-EP4 1/200   Dako GV805 Dako, NSW, Australia 




Epitope Host Species Reactivity Clone Dilution Conjugate Fixation Antigen Retrieval Supplier details 
Primary Antibody 
EpCAM mu hu Ber-EP4 1/200   Dako GV805 Dako, NSW, Australia 
F4/80 rat mouse BM8 1/80   Proteinase K eBioscience, CA, USA 
HNF4α goat mu C-19 
1/400 P-IF, 
1/700 Fr-IF 
 Ac-Me EDTA Santa Cruz Biotechnology, TX, USA 
Ki67 rabbit mu D3B5 1/400  Ac-Me Dako GV805 Cell Signaling, MA, USA 
Oval Cell rat mu MIC1-1C3 1/100  Ac-Me  Novus Biologicals, CO, USA 
panCK mu hu, mu AE1/AE3 1/50  Ac-Me Tris-EDTA Dako, NSW, Australia 
panCK rabbit mu  1/300  Ac-Me Proteinase K Dako, NSW, Australia 
αSMA mu mu 1A4 
1/2000 IHC, 
1/500 IF 
 Ac-Me Non Sigma-Aldrich NSW, Australia 
Sox9 rabbit hu, mu  
1/600 P-IF, 
1/600 IHC 
  Tris-EDTA 
Merck Millipore, VIC, Australia 
 
Secondary Antibody 
IgG donkey rabbit  1/500 Alexa Fluor 488   Life Technologies, VIC, Australia 
IgG donkey goat  1/500 Alexa Fluor 594   Life Technologies, VIC, Australia 
IgG goat rabbit  1/500 Alexa Fluor 488   Life Technologies, VIC, Australia 
IgG goat rabbit  1/500 Alexa Fluor 594   Life Technologies, VIC, Australia 
IgG goat rat  1/500 Alexa Fluor 488   Life Technologies, VIC, Australia 
IgG goat rat  1/500 Alexa Fluor 594   Life Technologies, VIC, Australia 
IgG goat rat  1/500 Alexa Fluor 647   Life Technologies, VIC, Australia 




Epitope Host Species Reactivity Clone Dilution Conjugate Fixation Antigen Retrieval Supplier details 
Secondary Antibody 
IgG goat mu  1/500 Alexa Fluor 488   Life Technologies, VIC, Australia 
IgG goat mu  1/500 Alexa Fluor 594   Life Technologies, VIC, Australia 
IgG rabbit goat  1/500 Alexa Fluor 594   Life Technologies, VIC, Australia 
IgG mu rat  1/100 Biotin   eBioscience, CA, USA 
IgG goat rabbit  1/300 Biotin   Dako, NSW, Australia 
Table 2.2: List of primary and secondary antibodies. Primary antibodies used for immunohistochemistry and immunofluorescence are listed. Ac-Me; Aceton-Methanol 
Fixative, hu, human; GV805, Target Retrieval Solution low pH (Dako, NSW, Australia); mu, murine  




2.2 General Methods 
2.2.1 Animals 
2.2.1.1 Animal handling 
Animals were housed under pathogen-free conditions on wheaten chaff bedding and 
kept on 12-hour day/night cycles in individually ventilated cages and in temperature-
controlled rooms. A maximum of six mice were grouped together in one cage with 
ad libitum access to food and water. All animal experiments were performed in 
accordance with the Australian code for the care and use of animals for scientific 
purposes at Curtin University, Perth, Australia with local Animal Ethics Committee 
approval. 
2.2.1.2 Mouse strains 
C57BL/6J mice were purchased from the Animal Resources Centre of Western 
Australia (Murdoch, WA, Australia). 
2.2.1.3 Experimental diets 
Mice had free access to either choline-deficient chow (MP Biomedicals, NSW, 
Australia) and drinking water containing 0.15% DL-ethionine (Sigma-Aldrich, NSW, 
Australia) (CDE diet) or normal chow and water containing 300 mg/l thioacetamide 
(Sigma-Aldrich) (TAA). Drinking water under both experimental conditions was 
changed every alternate day for the initial two weeks and twice a week thereafter. 
Control animals received normal chow and drinking water. 





Mice were anaesthetised by intraperitoneal injection of ketamine (Provet, WA, 
Australia) at a dose of 100 mg/kg body weight and xylazine (Provet, WA, Australia) 
at a dose of 10 mg/kg body weight. The amount of anaesthetics was calculated 
according to the individual body weight and diluted in PBS (2.1.2) to reach a total 
volume of approximately 200 µl for injection. Depth of anaesthesia was monitored 
using the leg withdrawal effect. 
2.2.1.5 Serum extraction 
Following complete anaesthesia, blood was extracted by cardiac puncture using a 
27½ G needle (Terumo
®
, NSW, Australia) attached to a 1 ml syringe (Terumo
®
, 
NSW, Australia). After allowing the blood to clot at RT, serum was separated from 
cellular components by centrifugation of samples at 16,100 x g for 10 min at 4°C. 
The serum-containing supernatant was transferred to a new microcentrifuge tube and 
stored at -80°C. 
2.2.1.6 Liver perfusion 
The liver was manually perfused by cannulating the portal vein using a 27½ G needle 
(Terumo
®
, NSW, Australia) attached to a 10 ml syringe (Terumo
®
, NSW, Australia), 
and subsequent flushing with PBS. The heart was cut after visible blanching of the 
liver, indicating appropriate positioning of the needle, and the liver was flushed with 
5 ml of PBS over a period of 1 min while maintaining a consistent flow rate. 
2.2.1.7 Liver isolation, preservation and processing 
Following perfusion, the liver was excised and the gall bladder removed. To preserve 
liver tissue for molecular and biochemical analyses, tissue pieces were snap-frozen in 
liquid nitrogen and stored at -80°C. For immunofluorescent staining experiments and 
lipid stainings, two liver pieces were embedded in ornithine carbamoyltransferase 




(OCT) (Sakura Finetek, South Holland, Netherlands), snap-frozen in liquid nitrogen 
and stored at -80°C. Sections were cut at 7 µm using a cryostat microtome (Microm 
HM550, Thermo Fisher Scientific, VIC, Australia) and stored at -80°C. 
For histology and immunohistochemistry experiments, one liver lobe was immersed 
in 10% formalin (Amber Scientific, WA, Australia) and incubated for 24 h at RT 
before transferring into 70% ethanol. Fixed tissue was processed in the Pathology 
Laboratory at Fiona Stanley Hospital (Murdoch, WA, Australia) and subsequently 
manually embedded in paraffin using a tissue embedder (Leica EG1150C, Leica 
Biosystems, NSW, Australia). Paraffin blocks were cut into 4 µm thick sections 
using a microtome (Leica RM2235, Leica Biosystems, NSW, Australia) and 
mounted onto Superfrost®Plus slides (Grale Scientific, VIC, Australia). Sections 
were dried at 37°C overnight and stored at RT. 
2.2.2 Histology Techniques 
2.2.2.1 Dewaxing and rehydration of paraffin sections 
Sections of formalin-fixed and paraffin-embedded liver tissue (2.2.1.7) were heated 
at 60°C prior to use. In order to dewax and rehydrate the tissue sections, the 
following incubations were performed for two min each while gently agitating: three 
times in xylene, three times in 100% ethanol, once in 70% ethanol and once in 50% 
ethanol. Slides were then placed in tap water for 10 min prior to further treatment.  
2.2.2.2 Fixation of frozen tissue sections 
Frozen tissue sections (2.2.1.7) were fixed in ice-cold Acetone-Methanol Fixative 
(2.1.2) for 2 min and then dried at RT for 1 h. Slides were placed in PBS for 10 min 
prior to further treatment. 




2.2.2.3 Haematoxylin and eosin staining 
Haematoxylin and eosin staining was performed in the Pathology Laboratory at 
Fiona Stanley Hospital (Murdoch, WA, Australia) using a standard protocol and 
sections of formalin-fixed and paraffin-embedded liver tissue (2.2.1.7). 
2.2.2.4 Reticulin staining 
Reticulin staining was performed using a Reticulin Stain Kit (Polysciences Inc., PA, 
USA). The manufacturer’s instructions were slightly modified. Following dewaxing 
and rehydration (2.2.2.1), paraffin sections were oxidised in 1% aqueous potassium 
permanganate for 5 min, washed in ddH2O for 1 min and bleached in 1% aqueous 
oxalic acid until the tissue was colourless. After washing in ddH2O, sections were 
sensitised in 2.5% aqueous ferric ammonium sulfate for 15 min, washed in running 
tap water and rinsed in three changes of ddH2O. Then silver impregnation of tissue 
sections was achieved by incubation of slides in Silver Solution (2.1.2) for 2 min and 
three quick immersions in two changes of ddH2O each. Incubation of sections in a 
10% aqueous formalin solution for 2 min induced a black colour reaction. Slides 
were then rinsed in ddH2O, quickly dipped into 0.2% aqueous gold chloride and 
rinsed well in ddH2O. Finally, sections were incubated in 5% aqueous sodium 
thiosulfate, washed in ddH2O, counterstained with 1% Nuclear Fast Red Stain 
Solution for 2 min and washed in running tap water prior to dehydration and 
mounting (2.2.2.9). 
2.2.2.5 Sirius Red staining 
Collagen fibers were stained using a Picrosirius Red Stain Kit (Polysciences Inc., 
PA, USA). The manufacturer’s instructions were slightly modified. Following 
dewaxing and rehydration (2.2.2.1), paraffin sections were immersed in 
Haematoxylin Solution (Dako, NSW, Australia) for 15 sec for nuclear 
counterstaining and rinsed in ddH2O. Then slides were incubated for 2 min in 
phosphomolybdic acid, rinsed in ddH2O and incubated in Picrosirius Red Solution 
for 1 h. After immersion in 0.01 N hydrochloric acid for 2 min, tissue sections were 




placed in 70% ethanol, further dehydrated and mounted (2.2.3.9). An additional 
Sirius Red staining was performed for every sample without the haematoxylin 
counterstaining step for better detection of thin collagen fibres. 
2.2.2.6 Apoptosis assay 
Apoptotic cells were detected using a DeadEnd
TM
 Fluorimetric Terminal 
Deoxynucleotidyl Transferase dUTP-biotin Nick End Labelling (TUNEL) assay 
(Promega, NSW, Australia). Following dewaxing and rehydration (2.2.2.1), paraffin 
sections were treated according to the manufacturer’s instructions. After the staining 
procedure, tissue sections were mounted with ProLong® Gold Antifade Reagent 
with DAPI (Life Technologies, VIC, Australia) to counterstain the nuclei. TUNEL
+
 
cells were quantitated in five non-overlapping fields of view at x200 total 
magnification. 
2.2.2.7 Antigen retrieval  
Epitope unmasking of paraffin sections (2.2.2.1) was achieved either by heat-
mediated antigen retrieval using Citrate Buffer (2.1.2), Tris-EDTA Buffer (2.1.2), 
EDTA-Buffer (2.1.2) or Dako Target Retrieval Solution low pH (Dako, NSW, 
Australia), proteolytic digestion with proteinase K (Dako, NSW, Australia) or no 
necessary treatment. Appropriate antigen retrieval was performed according to the 
respective antibody requirements (Table 2.2). 
2.2.2.8 Immunohistochemical detection of antigens 
Following dewaxing, rehydration (2.2.2.1) and antigen retrieval (2.2.2.7), paraffin 
sections were used for immunohistochemical detection of antigens. In order to 
inactivate tissue endogenous peroxidases, tissue sections were incubated in hydrogen 
peroxide for 5 min using a Peroxidase Blocking Reagent (Dako, NSW, Australia) 
and washed in PBS for 5 min. Tissue endogenous biotin was blocked by using a 
Biotin Blocking System (Dako, NSW, Australia). Therefore tissue sections were first 




incubated in Avidin Solution for 10 min, washed in PBS and incubated in Biotin 
Solution for 10 min before performing a second PBS wash for 5 min. Unspecific 
antibody binding was blocked by incubating the tissue sections for 30 min in serum-
free Protein Blocking Solution (Dako, NSW, Australia). Antibodies were diluted in 
Antibody Diluent (Dako, NSW, Australia), with optimal concentrations listed in 
table 2.2. Tissue sections were incubated with the primary antibody either over night 
at 4°C or for 1 h at room temperature in a humidified chamber, and washed 
afterwards for 5 min in PBS. The Dako LSAB+ System-HRP (Dako, NSW, 
Australia) was used to detect primary antibodies raised in mouse and rabbit. 
Additionally, primary antibodies raised in rat and rabbit were recognised by the 
secondary antibodies mouse anti-rat-Biotin (eBioscience, CA, USA) and goat anti-
rabbit-Biotin (Dako, NSW, Australia), respectively, in combination with the 
Streptavidin Peroxidase Solution from Dako LSAB+ System-HRP (Dako, NSW, 
Australia). Slides were washed in PBS before performing the colour detection using 
the Liquid DAB+ Substrate Chromogen System (Dako, NSW, Australia). Tissue 
sections were incubated in DAB chromogen until the colour developed and then 
placed in water. Nuclear counterstaining was performed by dipping the slides in 
Haematoxylin Solution (Dako, NSW, Australia) for 30 sec. Afterwards sections were 
rinsed in running tap water for 2 min, dehydrated and mounted (2.2.2.9). Images 
were taken using the Olympus BX51 microscope and the Olympus camera DP70 
(Olympus, VIC, Australia) or whole tissue sections were scanned using the 
ScanScope XT digital slide scanner (Aperio Technologies, CA, USA). Positive cell 
counts were performed manually in five non-overlapping fields of view at x200 total 
magnification. 
2.2.2.9 Dehydration of tissue sections 
Tissue sections were dehydrated by sequential incubation and gentle agitation in one 
change of 70% ethanol, two changes of 100% ethanol and three changes of xylene 
for 1 min each. Afterwards tissue sections were mounted with VectaMount
TM
 
Mounting Medium (Vector Laboratories, CA, USA) and covered with a cover slip 
(Grale Scientific, VIC, Australia) while avoiding any air bubbles. 




2.2.2.10 Immunofluorescent detection of antigens 
Fixed frozen liver sections (2.2.2.2) or antigen-retrieved paraffin sections (2.2.2.7) 
were used for immunofluorescent detection of antigens. In order to avoid unspecific 
antibody binding, tissue sections were blocked for 30 min in serum-free Protein 
Blocking Solution (Dako, NSW, Australia). Tissue sections were then incubated with 
primary antibodies diluted in Antibody Diluent (Dako, NSW, Australia) overnight at 
4°C in a humidity chamber or for 1 h at RT. After washing the slides for 5 min in 
PBS, sections were incubated for 30 min at RT in the dark with respective secondary 
antibodies diluted in Antibody Diluent (Dako, NSW, Australia). Optimal 
experimental conditions for primary and secondary antibodies are listed in table 2.2. 
After staining of sections, slides were washed for 5 min in PBS in the dark and 
briefly dried before adding ProLong Gold Antifade Reagent with DAPI (Life 
Technologies, VIC, Australia) to counterstain the nuclei. Sections were then covered 
with a cover slip and dried in the dark. The staining patterns were analysed with a 
fluorescent microscope (Olympus BX51, Olympus, VIC, Australia) or by using 
confocal analysis with the Eclipse Ti inverted microscope system and the NIS 
Element AR software version 4.1 (Nikon, NSW, Australia). Cells were counted 
manually for positive staining in five non-overlapping fields of view at x100 total 
magnification. 
2.2.2.11 Oil Red O staining 
To assess accumulation of neutral triglycerides and lipids, frozen liver tissue sections 
(2.2.1.7) were air-dried for 1 h at RT, then fixed for 5 min in ice-cold 4% PFA 
Fixative (2.1.2) and afterwards dried once more for 1 h at RT. Slides were immersed 
in 1,2-propanediol for 5 min, then transferred into pre-warmed 0.5% Oil Red O 
Solution (2.1.2) and heated for 8 min at 55°C in an oven. After incubating in 85% 
aqueous 1,2-propanediol for 5 min, sections were washed two times in ddH2O, 
immersed in Haematoxylin Solution (Dako, NSW, Australia) for 15 sec to 
counterstain the nuclei and mounted with Gelatine Mounting Medium (2.1.2). Tissue 
sections were scanned with the ScanScope XT digital slide scanner (Aperio 




Technologies, CA, USA) and assessed using an algorithm-based positive pixel count 
in five non-overlapping fields of view at x400 total magnification. 
2.2.3 Molecular Biology Techniques 
2.2.3.1 RNA extraction 
Total RNA was extracted from snap-frozen liver tissue using 1 ml TRIzol® Reagent 
(Life Technologies, VIC, Australia) according to the manufacturer’s instructions. 
RNA samples were dissolved in UltraPure
TM
 DNase/RNase-free water (Life 
Technologies, VIC, Australia) and stored at -80°C. Prior to long-term storage, an 
aliquot was diluted in UltraPure
TM
 DNase/RNase-free water (Life Technologies, 
VIC, Australia) and quantitated using the NanoDrop 1000 Spectrophotometer 
(Thermo Fisher Scientific, VIC, Australia) by measuring the absorbance at 260 nm. 
The RNA concentration was calculated by correlating the absorbance and the 
concentration using the Beer-Lambert law (A = ɛ c l; where A is the absorbance, ε is 
the extinction coefficient, c is the concentration and l is the light path length). Given 
the extinction coefficient for RNA is 40 (ng-cm/μl), RNA was quantitated as follows: 
RNA concentration (ng/μl) = A260 / l (cm) x 40 (ng-cm/μl) x dilution factor. By 
measuring the absorbance at 230 and 280 nm, RNA purity was evaluated according 
to the ratio of A260/A230 and A260/A280, respectively. RNA samples with values 
greater than 1.8 for A260/A280 and values between 2.0 and 2.2 for A260/A230 ratios 
were considered to be without significant contamination of proteins, phenol and 
other compounds. 
2.2.3.2 DNase treatment 
Contaminating genomic DNA was removed from RNA samples using the RQ1 
RNase-free DNase (Promega, NSW, Australia) according to the manufacturer’s 
instructions.  




2.2.3.3 Reverse transcription 
One microgram of DNase-treated RNA (2.2.4.2) was reverse-transcribed using 
Random Hexamers (Promega, NSW, Australia) and the Moloney Murine Leukemia 
Virus Reverse Transcriptase (M-MLV-RT), RNase H Minus, Point Mutant 
(Promega) according to the manufacturer’s instructions. No-RT-controls were 
prepared as described but without adding enzyme, and thus served as negative 
controls to assess genomic DNA contamination. 
2.2.3.4 Real time polymerase chain reaction (RT PCR) 
Gene expression levels were analysed by SYBR Green-based RT PCR using the 
GoTaq® qPCR Master Mix (Promega, WA, Australia). PCR reactions were 
performed in a total volume of 10 µl, with 2 µl of template cDNA (2.2.4.3) diluted 
1:2 in UltraPure
TM
 DNase/RNase-free water (Life Technologies, VIC, Australia), 
and 1 µl of 10x primer assays or primer concentrations of 0.5 µM (2.1.3), 
respectively. Amplification was achieved using the ViiA7 Real-Time PCR System 
(Life Technologies, VIC, Australia) and a two-step, fast qPCR program with cycling 
parameters of initial activation for 2 min at 95°C, followed by 40 cycles of 
denaturation for 3 sec at 95°C and annealing/extension for 30 sec at primer-specific 
temperatures (2.2.4.3). Data were normalised to the housekeeping genes 18S rRNA, 
TATA box binding protein associated factor (Taf) 4α and glyceraldehyde 3-
phosphate dehydrogenase (Gapdh) to confirm results and presented as normalised to 
18S rRNA throughout the thesis. All transcript levels were expressed relative to 
control mice. Primer efficiencies were calculated using standard curves generated 
from a 1:5 dilution series of cDNA and the ViiA7 Real-Time PCR System Software 
v1.2.1 (Life Technologies, VIC, Australia). 




2.2.4 Biochemical Techniques 
2.2.4.1 Serum alanine transaminase assay (ALT assay) 
Alanine transaminase catalyses the reaction of L-alanine and α-ketoglutarate to 
pyruvate and L-glutamate. The pyruvate produced in this reaction reacts with the 
colour reagent 2,4-dinitrophenylhydrazine to form hydrazone, which can be 
colorimetrically measured at 490 nm. To asses ALT levels, 25 µl of serum were 
added to 100 µl of ALT Substrate Solution (2.1.2), mixed gently and incubated for 1 
h at 37°C. Then 100 µl of ALT Colour Reagent was added followed by a 20 min 
incubation at RT. The colour reaction was terminated by adding 1 ml of 0.4 M 
NaOH, mixed by inversion and incubated for 5 min at RT. 200 µl of the reaction 
were transferred into a clear 96-well plate (Thermo Fisher Scientific, VIC, Australia) 
and the absorbance was measured at 490 nm (EnSpire
®
 Multimode Plate Reader, 
Perkin-Elmer Life Sciences, VIC, Australia). 
2.2.4.2 Hydroxyproline assay 
Approximately 130 mg of snap-frozen liver tissue (2.2.1.7) was used to quantitate 
tissue collagen deposition. Therefore, tissue was homogenised in 1 ml of 6 M HCl 
for 20 h at 95°C and then centrifuged at 13,000 x g for 10 min. For further treatment 
of samples, 40 μl of supernatant was used per reaction. Then 10 μl of 10 M NaOH 
and 450 μl of Chloramine-T Solution (2.1.2) were added to each sample and 
incubated for 25 min at RT. Subsequently 500 μl of DMAB Solution were added and 
samples were incubated for 20 min at 65°C before absorbance measurement at 560 
nm (EnSpire
®
 Multimode Plate Reader, Perkin-Elmer Life Sciences, VIC, Australia). 
2.2.4.3 Cholesterol assay 
Approximately 50 mg of snap-frozen liver tissue was homogenised in 500 ml of 5% 
NP-40 in ddH2O by heating the samples at 90°C in a water bath for 3 min until 
cloudiness was observed. After cooling the samples to RT, the heating process was 




repeated once before samples were centrifuged for 2 min at 16,100 x g. The 
supernatant was used to assess cholesterol levels using the Amplex® Red 
Cholesterol Assay Kit (Invitrogen, VIC, Australia), as per the manufacturer’s 
instructions. 
2.2.5 Statistical Analysis 
Quantitative data are presented as mean ± standard error of the mean (SEM). 
Statistical significance was evaluated by Student’s two-tailed, unpaired t test (normal 
distribution of data), Mann-Whitney U test (no normal distribution of data) and 
Kruskal-Wallis test (no normal distribution of data and more than two sample 
groups). Correlation studies were analysed using the Spearman method and SPSS. 











Comparison of two CLD models, CDE versus TAA, during 
early stages of injury induction, establishment and maintenance 
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Chronic liver diseases including cholestasis, viral hepatitis infection, 
haemochromatosis, alcoholic and non-alcoholic fatty liver disease or steatohepatitis, 
are all associated with hepatocyte injury and varying degrees of inflammation and 
fibrosis that predispose the patient to cirrhosis and eventually HCC development. In 
the Western World multiple risk factors with potentially additive effects are often 
encountered, such as a combination of viral hepatitis, diabetes and excessive alcohol 
consumption - coalesced settings in which the HCC risk can increase by in excess of 
100-fold compared to a cirrhotic patient with a single risk factor  (Chen et al. 2008). 
Even though treatment of HCC patients with the promising kinase inhibitor 
Sorafenib has led to a significantly prolonged time to HCC progression (Llovet et al. 
2008), there are considerable risks for side effects due to its multi-target nature and 
overall trials have fallen short of expectations. Hence, preventative and curative 
therapy approaches are still limited and new treatment targets are urgently required. 
Moreover, patient numbers are steadily increasing in the Western World due to a 
changing life style, which causes a major public health burden. Therefor it is of great 
interest to study the mechanisms of chronic injury progression and understand the 
driving forces behind these processes.  
Murine models are commonly used to study a wide variety of processes, which are 
associated with CLD. Since the injury response in the human liver is caused by 
different triggers such as viral infections, excessive alcohol consumption, obesity or 
autoimmune diseases, the pathology of the underlying diseases are not identical even 
though they share similar patterns (Ferrell 2000). Therefore, it is essential to use 
appropriate animal models to mimic particular characteristics of human pathologies 
to be able to link study outcome and clinical relevance, which is important for 
therapeutic applications. Several murine CLD models have been used in the 
literature, based on different treatments, such as the usage of CCl4, DDC, DEN, CDE 
or TAA (Liu et al. 2013b), which vary with regards to intralobular location, severity 
of tissue damage and disease progression patterns. In our laboratory, the CDE diet is 
well established for the study of processes, which are associated with CLD. It is 




widely used in mice to examine steatosis, chronic inflammation, fibrosis, LPC 
proliferation, and hepatocellular carcinoma formation if administered long-term 
(Shin et al. 2011; Knight et al. 2008; Akhurst et al. 2001; Tirnitz-Parker et al. 2010; 
Van Hul et al. 2009). Hepatotoxicity is induced through the deficiency of choline, 
which is critical for the assembly and secretion of very low density lipoproteins (Yao 
and Vance 1988), combined with the hepatocarcinogen ethionine. A more recently 
adapted murine model is based on TAA administration, which can be delivered 
orally or via intraperitoneal injection. TAA is metabolised to thioacetamide sulfine 
and subsequently activated to the hepatotoxic compound sulfene (Hunter et al. 1977). 
This metabolic transformation is mediated by the microsomal flavin-adenine 
dinucleotide-containing monooxygenase as well as the P450 cytochrome enzyme 
CYP2E1 and generates the reactive oxygen species superoxide anion and hydrogen 
peroxide, resulting in oxidative stress, which in turn leads to lipid peroxidation and 
centrilobular necrosis (Low et al. 2004). TAA supplementation has traditionally been 
used to study fibrosis, cirrhosis and the development of liver tumours, especially CC, 
when administered long-term (Grzelak et al. 2014; Boulter et al. 2015; Guest et al. 
2014). The introduction of the TAA model as an alternative regimen will enable us to 
mimic a broader range of human pathologies and to identify model-specific 
processes. 




3.2 Study Aims 
The induction, severity and progression of CLD vary greatly between animal models, 
depending on the underlying mechanisms. It is therefore vital to understand the 
molecular and histopathological patterns in order to select the most appropriate 
regimen and time points to mimic a human pathology of interest. Thus, the aim of 
this chapter was to compare the dynamics of liver injury as well as the inflammatory, 
fibrogenic, endothelial and progenitor cell responses in two common mouse models 
of CLD - CDE versus TAA administration. 
3.3 Methods 
Six-week old male C57BL/6J mice were randomly grouped and subjected to 
experimental conditions of the CDE and TAA model as well as a control diet. 
Animal numbers in each experimental group are listed in Table 3.1. Liver tissue and 
serum were harvested on days 3, 7, 14, 21 and 42 for further investigations. Firstly, 
overall liver damage was evaluated by body weight loss, histological assessment by 
haematoxylin and eosin staining, biochemical analyses of serum ALT levels, number 
of apoptotic cells, lipid accumulation and oxidative stress. Quantitation of apoptotic 
cells was performed by using the TUNEL assay, lipid accumulation was measured 
using Oil Red O staining and oxidative stress was evaluated according to gene 
expression levels of associated factors such as nuclear factor erythroid-derived 2-
related factor 1 (Nrf1), thioredoxin (Txn) and NAD(P)H quinone oxidoreductase 
(Nqo1). The inflammatory response to either of the two dietary models was 
evaluated by fluorescent-labelling of CD45
+
 cells and their quantitation, and also 
more specifically by analysing populations of liver-resident KCs by 
immunohistochemical analysis of F4/80
+ 
cells as well as infiltrating monocyte-
derived macrophages by immunofluorescent detection of CD11b
+
 cells. The resulting 
inflammatory microenvironment was assessed by gene expression analysis of 
cytokines and growth factors such as TWEAK, TNF, LTβ, IL6 and IFN, as well as 
HGF, using real-time PCR. Resulting special, temporal and numerical changes of 




LPCs, HSCs and inflammatory cells were evaluated by immunofluorescent stainings 
using the markers panCK, αSMA and CD45. Furthermore, fibrotic patterns were 
assessed by analysing gene expression levels of the fibrosis-associated factors TGFβ, 
Collagen I (Col1), MMP2 and 9, and tissue TIMP1 and 2, and finalised by 
visualising collagen (I and III) deposition by Sirius Red staining and biochemical 
analysis of hydroxyproline levels. Changes in the hepatic vasculature were assessed 
by fluorescent staining of the endothelial markers CD31 and CD34. Disease-related 
histological findings were confirmed by an expert pathologist. 
 
Time point (days) Animal number 
 Control CDE TAA 
3 4 6 6 
7 4 7 6 
14 4 4 6 
21 4 4 6 
42 4 4 6 
Table 3.1: Number of animals in each experimental group. 
 
 





3.4.1 Divergent tissue damage dynamics and mechanisms in CDE- and TAA-
induced liver injury. 
To establish and compare the dynamics of CDE- and TAA-induced liver injury, 
alterations to liver architecture, markers of hepatocyte health and body weight, as an 
indicator of overall animal health, were evaluated. Throughout the study, disease 
parameters were assessed on days 3 and 7 (induction phase), 14 and 21 
(establishment phase) and 42 days (maintenance phase). 
Moderate weight loss of 5-10% was observed in TAA-induced injury compared to 
the CDE regimen, which caused the animals to lose up to 20% of their initial body 
weight during the induction phase. After this initial adaptation period, body weights 
of mice on both liver injury protocols recovered, but remained considerably lower 
than non-injured controls over the time course (Fig. 3.1).  
 
 
Fig. 3.1: Body weight of mice exposed to CDE, TAA and control diet. The body weight of CDE, 
TAA and control mice was measured progressively throughout the time course of 0-42 days. All mice 
from each time point were included in this figure. Data are shown as mean ± SEM and include all 
animals of each experimental group. 




Histological assessment of liver architecture revealed overt differences in 
morphology associated with CDE or TAA administration. Major tissue damage was 
seen in CDE mice throughout the liver during the induction phase marked by 
hepatocyte degeneration, cell enlargement, swelling, rounding and sometimes 
hepatocyte ballooning. This was accompanied by periportal enrichment of small 
basophilic cells up to day 14. The liver architecture then returned to normal 
hepatocyte and general lobular morphology during the maintenance phase (Fig. 3.2). 
In contrast, TAA provoked centrilobular tissue damage with significant basophilic 
cell enrichment and formation of eosinophilic bands of hepatocytes as early as day 3, 
which remained unresolved during the time course (Fig. 3.2).  
Dynamic alterations to liver architecture in each liver injury model were reflected in 
quantitative biochemical assessments of liver damage. Significant increases were 
observed in serum alanine transaminase (ALT) levels, a reliable indicator of 
hepatocyte injury, peaking at three days in both injury models (CDE, 64.9 ± 6.6 U/l; 
TAA, 68.7 ± 0.34 U/l). Serum ALT normalised to control levels after six weeks in 
CDE-treated mice (22.13 ± 3.6 U/l) but remained elevated in the TAA model 
(44.5 ± 1.2 U/l, Fig. 3.4.3A). Similarly, the number of TUNEL
+
 apoptotic cells 
increased over the first seven days in both regimens but resolved by day 42 in the 
CDE injury. Conversely, apoptotic cells further increased by day 21 and remained 
elevated throughout the TAA-injury time course (Fig. 3.3B). 





Fig. 3.2: Liver histology changes in response to CDE and TAA treatment. Formalin-fixed, 
paraffin-embedded liver sections of mice treated for 3, 7, 14, 21 and 42 days and respective controls 
were used for histological assessment by haematoxylin and eosin staining. The scale bar represents 
100 μm, original magnification: x100. CV, central vein; PV, portal vein. 











Fig. 3.3: CDE and TAA-induced CLD results in overall liver damage measured by increased 
ALT levels and enhanced apoptotic cell numbers. (A) Liver damage was assessed biochemically by 
measuring serum alanine transaminase (ALT) levels of mice exposed to CDE, TAA or control diet. 
(B) Apoptotic cells were fluorescently labelled and quantified as TUNEL
+
 cell numbers in five fields 
of view (FOV) per sample. Data are expressed as mean ± SEM (4 to 6 mice per group). *p<0.05, 
p**<0.01, p***<0.001 compared to control mice. 




Since lipid accumulation was observed in hepatocytes, a common histological 
finding in human CLD biopsies predisposing the patient to further complications, 
lipid deposition was compared between the two models. Livers were stained with Oil 
Red O, which detects lipids including mono-, di- and triglycerides, phospholipid and 
cholesterol. Mice exposed to TAA and CDE quickly induced substantial fatty 
changes in hepatocytes during the induction phase. The CDE model displayed 
significantly higher levels of lipid accumulation, resulting in macro- and 
microvesicular hepatic steatosis throughout the parenchyma and resolving from 
portal areas over time. Conversely, TAA supplementation induced pericentral hepatic 
fat deposition with a strong zonal distribution (Fig. 3.4 and 3.5A).  
Furthermore, hepatic lipid deposition was examined by biochemically measuring 
total cholesterol levels as another indicator of steatosis. The hepatic cholesterol 
levels increased during the induction phase in CDE mice, consistent with the Oil Red 
O-determined lipid level elevations, then returned to control levels in the 
establishment and maintenance phases. Surprisingly, and in contrast to Oil Red O-
determined steatosis, cholesterol levels were not increased at any time in the TAA 
regimen (Fig. 3.5B).  
Since oxidative stress is implicated in the pathogenesis of CLDs that are associated 
with steatotic liver changes, oxidative stress markers were measured at the transcript 
level. Consistent with the detected hepatic lipid changes, expression levels of 
oxidative stress response mediator Nrf1 (Biswas and Chan 2010) and the anti-oxidant 
Txn (Okuyama et al. 2005) were significantly elevated during the induction phase 
with a peak at day 3 in CDE mice (Fig. 3.6). As with previously assessed parameters 
of liver injury, oxidative stress quickly decreased after an early induction phase in 
CDE-fed mice. In contrast, expression levels of Nrf1 and Txn remained elevated or 
progressively increased in the TAA model, with additional activation of the sensitive 
redox indicator Nqo1 (Hardwick et al. 2010) (Fig. 3.6). 
 







Fig. 3.4: Lipid accumulation and the distinct zonal distribution pattern caused by CDE and 
TAA exposure. Liver sections of CDE, TAA and control mice were stained for lipids using Oil Red 
O at day 3, 7, 14, 21 and 42. The scale bar represents 100 μm, original magnification: x100 and x400 
for inserts. CV, central vein; PV, portal vein. 










Fig. 3.5: CDE and TAA exposure induces enhanced lipid levels. (A) Liver sections of CDE, TAA 
and control mice were stained for lipids using Oil Red O at day 3, 7, 14, 21 and 42, (B) and quantified 
by positive (+) pixel counts (expressed as percentage) in five fields of view (FOV) per sample. Data 
are shown as mean ± SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001 compared to 
control mice. 








Fig. 3.6: Increased oxidative stress in response to CDE and TAA treatment. Oxidative stress was 
assessed through transcriptomic analysis of nuclear factor erythroid-derived 2-related factor 1 (Nrf1), 
thioredoxin (Txn) and NAD(P)H quinone oxidoreductase (Nqo1) expression levels. Data are shown as 
mean ± SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001 compared to control mice. 




3.4.2 Injury-specific inflammatory signatures dictate disease progression 
patterns in the CDE- and TAA-induced liver injury. 
The inflammatory response kinetics in these injury models were characterised by 
comparing the abundance of cells immunofluorescence-positive for the leukocyte 
common antigen CD45. Furthermore, monocyte-macrophage populations were more 
specifically examined by immunohistochemically staining for F4/80 (liver-resident 
macrophages or KCs) and immunofluorescent staining for CD11b (monocyte-
derived macrophages) (Elsegood et al. 2015). Both regimens induced a rapid 
inflammatory response with CD45
+
 (Fig. 3.7A), CD11b
+
 (Fig. 3.7B and Fig. 3.8) and 
F4/80
+
 cell numbers (Fig. 3.7C and Fig. 3.9) peaking at day three in the TAA and 
day seven in the CDE model. The number of inflammatory cells then slowly returned 
towards control levels in both regimens but remained significantly elevated in TAA-
treated mice. However, Kupffer cell numbers in mice exposed to TAA treatment 
returned towards control levels similarly to cell numbers in CDE mice. Both models 
induced increasing cell numbers of liver resident (F4/80
+
) and infiltrating, monocyte-
derived macrophage populations (CD11b
+
) in damaged lobular regions (CDE, portal; 
TAA, central). Although this spatial arrangement persisted in the TAA model, the 
clustered localisation of inflammatory cells reversed to an even lobular distribution 
from day 14 in CDE-fed mice (Fig. 3.8 and 3.9). 
The early expansion of inflammatory cell numbers in both models was accompanied 
by rapid modulation of the liver microenvironment. An induction or significant 
increase in transcript expression levels was observed for the proinflammatory 
cytokines TWEAK, TNF, LTβ, IL6 and IFN, as well as HGF, which plays a key 
role in hepatocyte survival and tissue remodelling during liver injury. Once again, in 
the CDE model, expression levels normalised, while they remained elevated in TAA-
treated mice (Fig. 3.10). 










Fig. 3.7: CDE- and TAA-induced CLD results in increased inflammatory cell numbers. Cells 
positively stained for (A) CD45, (B) the monocyte-derived macrophage marker CD11b and (C) the 
liver-resident Kupffer cell marker F4/80, respectively, were quantified in five fields of view (FOV) 
per sample. Data are shown as mean ± SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001 
compared to control mice. 





Fig. 3.8: CDE and TAA exposure induce enhanced CD11b
+
 cell numbers. Frozen liver sections 
from day 3, 7, 14, 21 and 42 were fluorescently labelled for the monocyte-derived macrophage marker 
CD11b and the LPC marker pan-cytokeratin (panCK). Nuclei were visualised by DAPI staining. 
Representative images are shown. The scale bar depicts 100 μm. CV, central vein; PV, portal vein. 





Fig. 3.9: Increased F4/80
+
 cell numbers following CDE and TAA treatment. Formalin-fixed, 
paraffin-embedded liver sections of CDE, TAA and control mice were immunohistochemically 
labelled for the liver-resident KC marker F4/80. Representative images of are shown. The scale bar 
represents 100 μm. CV, central vein; PV, portal vein. 









Fig. 3.10: Inflammatory marker expression is increased in CDE- and TAA-induced CLD. Real-
time PCR data for mRNA expression levels of tumour necrosis factor (TNF), TNF-like weak inducer 
of apoptosis (TWEAK), lymphotoxin β (LTβ), interleukin 6 (IL6), interferon  (IFN) and hepatocyte 
growth factor (HGF) were normalised and expressed as mean ± SEM (4 to 6 mice per group). 
*p<0.05, p**<0.01, p***<0.001 compared to controls. 




3.4.3 Regenerative niches of CDE- and TAA-induced injury display temporal, 
compositional and spatial differences.  
On the background of a significantly altered liver microenvironment, the 
organisation of the cellular niche, which is proposed to mediate injury, fibrosis and 
regeneration in most CLDs comprising (i) injury-responsive inflammatory cells, (ii) 
regenerative LPCs and/or DRs and (iii) fibrosis-driving, activated HSCs 
(myofibroblasts) was investigated. Immunofluorescent triple staining for CD45, the 
biliary cell and LPC marker panCK (distinguished by morphology) and the 
myofibroblast marker αSMA revealed a close spatial and temporal relationship 
between all three cell populations during the early induction phase in the CDE 
model. This niche was detected periportally, where numbers of panCK
+
 cells peaked 
at 14 days post-induction and maintained a steady-state throughout the remaining 
four weeks. Strikingly, TAA treatment resulted in niche formation in centrilobular, 
rather than periportal regions. PanCK
+
 biliary structures and LPCs, the majority of 
CD45
+
 inflammatory cells and αSMA
+
 myofibroblasts were only observed in close 
association from about day 21 onwards. Furthermore, numbers of panCK
+
 cells 









Fig. 3.11: CDE- and TAA-induced tissue regeneration is mediated by the cellular niche hosting 
LPCs, inflammatory cells and activated HSCs as part of the DR. Please refer to following page for 
figure legend.  




Fig. 3.11: CDE- and TAA-induced tissue regeneration is mediated by the cellular niche hosting 
LPCs, inflammatory cells and activated HSCs as part of the DR. Control, CDE and TAA liver 
sections of day 3, 7, 14, 21 and 42 were fluorescently labelled for the biliary cell and LPC marker pan-
cytokeratin (panCK), inflammatory cell marker CD45, the activated HSC marker α-smooth muscle 
actin (αSMA) and DAPI for nuclear quantitation. Representative images are shown and the scale bar 










Fig. 3.12: Increased panCK
+
 cell numbers induced by CDE and TAA. Cells positively stained for 
panCK were quantified in five fields of view (FOV) per sample. Numbers are expressed as mean ± 
SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001 compared to controls. 




3.4.4 CDE- and TAA-induced injuries lead to distinct fibrogenic responses.  
Since the progression of most chronic liver injuries is associated with ECM 
remodelling and the excessive deposition of matrix proteins, it was of particular 
interest to compare fibrosis-associated processes in both models. These were 
evaluated in detail by transcriptomic analysis of fibrogenic markers, quantitation of 
activated HSC numbers, visualisation of collagen deposition by Sirius Red staining, 
and biochemical hydroxyproline assessment. 
Expression levels of the fibrosis-associated factors TGFβ, Col1, MMP 2 and 9, and 
TIMP 1 and 2 were significantly increased in both injury models. Increased 
expression of these factors was induced during the initial phase at day 3 and 7, and 
normalised thereafter in the CDE model. Conversely, consistent with previously 
investigated injury parameters, a mostly progressive increased expression in fibrosis-
associated genes was observed in TAA-fed mice over the course of six weeks (Fig. 
3.13).  
Since activated HSCs represent the main fibrosis-driving hepatic cell type, the 
numbers of αSMA
+
 myofibroblasts were assessed in all phases of induced liver 
injury. Indeed, the quantitation results followed the same trend in both models, with 
an early peak and subsequent normalisation of activated HSC numbers in CDE mice 
and a gradual significant increase in the TAA model (Fig. 3.14). While HSCs were 
mainly activated in periportal regions during the induction phase of CDE treatment, 
they were localised to central areas in TAA-induced mice, demonstrating a 


















Fig. 3.13: Fibrogenic marker expression is enhanced in CDE- and TAA-induced CLD. Real-time 
PCR data for mRNA expression levels of transforming growth factor β (TGFβ), Collagen I (Col1), 
matrix metalloproteinase (MMP) 2 and 9, tissue inhibitor of metalloproteinase (TIMP) 1 and 2 are 
expressed as mean ± SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001 compared to 
controls. Data are normalised and expressed relative to control levels. 














Fig. 3.14: Increased αSMA
+
 cell numbers induced by CDE and TAA treatment. Cells positively 
stained for the activated HSC marker α-smooth muscle actin (αSMA) were quantified in five fields of 
view (FOV) per sample. Cell numbers are expressed as mean ± SEM (4 to 6 mice per group). 
*p<0.05, p**<0.01, p***<0.001 compared to controls. 




Additionally, gross collagen deposition and associated fibrosis patterns were 
examined using the histopathological stain Sirius Red. Thin layers of collagen 
surrounded the portal tracts and central veins in control mice, and are a typical 
feature of a healthy liver. In contrast, both liver injury regimens induced significant 
collagen accumulation, albeit with very different dynamics and spatial organisation. 
CDE exposure resulted in early portal fibrosis with ‘chicken wire’ appearance in the 
induction phase, and normalisation thereafter. However, TAA-treated livers 
displayed significant collagen deposition in central areas, as early as day 3 post-
induction. The substantial pericentral fibrosis then progressed to form central-central 
septa in the late establishment and maintenance phase. In addition, portal-to-central 
bridging fibrosis was occasionally observed when portal and central fields were in 
close proximity during the later injury phases (Fig. 3.15). 
Finally, biochemical examination of hepatic hydroxyproline content confirmed 
increased collagen deposition, consistent with previously established fibrosis-
associated patterns. Thus CDE-mediated collagen deposition peaked at day 7 (225.1 
± 7.4 ng/mg of liver tissue), and then subsequently resolved, whereas the TAA 
regimen stimulated a progressive collagen accumulation throughout the examined 
time period, showing the highest level (208.6 ± 25.8 ng/mg of liver tissue) at day 42 









Fig. 3.15: CDE and TAA exposure induces the deposition of collagen and dictates a divergent 
fibrogenic response. Liver sections of control, CDE and TAA mice were assessed for collagen 
deposition by Sirius Red staining at days 3, 7, 14, 21 and 42. Representative images are shown. The 
scale bar represents 100 μm (original magnification: x100). CV, central vein; PV, portal vein. 













Fig. 3.16: Elevated hydroxyproline levels in response to CDE and TAA treatment. Homogenised 
liver tissue was used to quantitate collagen deposition by measuring the corresponding hydroxyproline 
level. Hydroxyproline levels were calculated as μg per mg liver tissue. Data are shown as mean ± 
SEM (4 to 6 mice per group). *p<0.05, p**<0.01, p***<0.001, compared to control mice. 




3.4.5 Hepatic endothelial cell phenotypes in response to CDE- and TAA-induced 
CLD 
Since fibrosis is associated with severe changes in the hepatic vascular system 
(Iwakiri et al. 2014), endothelial phenotypes were investigated by 
immunofluorescent staining of the endothelial markers CD31 and CD34 in mice 
subjected to CDE and TAA for 14 and 42 days. 
The examination of the CD31 staining pattern revealed universal expression in both 
models as well as the controls and thus CD31 represents a general marker for hepatic 
sinusoidal epithelial cells regardless of the treatment status (Fig. 3.17, Fig. 3.18 and 
Fig. 3.19). The common pattern of CD31 expression showed positive staining in 
portal vessel-lining cells including portal veins and hepatic arteries, as well as 
endothelial cells of central veins. Moreover, CD31 expression was seen in the 
parenchyma, staining sinusoids with a characteristic elongated shape but also 
rounded LSECs. In contrast to CDE and control mice, the TAA model induced 
enhanced positivity for CD31 in central areas at day 42 (Fig. 3.19), consistent with 
injury progression and establishment of the regeneration niche, indicating 
progressive angiogenesis in response to TAA treatment. In addition, analysis of the 
location of CD31
+
 cells and panCK
+
 LPCs showed no spatial or temporal 
relationship in CDE-treated mice, however TAA exposure induced close proximity 





Fig. 3.17: Investigation of the endothelial marker CD31 in control mice. Frozen sections of mice fed a control diet for 14 and 42 days were fluorescently labelled with the 
endothelial marker CD31 and the LPC/biliary cell marker panCK. Nuclei were visualised by DAPI staining. Representative pictures are shown and the scale bar represents 





Fig. 3.18: Investigation of the endothelial marker CD31 in CDE-treated mice. Frozen sections of mice exposed to CDE treatment for 14 and 42 days were labelled with 
the endothelial marker CD31 and the LPC/biliary cell marker panCK using immunofluorescence. Nuclear staining was performed with DAPI. Representative pictures are 





Fig. 3.19: Evaluation of the endothelial marker CD31 in TAA-treated mice. Frozen sections of mice treated with TAA for 14 and 42 days were fluorescently labelled with 
the endothelial marker CD31 and the LPC/biliary cell marker panCK. Nuclei were counterstained using DAPI staining. Representative pictures are shown and the scale bar 
represents 100 μm. CV, central vein; PV, portal vein. 




In contrast to CD31 expression, CD34 staining showed model-specific patterns 
varying greatly between CDE- and TAA-induced CLD. In control mice at day 14 and 
42, CD34 expression was limited to portal areas, where CD34
+
 cells represent portal 
endothelial cells that line the portal vein and hepatic artery but also surround the 
panCK
+
 biliary cells (Fig. 3.20). Similar to controls, CDE mice showed CD34
 
positivity mainly in portal fields, with occasional appearance of rounded single 
CD34
+
 cells in the parenchyma in close proximity to panCK
+
 LPCs (Fig. 3.21). 
Significant differences were observed in mice treated with TAA at all investigated 
time points (Fig. 3.22). Increasing numbers of cells expressing CD34 were found in a 
time-dependent manner, associated with the LPC response at day 14. On the 
background of progressive injury, a further increase of CD34 expression was 
detected centrally in a close spatial relationship with the regeneration niche at day 42 





 cells with an elongated shape were also frequently located in the 





Fig. 3.20: Assessment of CD34 expression in control mice. Frozen sections of mice fed a control diet for 14 and 42 days were labelled with the endothelial marker CD34 
and the cholangiocytic LPC marker panCK using immunofluorescence. Nuclei were stained with DAPI. Representative images are shown and the scale bar depicts 100 μm. 





Fig. 3.21: Evaluation of CD34 expression in CDE-induced CLD. Frozen sections of mice treated with CDE for 14 and 42 days were fluorescently labelled with the 
endothelial marker CD34 and the cholangiocytic LPC marker panCK. Nuclear staining was performed with DAPI. Representative pictures are shown and the scale bar 





Fig. 3.22: Investigation of CD34 expression in TAA-induced CLD. Frozen sections of mice exposed to TAA treatment for 14 and 42 days were labelled with the 
endothelial marker CD34 and the cholangiocytic LPC marker panCK using immunofluorescence. Nuclei were counterstained with DAPI. Representative images are shown 
and the scale bar depicts 100 μm. CV, central vein; PV, portal vein. 










Fig. 3.23: TAA-induced CD34
+
 cells in the parenchyma co-express the endothelial marker 
CD31. Frozen tissue sections of mice treated with TAA for 42 days were fluorescently labelled with 
the endothelial markers CD34 and CD31. DAPI was used for nuclear staining. Representative images 
are shown and the scale depicts 50 µm. 




3.5 Discussion  
The CDE diet and TAA supplementation regimens are both commonly used to 
experimentally induce liver injury and fibrosis (Boulter et al. 2015; Darweish et al. 
2014; Knight et al. 2008; Tirnitz-Parker et al. 2010; Patsenker et al. 2009; Van Hul 
et al. 2009; Grzelak et al. 2014). This study now comprehensively compared the two 
models in a time course over a 42-day period. The injury induction phase was 
represented by days 3 and 7, the establishment phase by days 14 and 21 and the 
maintenance phase by day 42. The data clearly indicate that the spatial and temporal 
kinetics differ significantly between the two CLD regimens. Injury, hepatic fat 
loading, inflammation and fibrosis all peak during the induction phase of the CDE 
diet before returning to control levels in the establishment and maintenance phase. 
This ‘flare’ is sufficient to orchestrate an LPC response that reaches a steady-state 
from about two weeks, most likely reflecting an equilibrium of LPC activation and 
lineage maturation. In contrast, the TAA model produces a more severe, progressive 
(chronic) phenotype with disease parameters persistently upregulated or gradually 
increasing throughout the time course. The succession of events is therefore 
significantly different in both regimens: (i) CDE, liver injury induction – lipid 
accumulation and inflammation - fibrosis and LPC response - alleviation or 
regression; and (ii) TAA, liver injury induction - inflammation - fibrosis and LPC 
response - progressive aggravation. 
This study demonstrated that CDE feeding is associated with excessive fat loading in 
the parenchyma, most likely caused by reduced secretion of very low density 
lipoproteins, which in turn leads to increased oxidative stress (Aharoni-Simon et al. 
2011; Yao et al. 1988), instigating the molecular and cellular injury cascade 
emanating from periportal areas. TAA, on the other hand, is a thiono-sulfur-
containing hepatotoxin that is converted via dioxygen and superoxide anion to 
hydrogen peroxide in pericentral regions, thereby directly causing oxidative stress, 
lipid peroxidation and centrilobular necrosis (Low et al. 2004). It is therefore not 
surprising that CDE-fed mice displayed inflammation in periportal and parenchymal 
areas, while the TAA regimen induced a persistent pericentral inflammatory 




response, reflective of the injury present in this lobular region. The accumulation of 
inflammatory cells may then orchestrate the initiation of the regeneration process by 
releasing mediating factors such as cytokines and growth factors that are known to 
activate and maintain either or both key cellular players, HSCs and LPCs. These 
include TWEAK (Tirnitz-Parker et al. 2010), TNF (Knight et al. 2005c), LTβ 
(Ruddell et al. 2009), IL6 (Matthews et al. 2004), IFN (Brooling et al. 2005) and 
HGF (Ishikawa et al. 2012), which were demonstrated to be upregulated in both 
models, yet with different expression dynamics. 
In the CDE model, immune cells and myofibroblasts were present periportally from 
the induction phase, which has been demonstrated to facilitate LPC activation 
(Elsegood et al. 2015; Tirnitz-Parker et al. 2010) and cytokine crosstalk-mediated 
migration of HSCs and LPCs from portal areas into the hepatic parenchyma (Ruddell 
et al. 2009). In contrast, TAA is known to induce centrilobular damage and immune 
cells were therefore attracted to central areas, where they, together with sinusoidal 
endothelial cells and injured hepatocytes, may activate HSCs. The cellular injury and 
regeneration niche (that is here proposed to consist of closely associated 
inflammatory cells, LPCs and/or the DR and activated HSCs) was only identified 
during later injury phases when panCK
+
 structures were detected pericentrally.  
Livers of both the CDE and TAA model displayed deposition of ECM components, 
however to varying degrees, resulting in divergent degrees and patterns of fibrosis. In 
the CDE model periportal fibrosis was induced, however fibrosis eventually resolved 
and returned towards control levels after an initial peak in the induction phase, as 
demonstrated by immunofluorescent detection of αSMA
+
 myofibroblasts, mRNA 
expression of fibrosis mediators as well as Sirius Red-visualised, and 
hydroxyproline-quantitated collagen deposition. This fibrosis pattern is typically 
observed in autoimmune or chronic viral hepatitis and chronic biliary diseases or 
cholestasis (Ferrell 2000). In contrast, investigation of the same parameters in the 
TAA model revealed gradually increasing fibrosis in central areas, which progressed 
towards cirrhosis during the injury establishment and maintenance phase, a pattern 
usually observed in fibrosis resulting from alcoholic or non-alcoholic steatohepatitis 
(Ferrell 2000). Interestingly, some previous studies using TAA to induce CLD have 
also reported portal, portal-to-portal bridging or portal-to-central bridging fibrosis, as 
well as inflammatory cell accumulation in portal areas (Aydin et al. 2010; Kornek et 




al. 2006; Patsenker et al. 2009; Wallace et al. 2015). It is important to note that TAA 
induces severe morphological changes in hepatic lobules, including irregular patterns 
of portal tracts and central veins, DRs and high vascularisation directed to fibrotic 
areas (Gao et al. 2013; Lee et al. 2014b; Patsenker et al. 2009), providing a rich 
feeding ground for potential misinterpretation with regards to clear identification of 
portal as opposed to central areas. It cannot be ruled out that studies from other 
groups using TAA caused an increased disease activity in periportal areas, since 
results in experimental CLD greatly depend on the genetic background of the 
animals, concentration and administration route of the disease-inducing agent, and 
indeed the point-in-time of experimental design for example. However, the data of 
this study emphasise that it is fundamental to perform detailed time course analyses 
instead of snapshot evaluations at later time points when the liver architecture is 
already well distorted, in order to follow histological changes and thus correctly 







 cells over the course of six weeks provide clear evidence that 
periportal expansion of LPCs is limited in the TAA regimen, and both inflammation 
and fibrosis are predominantly provoked in the central, toxicity-burdened areas, 
which in the initial injury phase lack ductular structures characteristic for portal 
triads. At later stages of TAA-induced injury, panCK
+
 ductular structures and LPCs 
also appear in central areas, tempting to misinterpret the local histology as portal 
instead of central. 
Analysis of the vasculature in CLD-induced versus healthy livers revealed no 
alterations in the CDE model but distinct patterns in mice subjected to TAA. Firstly, 
it is important to note that hepatic endothelial phenotypes, and accordingly their 
marker expressions, are controversially discussed due to differences in vessel types 
and tissue compartments as well as to the underlying experimental models or human 
pathologies (Pusztaszeri et al. 2006; Lalor et al. 2006; Scoazec and Feldmann 1991; 
Couvelard et al. 1993; Do et al. 1999). The data presented in this chapter showed 
that CD31 is a marker for LSECs in mice regardless of the investigated injury status. 
In contrast to the CDE model, the progressive injury pattern in TAA mice was 
associated with an increased angiogenesis illustrated by increased CD31 expression 





endothelial subpopulation. Similar results were reported in human 




studies, where CD31 expression increased with advancing fibrotic stages in NAFLD 
patients (Akyol et al. 2005), and CD34 expression functioned as indicator of 
sinusoidal capillarisation and agiogenesis under pathological conditions (Pusztaszeri 
et al. 2006; Ohmori et al. 2001; Amarapurkar et al. 2007; Di Carlo et al. 2002). 
Moreover, CD34
+
 LSEC numbers were correlated with a high risk of HCC 
development in patients with HCV-associated CLD (Ohmori et al. 2001). Due to 





single cells and groups of cells most likely contribute to the regulation of 
regenerative processes. As CD34 was reported to represent a marker for progenitors 
of the haematopoietic cell lineage (Kollet et al. 2003; Nielsen and McNagny 2008; 
Sidney et al. 2014), positive CD34 staining in the regeneration niche may also be 
associated with the inflammatory cell response. Overall, this further highlights the 
value of TAA as an alternative model to study patterns of CLD seen in human 
pathologies. 
Taken together, this detailed comparison of CDE- and TAA-induced liver injury has 
revealed remarkable differences in the cellular and underlying molecular dynamics, 
creating distinct disease establishment and progression patterns, and will serve as a 
valuable basis for future research utilising these two common models of 
experimental CLD. The data also confirm that both models are suitable for the study 










Characterisation of the LPC response during CDE- and TAA-
induced chronic liver disease 
Parts of this chapter have already been published and the article is included in the 
appendix (Köhn-Gaone et al. 2016a). 
Köhn-Gaone J., Dwyer B.J., Grzelak C.A., Miller G., Shackel N.A., Ramm G.A., McCaughan 
G.W., Elsegood C.L., Olynyk J.K., and Tirnitz-Parker J.E. (2016). Divergent Inflammatory, 
Fibrogenic, and Liver Progenitor Cell Dynamics in Two Common Mouse Models of Chronic Liver 
Injury. Am J Pathol, 186: 1762-1774. 
 





Liver progenitor cells are transit-amplifying cells, committing towards a cell lineage 
depending on the injury stimulus. Thus they most likely represent a cell pool of 
different phenotypes depending on their differentiation and maturation status, 
making this population highly heterogeneous (Jelnes et al. 2007). During early 
investigations, common markers for identifying LPCs included AFP, albumin, OV-6 
and a range of different cytokeratins such as CK7, CK8, CK18, CK19 (Sell 1978; 
Evarts et al. 1987; Yang et al. 1993; Sarraf et al. 1994). Over the last two decades a 
great variety of markers have emerged in the field and have highlighted the diversity 
of this cell population. Several LPC markers are described in the literature, which are 
not specific for LPCs but instead share their expression with other cell types such as 
hepatocytes, cholangiocytes or haematopoietic cells (see Table 1.1 and 1.2). 
Nowadays, studies of LPC biology, often comprising lineage tracing and cell 
isolation strategies, are based on LPC markers of the cholangiocytic lineage such as 
CD24, CD133, CK19, EpCAM, OPN and Sox9 (Suzuki et al. 2008; Espanol-Suner 
et al. 2012; Schievenbusch et al. 2012; Guest et al. 2014; Tarlow et al. 2014a; Lu et 
al. 2015; Mu et al. 2015). Some of the more recent markers, such as Foxl1 and Lgr5 
(Sackett et al. 2009; Shin et al. 2011; Huch et al. 2015), are not available for 
antibody detection, instead lineage tracing in genetically modified mice is performed 
for their study. 
Most LPC marker-based studies have in common that they address the question of 
LPC function, their contribution during tissue repair and their tumorigenic potential. 
However, it is often problematic to directly compare LPC responses and regeneration 
outcomes between studies since they often utilise a diverse range of markers. 
Consequently, it is not clear if the same LPC population is addressed, since despite 
the accepted feature, the differentiation into hepatic cell lineages such as hepatocytes 
and cholangiocytes, it is still unresolved whether LPCs represent equivalent cell 
populations or cells of different stages during lineage commitment. Some evidence 
that the progenitor pool in the adult liver consists of different LPC phenotypes, and 
might be context-specific dependent on the stimulus, comes from a study by Jelnes 
and colleagues. They demonstrated phenotypic discrepancies in the LPC response of 
mice compared to rats and furthermore identified divergent subpopulations of LPCs 




when comparing AAF/PH-, CDE-, DDC- and N-acetyl-paraaminophen-induced CLD 
(Jelnes et al. 2007). Thus, it is of great interest to analyse LPC marker expression 
and characterise the involved subpopulations in different experimental models to set 
the foundation for studying LPC biology. 
This chapter is an extension to the CDE- and TAA-induced injury patterns described 
in Chapter 3 and characterises the LPC populations that can be observed in both time 
courses. This study focussed on commonly used LPC markers, which are available 
for antibody detection. LPCs were discriminated from cholangiocytes by 
morphology and the relevance of these markers in our experimental models was 
evaluated. 
4.2 Study Aims 
This chapter introduces the TAA regime as an experimental model to study LPCs 
and compares the LPC response following TAA treatment with the well-established 
induction through CDE exposure. It was shown in Chapter 3 that the DR including 
the intralobular location and time of niche formation is highly dependent on the 
underlying model, CDE vs. TAA. Therefore, the experiments in this chapter aimed to 
provide a detailed characterisation of LPC phenotypes during the injury induction, 
establishment and maintenance phase of CDE- or TAA-induced chronic liver injury. 





Mice from the 6-week time course exposed to CDE, TAA or control treatment, 
which were previously introduced in Chapter 3, were used in this chapter. Liver 
tissue was further analysed by immunofluorescence to analyse stages of LPC 
induction and proliferation. Here day 7, 14 and 42 were used since indicated in 
Chapter 3, these time points represent the progress of changing LPC numbers in both 
models. LPC proliferation was assessed by labelling A6-positive LPCs with the 
proliferation marker Ki67. LPC phenotypes were characterised by co-staining of 
several markers including A6, CD133, CK19, E-cadherin, EpCAM, MIC1-1C3, 
panCK and Sox9. Pericentral hepatocytes exposed to TAA were evaluated by co-
localisation of the hepatocyte marker hepatocyte nuclear factor alpha (HNF4α) and 
panCK or HNF4α and CK19, respectively. Co-expression analysis of panCK and 
markers that do not label the bulk of LPCs such as CD44 and CD90 were used to 
assess the existence of distinct LPCs subpopulations. 
 





4.4.1 Characterisation of LPC proliferation in response to CDE and TAA 
treatment  
The pro-inflammatory factors TWEAK, TNF, LTβ, IL6 and IFN, as well as HGF, 
which were demonstrated to be increased in the induction phase of the CDE and 
TAA model (see 3.4.2), do not only perpetuate the inflammatory response but also 
provide critical mitogens that activate the LPC compartment in a chronically injured 
liver. Therefore, on the background of elevated mitogen expression levels, LPC 
proliferation was investigated by identifying A6
+
 biliary cells/LPCs that express the 
proliferation marker Ki67. In control mice, A6 staining was restricted to the bile 
ducts, as expected, and Ki67 expression was limited to only a few non-biliary cells 
(Fig. 4.1). Following CDE treatment, A6
+
 biliary structures and single LPCs 





mainly being observed in the dynamic early phase of the LPC response shown for 
day 7. During the entire CDE time course, only a few hepatocytes expressed Ki67, as 
judged by cell and nucleus morphology and lack of A6 expression (Fig. 4.2). In 




 structures were mainly detected at 
later time points, in particular on day 42, when the inflammatory/fibrogenic/LPC 
niche had been well established in pericentral areas (as shown in chapter 3.4.3), 





In addition, many mitotically active Ki67
+
 hepatocytes were observed following 
TAA exposure (Fig. 4.3). 





Fig. 4.1: Proliferation and LPC marker expression in control mice. Frozen sections of non-treated 
control mice were stained for the biliary cell and LPC marker A6 and the proliferation marker Ki67 
using immunofluorescence. There were no proliferating biliary cells/LPCs detected on day 7, 14 and 
42. The scale bar represents 100 μm and dashed boxes identify the regions of enlarged images PV, 
portal vein. 





Fig. 4.2: CDE treatment induces LPC proliferation. Liver sections of CDE-treated mice were 
fluorescently labelled for the biliary cell and LPC marker A6 and the proliferation marker Ki67. CDE 




 cells during the induction phase (day 7) where 
proliferating A6
+
 biliary structures and single LPCs migrated from periportal areas into the 
parenchyma. The scale bar depicts 100 μm and dashed boxes highlight the area of magnification. CV, 
central vein; PV, portal vein. 





Fig. 4.3: TAA exposure induces LPC proliferation. Liver sections of TAA-treated mice were 
labelled for the biliary cell and LPC marker A6 and the proliferation marker Ki67 using 
immunofluorescence. A6+/Ki67+ cells were mainly observed at later time points (day 42) as part of 
the centrally located DR. The scale bar depicts 100 μm and dashed boxes identify the areas of 
enlarged images. CV, central vein; PV, portal vein. 




4.4.2 CDE and TAA-induced LPC phenotypes 
In order to capture the dynamics of a broader ductular cell and LPC population, and 
to further characterise their corresponding phenotypes induced by CDE and TAA 
treatment, different co-stainings for commonly used cholangiocytic LPC markers 
were performed including A6, CD133, CK19, EpCAM, MIC1-1C3, panCK and 
Sox9, as well as the epithelial cell marker E-cadherin. 
Interestingly, when comparing the staining patterns for A6 as the gold standard 
marker and panCK, previously reported to detect A6
+
 structures with a sensitivity of 
>99% in response to N-acetyl-paraaminophen (Kofman et al. 2005), significant 
differences were discovered between the CDE and TAA model. In control mice, it 




 cells exist in the cholangiocytic 
population (Fig. 4.4). There was a substantial overlap of both markers in CDE-
treated mice at all investigated time points (shown for day 14 and 42) with 













population comprised slightly larger cells when located at the site of central damage 
(day 42) resembling intermediate hepatocytes as well as a minor number of small 
oval-shaped cells in portal areas resembling LPC morphology (day 14). Similar 
results were obtained for co-labelling cells with the markers CK19 and panCK, 
MIC1-1C3 and panCK, as well as CD133 and panCK (Fig. 4.7, Fig. 4.8, Fig. 4.9, Fig 
4.10, Fig. 4.11 and Fig 4.12). However, stainings in control mice mainly generated a 
double-positive cholangiocyte population (Fig. 4.) A great overlap of the markers 
CK19 and EpCAM was observed in both CDE- and TAA-induced LPC populations 




 cells at all 





Fig. 4.4: Assessment of the LPC markers A6 and panCK in control mice. Frozen liver sections of control mice at day 14 and 42 were fluorescently labelled for the two 
biliary cell and LPC markers A6 and panCK. Representative images are shown and inserted boxes identify the regions of enlarged images. The scale bar represents 100 μm. 





Fig. 4.5: CDE-induced LPC populations defined by the markers A6 and panCK. Frozen liver sections of mice fed a CDE diet for 14 and 42 days were fluorescently 
labelled for the two biliary cell and LPC markers A6 and panCK. Representative images are shown and inserted boxes identify the regions of enlarged images. The scale bar 





Fig. 4.6: TAA-induced LPC populations defined by A6 and panCK expression. Liver sections of mice exposed to TAA for 14 and 42 days were labelled for the two 
biliary cell and LPC markers A6 and panCK using immunofluorescence. Representative images are shown and inserted boxes identify the regions of magnification. The scale 









 LPCs following CDE exposure. Frozen liver sections of mice exposed to CDE treatment for 14 and 42 days 










 LPCs in TAA-treated mice. Frozen liver sections of mice exposed to TAA treatment for 14 and 42 days 
were labelled with the cholangiocytic LPC markers panCK and CD133. The scale bar represents 100 μm and the inserts identify the area of magnification. CV, central vein; 





Fig. 4.9: Co-localisation of panCK and CK19 in CDE-induced CLD. Frozen liver sections of CDE-treated mice at day 14 and 42 were fluorescently labelled with the 





Fig. 4.10: Co-localisation of panCK and CK19 in TAA-induced CLD. Frozen liver sections of mice exposed to TAA for 14 and 42 days were fluorescently labelled with 









 LPCs in the CDE model. Frozen liver sections of mice fed a CDE diet for 14 and 42 days were 














 LPCs in the TAA model. Frozen liver sections of mice exposed to TAA treatment for 14 and 42 days 
were labelled with the cholangiocytic LPC markers panCK and MIC1-1C3. The scale bar depicts 100 μm and the inserted boxes highlight the area of magnification. Arrows 




 cells. CV, central vein; PV, portal vein. 





Fig. 4.13: Immunofluorecent staining of panCK, CD133, CK19, MIC1-1C3 and EpCAM in 
control mice. Frozen liver sections of control mice at day 14 were labelled with the cholangiocytic 
LPC markers panCK, CD133, CK19, MIC1-1C3 and EpCAM. The scale bar represents 100 μm and 





Fig. 4.14: Co-localisation of CK19 and EpCAM in CDE-treated mice. Frozen liver sections of mice treated with CDE for 14 and 42 days were fluorescently labelled with 





Fig. 4.15: Co-localisation of CK19 and EpCAM following TAA treatment. Frozen liver sections of mice exposed to TAA for 14 and 42 days were fluorescently labelled 
with the cholangiocytic LPC markers CK19 and EpCAM. The scale bar represents 100 μm and the inserted boxes highlight the area of magnification. CV, central vein; PV, 
portal vein. 




Interestingly, the staining patterns of the markers panCK and Sox9 revealed the 




 cell population in close proximity to the portal area in 
CDE- and TAA-treated mice as well as in control mice at day 14 and 42 (Fig. 4.16, 




cell population had larger nuclei 
than LPCs without the characteristic oval shape. Additionally, in TAA-induced CLD, 
the previously observed cell population single-positive for panCK was detected 
mainly central at 14 and 42 days post treatment (Fig. 4.18). 
Hepatocyte loss and the expansion of CLD-induced cellular components involve the 
reorganisation of cell-cell contacts. Cadherins mediate contacts between adjacent 
cells by interactions of the extracellular domains and the formation of adherens 
junctions (Shapiro and Weis 2009). E-cadherin was found to be expressed in biliary 
cells and LPCs in healthy and injured livers, as well as in periportal hepatocytes in 
uninjured livers (Ueberham et al. 2007; Van Hul et al. 2009). The staining pattern 
demonstrated by Ueberham and colleagues (Ueberham et al. 2007) was confirmed in 
control mice, in which E-cadherin expression was restricted to hepatocytes in the 
periportal areas and a stronger staining was observed in cholangiocytes that co-
expressed CK19 (Fig. 4.19). There was a great overlap of CK19 and E-cadherin 
expression in CDE-induced LPCs and decreasing E-cadherin staining intensities 
were observed in hepatocytes from day 14 to day 42 (Fig. 4.20). In contrast to the 
study from Ueberham et al. a weak hepatocytic staining remained in the area of LPC 
expansion. Similarly, TAA-induced CK19
+
 LPCs mainly co-expressed E-cadherin 
(Fig. 4.21). However, hepatocytic E-cadherin staining has been observed in damaged 
central instead of periportal areas at day 14 and positively stained hepatocytes were 





Fig. 4.16: Co-localisation of panCK and Sox9 in control mice. Formalin-fixed, paraffin-embedded liver sections of mice fed with control diet for 14 and 42 days were 






Fig. 4.17: Co-localisation of panCK and Sox9 in the CDE model. Formalin-fixed, paraffin-embedded liver sections of CDE-treated mice for 14 and 42 days were 
fluorescently labelled with cholangiocytic LPC markers panCK and Sox9. The scale bar represents 100 μm and the inserts highlight the area of magnification. CV, central 





Fig. 4.18: Co-localisation of panCK and Sox9 in the TAA model. Formalin-fixed, paraffin-embedded liver sections of mice exposed to TAA for 14 and 42 days were 
labelled with the biliary cell and LPC markers panCK and Sox9 using immunofluorescence. The scale bar represents 100 μm and the inserts identify the field of 





Fig 4.19: Immunofluorescent staining of CK19 and E-cadherin in control mice. Frozen liver sections of mice fed a control diet for 14 and 42 days were labelled with the 





Fig 4.20: Immunofluorescent staining of CK19 and E-cadherin following CDE treatment. Frozen liver sections of mice exposed to CDE treatment for 14 and 42 days 
were labelled with the biliary cell and LPC markers CK19 and E-cadherin. The scale bar represents 100 μm and the inserts identify the field of magnification. CV, central 





Fig 4.21: Immunofluorescent staining of CK19 and E-cadherin in TAA-induced CLD. Frozen liver sections of mice treated with TAA for 14 and 42 days were labelled 
with the cholangiocytic LPC markers CK19 and E-cadherin. The scale bar depicts 100 μm and the inserted boxes highlight the area of magnification. CV, central vein; PV, 
portal vein. 




4.4.3 TAA-induced pericentral HNF4α
+ 
hepatocytes co-express the LPC marker 
panCK
 
but not CK19 




 after 14 
and 42 days of treatment. Since some of these single-positive cells had the 
morphology of small intermediate hepatocytes or damaged necrotic hepatocytes, 
their phenotype was further assessed using the hepatocyte lineage marker HNF4α. 
Co-labelling revealed that several panCK
+
 cells in pericentral areas expressed 




 cell population in 
central TAA-damaged areas, a co-staining with the additional LPC marker, CK19, 
and HNF4α was performed. The data show that CK19 only captures LPCs/biliary 
structures and there was no overlap with HNF4α-expressing cells (Fig. 4.23). 
4.4.4 CLD-induced LPCs comprise small cell subpopulations 
In addition to chapter 4.4.2 where LPC populations were labelled using 
cholangiocytic LPC markers, this paragraph analyses the co-expression of markers 
which do not label a bulk of LPCs but rather are expressed in other cell populations 
present in the liver and when co-existent in LPCs may define smaller subpopulations 
with distinct features. Therefore, to further characterise CDE- and TAA-induced 
LPC populations, the broad LPC marker panCK (as shown in 4.4.2) was used in co-
expression analyses with the markers CD44 and CD90, which have been associated 
with LPCs in earlier studies (Petersen et al. 1998; Petersen et al. 2003; Ueberham et 
al. 2007). 
The expression pattern of CD44 in control mice showed several positively stained 
single cells and small cell groups around portal areas and throughout the 
parenchyma, most likely representing KCs since CD44 has been demonstrated to 
mark macrophages (Shi et al. 2006). However, there were no cells positive for both 
markers panCK and CD44 (Fig. 4.24). Similar results were obtained when staining 









cell population. Formalin-fixed, paraffin-embedded liver sections were fluorescently labelled for the biliary 
cell/LPC marker panCK and the hepatocyte marker HNF4α. Nuclei were stained using DAPI. Representative images are shown and the scale bar represents 100 μm. The 





Fig. 4.23: TAA-induced CK19-positive cells do not co-express HNF4α. Frozen sections were fluorescently labelled for the biliary cell/LPC marker CK19 and the 





Fig. 4.24: Immunofluorescent staining of panCK and CD44 in control mice. Frozen liver sections of control mice at day 14 and 42 were labelled with the cholangiocytic 





Fig. 4.25: Immunofluorescent staining of panCK and CD44 in CDE-induced CLD. Frozen liver sections of mice fed a CDE for 14 and 42 days were labelled with the 






Fig. 4.26: Co-localisation of panCK and CD44 in TAA-induced CLD. Frozen liver sections of mice exposed to TAA treatment for 14 and 42 days were fluorescently 





 cells. CV, central vein; PV, portal vein. 









 single cells and small strings of cells in damage burden areas (Fig. 
4.26). CD90 expression in control mice was found in cells lining the portal vessels 
and a few single cells were detected in the parenchyma (Fig. 4.27). Interestingly, in 
CDE-treated mice, CD90
+
 cells became more frequent around portal areas and 
occasionally co-expressed panCK following treatment for 14 and 42 days (Fig. 2.28). 










Fig. 4.27: Immunofluorescent staining of panCK and CD90 in control mice. Frozen liver sections of control mice at day 14 and 42 were labelled with the cholangiocytic 





Fig. 4.28: Immunofluorescent staining of panCK and CD90 induced by CDE treatment. Frozen liver sections of mice exposed to CDE treatment for 14 and 42 days were 











Fig. 4.29: Immunofluorescent staining of panCK and CD90 induced by TAA treatment. Frozen liver sections of mice treated with TAA for 14 and 42 days were labelled 
with the cholangiocytic LPC marker panCK and the marker CD90. The scale bar depicts 100 μm and the inserts highlight the field of magnification. 





The studies in this chapter provide a detailed characterisation of the LPC response in 
CDE- versus TAA-induced CLD during injury induction (day 7), establishment (day 
14) and maintenance (day 42). As already shown in the previous chapter (chapter 3), 
both CDE and TAA treatments induce biliary cell/LPC expansion as part of the DR. 
This chapter focuses in more detail on the proliferation status and different 
phenotypes of LPCs using immunofluorescent staining techniques. 
On the background of an LPC-stimulating environment, showing increased mitotic 
cytokine levels (as documented in Chapter 3), both models induced biliary cell/LPC 
proliferation, however the timing and location differed between the two regimens. In 




 cells was induced in 
portal areas during early injury induction at day 7, whereas TAA treatment caused 
increased proliferation of this cell population during injury progression at day 42 in 
central areas within the well-established regeneration niche. Hepatocyte proliferation 
was increased in TAA- compared to CDE-induced injury, indicating that TAA 
induces more severe hepatocyte injury and consequently requires more compensatory 
regeneration, or CDE more effectively inhibits the mitotic activity of hepatocytes. 
Consistent with these results, a 30-week TAA treatment in rats caused alterations in 
cell cycle-related proteins with increasing pro-mitotic protein expression in 
hepatocytes and the ductular cell compartment but also increased expression levels of 
the cell-cycle inhibitor cyclin-dependent kinase inhibitor p21 (Jeong et al. 2001). 
Consequently, TAA exposure in mice led to a combination of cell cycle arrest in 
damaged cells and compensatory proliferation of healthy cells including both 
hepatocytes and biliary/LPC structures. As demonstrated in Chapter 3, it was clear 
that in the CDE model at day 7, the LPC response was initiated periportally and 
further expanded into the parenchyma. In contrast, in the TAA model the expansion 
of biliary structures and the LPC compartment had shifted from the initial periportal 
localisation in the induction phase to an accumulation in central areas at later time 
points consistent with the location of the regeneration niche.  
Interestingly, immunofluorescent co-localisation analysis of panCK with other LPC 
markers such as A6, CD133, MIC1-1C3 and CK19 revealed that CDE feeding 




mainly induced double-positive populations. TAA treatment on the other hand 
produced a population of single panCK
+
 cells that do not co-express other 
investigated LPC markers, morphologically resembled an intermediate hepatocyte 
and were mainly seen in central areas, co-existing in the injury and regeneration 
niche with double-positive cells. It is tempting to speculate that the double-positive 
populations represent LPCs with a biliary origin, such as seen for lineage-traced 
CK19
+
 CC cells on a TAA background (Guest et al. 2014). On the other hand, 
expression of the hepatocyte marker HNF4α in the panCK
+
 cell population suggests 
that they might be a result of hepatocytic dedifferentiation, which has been 
demonstrated to occur after Notch-mediated conversion of TAA-targeted hepatocytes 
into biliary cells (Sekiya et al. 2012). Since co-staining with the LPC marker CK19 
and HNF4α showed no overlap in the expression profile, it is more likely that the 
single-positive panCK population represents damaged hepatocytes in toxicity-
burdened central areas that have changed their cytokeratin phenotype. The pan 
marker for cytokeratins recognises a cocktail of multiple low and high molecular 
weight cytokeratins and thus detects a wide range of cytoskeletal changes. Previous 
studies have demonstrated that hepatocytes can express biliary cell specific 
cytokeratins under chronic liver injury conditions (Van Eyken et al. 1988; Yabushita 
et al. 2001; Bateman and Hubscher 2010). 
In general, the investigated markers showed a great overlap in their expression 
profile regardless of CDE, TAA or control treatment. However, consistent with 
previous studies (Ueberham et al. 2007), co-staining of liver tissue with two markers 
revealed the existence of many single-positive LPC populations. These included 



















/E-cadherin. Interestingly, investigations of the 





cells existing in close proximity to portal areas. Most likely, single Sox9
+
 cells 
represent “hybrid hepatocytes” which were recently described by Font-Burgada and 







population was capable of replacing damaged hepatocytes by expanding from portal 
triads into the parenchyma under certain injury conditions. 
Furthermore, some LPCs co-expressed the marker CD44, which also marks 
macrophages and represents the signalling component of the macrophage migration 




inhibitory complex CD74-receptor complex (Shi et al. 2006). Another LPC 
subpopulation co-expressed CD90, which is expressed in activated endothelial cells 
and involved in binding ligand-positive leucocytes (Saalbach et al. 2000) as well as 
in cells of the haematopoietic lineage (Baum et al. 1992). Therefore, these markers 
can be used to further define a smaller LPC population with potentially distinct 










 cell population after 14 and 42 on the diet. 
Taken together all the investigated LPC markers were suitable to define a broad 
population of LPCs in CDE- and TAA-induced CLD. Moreover, co-localisation 
studies further described the heterogeneity of LPC populations by identifying 
different subpopulations. A detailed multichannel flow cytometry analysis is planned 
to investigate all LPC markers used in this thesis with additional markers including 
Fn14, Integrin α5β6 and OPN (Dorrell et al. 2008; Tirnitz-Parker et al. 2010; 
Carpentier et al. 2011). This will provide insight into the abundance of different LPC 
subpopulations induced by CDE or TAA treatment. Distinct subpopulations will then 
be isolated and characterised according to their function (differentiation potential) 
and gene expression profile, which might be useful to generate a “developmental 











Characterisation of LPC populations and tumour formation 
following long-term CDE and TAA exposure 
 





To understand the pathogenesis of liver cancer, several mouse models are utilised in 
the literature, including the use of transgenic mice and chemical or dietary induction 
(Newell et al. 2008; Bakiri and Wagner 2013). None of these represents an ideal 
animal model that meets all the criteria necessary to perfectly reflect all stages of 
hepatocarcinogenesis. Instead adequate experimental conditions are provided to 
induce the pathology and disease state of interest, depending on the research 
question. Thus, a thorough characterisation of all steps of carcinogenesis in the 
experimental models is fundamental to be able to select appropriate time points and 
settings for individual study designs. Moreover, since the differential diagnostic of 
nodules in humans highly depends on the non-tumorous tissue background (Brunt 
2012), a detailed description of injury-induced tissue dynamics in the liver 
environment, in addition to the histopathology of neoplasms, is inevitable. Most 
discussed parameters associated with tumour development include fibrosis, 
inflammation and LPC expansion (Berasain et al. 2009; Cai et al. 2012; Zhang and 
Friedman 2012). 
The earlier introduced CLD models, CDE and TAA, represent promising regimens to 
mimic a wide spectrum of human pathological conditions associated with liver 
cancer. The progressive fibrosis pattern in the TAA model has been demonstrated to 
resemble the injury dynamics of chronic viral hepatitis (Ferrell 2000), which is one 
of the most common risk factors for HCC developing on the background of liver 
cirrhosis (Gomaa et al. 2008; Hoshida 2012; Toshikuni et al. 2014). The dietary 
CDE model, on the other hand, induces changes similar to those seen in NAFLD 
patients. This regime gained importance in recent years since a worldwide dietary 
change has led to an increase in numbers of patients suffering from obesity and 
diabetes - conditions that have been associated with NAFLD, NASH and HCC (Nair 
et al. 2002; Regimbeau et al. 2004; Sun and Karin 2012; Pocha et al. 2015). In 
contrast to viral hepatitis-induced carcinogenesis in the liver (McGivern and Lemon 
2011), the knowledge of mechanisms leading to NAFLD-related cancer in humans is 
very limited (Yeh and Brunt 2014). Cohort studies suggest that steatosis represents 




an independent predictor for HCC, regardless of the presence of cirrhosis (Pekow et 
al. 2007; Alexander et al. 2013). 
In chapter 3, the induction, establishment and maintenance phase of CLD, induced 
through CDE and TAA administration, respectively, have been explicitly described. 
Liver tumour development has been demonstrated in both models (Becker 1983; 
Knight et al. 2008). While the CDE diet is more frequently used in mice to study 
HCC development, the TAA regimen has been utilised in the context of CC 
formation (Guest et al. 2014). To date no systematic study has been published 
characterising the sequential changes leading to neoplastic lesions and tumour 
development, including the injury-related tissue environment. Therefore, two 
detailed time courses of CDE and TAA treatment were performed in mice over the 
period of 7 months to (a) thoroughly characterise the molecular and cellular changes 
and to (b) compare the two models with regard to histopathological differences. Due 
to time constraints, this chapter provides a preliminary analysis including a limited 
number of mice at selected time points. The generated material will be further 
analysed in future experiments. 
5.2 Study Aims 
Since liver tumours comprise several phenotypes and arise on the background of 
different injury conditions, a thorough description of experimental models is 
necessary to be able to mimic distinct human pathologies and choose the right 
settings and time points for particular research questions. The studies in this chapter 
characterise the response dynamics induced by CDE and TAA long-term treatment 
and analyse model-specific injury patterns during CLD progression and 
carcinogenesis. This includes a detailed characterisation of induced tumours -
phenotype assessment of HCC vs CC - as well as the examination of tissue injury 
parameters in the surrounding environment such as inflammation, LPC expansion 
and fibrosis. 





Liver tissue and serum of 5 to 7 week-old, male C57BL/6J mice that had been 
subjected to CDE, TAA and control treatment (see Chapter 3), were harvested after 
3, 5 and 7 months for further investigations. Due to the expected high diversity of 
tissue responses at later time points, animal numbers were increased to 8 to 12 mice 
per experimental group compared to the short-term experiments. Overall animal 
health was evaluated by body weight changes and liver weight to body weight ratios. 
Serum ALT levels informed about liver damage. Tumour formation was investigated 
by assessing gross liver morphology and neoplastic changes were analysed using 
Reticulin staining and immunohistochemical studies of the HCC marker CPS1 
(HepPar 1 antigen) (Butler et al. 2008) and the CC marker CK7 and CK19. Tumours 
and non-tumorous tissue (referred to as background injury) were further 
characterised during injury progression and carcinogenesis through examination of 
liver histology and lipid accumulation by haematoxylin and eosin and Oil Red O 
staining, respectively. Magnitude and pattern of the model-specific inflammatory 
response was investigated by labelling CD45
+
 inflammatory cells and F4/80
+
 resident 
KCs using immunohistochemistry, as well as fluorescent labelling of CD11b
+
 
monocyte-derived macrophages. The expansion of LPC subpopulations was 
examined by immunohistochemical and fluorescent detection of the markers panCK, 
CK19, CD133, EpCAM and CD44. Evaluation of the injury-associated fibrogenic 
patterns was performed by Sirius Red staining. The regeneration niche was assessed 




 inflammatory cells and 
SMA
+
 activated HSCs. 





5.4.1 Overall health of animals exposed to long-term CDE and TAA treatment 
Overall animal health in response to long-term CDE and TAA treatment was 
evaluated throughout the time course of seven months by measuring the body weight 
and the liver-to-body weight ratios of mice. Furthermore, overall liver damage was 
assessed by serum ALT levels, reflecting hepatocyte health. 
The initial body weight loss induced by TAA and CDE within the first week of 
treatment was documented in Chapter 3 and was confirmed in this study (not shown). 
In response to further TAA treatment beyond six weeks, body weights of mice 
remained significantly lower than the corresponding controls at all investigated time 
points (p ≤ 0.05, not shown in graph) (Fig. 5.1). In contrast, CDE exposure caused 
significantly lower body weights in mice up to eight weeks of treatment (p ≤ 0.05, 
not shown in graph) with normalisation towards non-injured mice thereafter (Fig. 
5.1). 
In rats, there is a correlation between the liver-to-body weight ratio and the time of 
TAA exposure, reflecting an increase in liver mass relative to body weight as the 
injury progresses (Jeong et al. 2001). These findings were confirmed in mice after 5 
and 7 months of TAA treatment and were due to reduced body weight gain and 
increasing liver weights (Fig. 5.2). Similar results were observed in CDE-fed mice 
after seven months on the diet. However, since body weights in CDE-treated mice 
were comparable to controls at later time points, the increased liver-to-body weight 
ratio reflects a significant increase in liver mass rather than a decrease in body 
weight. 





Fig. 5.1: Body weight dynamics in response to CDE and TAA treatment. Body weights of mice 




Fig. 5.2 Liver-to-body weight ratios of mice exposed to CDE and TAA treatment. Liver-to-body 
weight ratios were calculated in mice treated with CDE or TAA for 3, 5 and 7 months, as well as in 
controls. Ratios are expressed as mean ± SEM (4 to 12 mice per group). *p<0.05, p**<0.01, 
p***<0.001 compared to controls.   




The biochemical assessment of serum ALT activity revealed a continuous liver 
damage induced by CDE and TAA treatment at all investigated time points (Fig. 
5.3). However, different dynamics were observed since ALT levels in TAA mice 
showed only minor fluctuations (46.9 ± 3.5 U/l, 47.1 ± 1.2 U/l and 43.2 ± 3.1 U/l) 
whereas CDE exposure provoked a progressive increase from three (39.3 ± 3.7 U/l) 
to seven months (63.9 ± 4.6 U/l). 
5.4.2 Gross liver morphology following long-term CDE and TAA treatment 
To assess liver tumour development on the background of CDE- and TAA-induced 
CLD, the gross liver morphology of mice exposed to experimental conditions were 
evaluated at the time of sacrifice and compared to uninjured control livers of the 
same age (Fig. 5.4A). Both treatments induced substantial gross morphological 
changes ranging from one to numerous neoplastic lesions of 1-12 mm in diameter 
that appeared as white or brown/yellow nodules. According to their size, these 
subcapsular nodules were grouped into different categories (Fig. 5.4). Single or 
multiple neoplasms with a diameter of < 1 mm, distinguished by their white 
appearance within the liver lobe, most likely represent precursor lesions (Fig 5.4B). 
Outgrowing nodules of 1-5 mm in size were grouped as intermediate tumours 
(Fig. 5.4C and Fig. 5.4D), whereas nodules with a diameter of > 5 mm were listed as 
advanced tumours (Fig. 5.4E-H).  
Following CDE and TAA treatment, several categories of neoplastic changes were 
identified as early as three months of CDE feeding (Table 5.1A) and after five 
months of TAA exposure (Table 5.1B). All detected tumours were primary tumours 
since no other organs in the body showed any abnormalities. 











Fig. 5.3: Serum ALT levels were increased in CDE- and TAA-induced CLD. Hepatocyte health 
was evaluated by biochemically measuring serum alanine transaminase (ALT) levels of mice exposed 
to CDE, TAA or control treatment for 3, 5 and 7 months. 





Fig. 5.4: Tumour morphologies induced by CDE and TAA long-term exposure. Gross liver 
morphologies of CDE-, TAA-treated, and control mice are illustrated. Representative images are 
shown for (A) a healthy control liver, (B) potential precursor lesions (C, D) intermediate tumours and 
(E-H) advanced tumours. 


















7 11/11 (100) 6 3 2 
5 2/7 (29) 1 0 1 












7 9/13 (69) 3 3 3 
5 5/10 (50) 1 1 3 
3 0/8 (0) 0 0 0 
 
Table 5.1: Long-term CDE and TAA exposure induced tumour formation in mice. Total animal 
numbers showing neoplasms after 3, 5 and 7 months of (A) CDE and (B) TAA treatment are listed 
and further categorised into subgroups according to the gross liver morphology: Precursor lesions: 
diameter < 1 mm, intermediate tumours: 1-5 mm and advanced tumours: > 5 mm. 




5.4.3 CDE- and TAA-induced background injury of non-tumorous tissue 
The following paragraphs characterise and compare the injury dynamics in non-
tumorous liver tissue in mice treated with CDE or TAA and describe the background 
settings during disease progression and carcinogenesis. This enables the correlation 
of tumour occurrence and different response dynamics including histological 
changes, the DR and fibrogenic patterns. 
5.4.3.1 Histological evaluation of tissue damage 
Histological assessment of liver sections after long-term treatment revealed distinct 
CDE- and TAA-induced morphological changes when compared to controls (Fig 5.5, 
Fig. 5.6 and Fig. 5.7). Moderate tissue damage was detected in livers after three 
months of CDE treatment, based on infiltrating small basophilic cells in periportal 
areas and parenchymal foci as well as pale appearing swollen or enlarged 
hepatocytes - ballooning - with granulated cytoplasm situated around central veins. 
Prolonged treatment for five and seven months resulted in liver damage progression 
as hepatocyte degeneration, enrichment of basophilic cells and their parenchymal 
infiltration was detected in agreement with corresponding increased serum ALT 
levels assessed earlier (see 5.4.1) (Fig. 5.6). In contrast, TAA long-term exposure 
provoked a progressive injury pattern following the maintenance phase introduced in 
Chapter 3.4.1 (Fig. 5.7). Eosinophilic hepatocytes were seen in pericentral areas and 
were connected by eosinophilic bands of hepatocytes, which were both associated 
with increasing small basophilic cell infiltrates during injury progression and 
carcinogenesis. 
Since there is a high risk for HCC development on the background of hepatic 
steatosis (Baffy et al. 2012) and the CDE diet induced excessive lipid accumulation 
in hepatocytes during early time points of the 6-week time course (see 3.4.1), effects 
of long-term CDE in comparison to long-term TAA treatment were investigated. 
Therefore, lipid deposition was visualised using Oil Red O staining (Fig. 5.8). In the 
CDE model, high levels of macrovesicular and microvesicular lipid accumulation 
were detected at all investigated time points. 






Fig. 5.5: Liver histology of control mice. Formalin-fixed, paraffin-embedded liver sections of mice 
fed a control diet for 3, 5 and 7 months were stained with haematoxylin and eosin. Representative 
images are shown for each time point and the inserted boxes highlight the area of magnification. The 
scale bar represents 200 μm. CV, central vein; PV, portal vein. 






Fig. 5.6: CDE-induced morphological changes of the liver after long-term treatment. Formalin-
fixed, paraffin-embedded liver sections of mice treated with CDE for 3, 5 and 7 months were 
histologically assessed using haematoxylin and eosin staining. Representative images of experimental 
groups are illustrated. The inserted boxes identify the field of enlarged images and the scale bar 
depicts 200 μm. CV, central vein; PV, portal vein. 






Fig. 5.7: TAA-induced morphological changes of the liver after long-term treatment. The 
morphology of formalin-fixed, paraffin-embedded liver sections of mice exposed to TAA treatment 
for 3, 5 and 7 months were was assessed by haematoxylin and eosin staining. Representative images 
of experimental groups are demonstrated and the inserted boxes identify the enlarged areas. The scale 





Fig. 5.8: Lipid accumulation in CDE- and TAA-induced CLD. Frozen liver sections of mice exposed to CDE and TAA treatment for 3, 5 and 7 months and respective 
controls were stained with Oil Red O. Representative images of experimental groups are shown. The scale bar depicts 100 μm. 




In contrast, the zonal distribution of fatty changes identified at earlier time points of 
the 6-week time course (see 3.4.1) was no longer detected in long-term TAA-treated 
livers. 
5.4.3.2 Inflammatory response 
The associated inflammatory response dynamics in CDE- and TAA-induced CLD 
were characterised using the inflammatory cell marker CD45. To further define KCs 
and monocyte-derived macrophages, expression profiles of the markers F4/80 and 
CD11b were assessed, respectively. Both regimens induced an inflammatory 
response at all investigated time points, shown by progressively increasing areas of 
CD45 expression from 3 months (CDE, 5.7 ± 1%; TAA, 7.3 ± 2.3% positive pixel 
per FOV) towards 7 months of treatment (CDE, 12.5 ± 2.7%; TAA, 9.9 ± 1.8% 
positive pixel per FOV) (Fig. 5.9 and Fig. 5.10). However, the spatial arrangements 
of CD45
+
 inflammatory cells differed in both models. The CDE diet provoked a 
mainly lobular and milder periportal response, including inflammatory cell foci, 
whereas TAA-damaged livers displayed a pericentral and central-to-central located 
response directed to the site of tissue damage (Fig. 5.9). Examination of CD11b 
expression revealed a corresponding pattern and showed that monocyte-derived 
macrophages are a part of the CD45
+
 cell response (Fig. 5.11). Investigations of 
F4/80 marker expression demonstrated that the KC population is represented by cells 
with a low CD45 expression. The typical distribution of KCs, mainly present in 
periportal and intermediate areas, was distorted after five months of CDE treatment. 
In TAA mice, KCs were located in the damaged lobular regions and the adjacent 
intermediate zones at all investigated time points (Fig. 5.12). 
 









Fig. 5.9: Long-term exposure to CDE and TAA induced a CD45
+
 cell response. Formalin-fixed, 
paraffin-embedded liver sections of CDE, TAA and control mice at 3, 5 and 7 months were 
immunohistochemically labelled for the inflammatory cell marker CD45. Representative images are 
shown. The scale bar represents 200 μm. CV, central vein; PV, portal vein. 










Fig. 5.10: Long-term CDE and TAA treatment induced increased numbers of CD45
+
 cells. 
Control, CDE and TAA liver sections of 3, 5 and 7 months were immunohistochemically labelled 
with the inflammatory cell marker CD45. Positive pixel counts were performed in five non-
overlapping fields of view (FOV) per sample. Data are expressed as mean ± SEM. n = 4 to 6 mice per 
group. * P < 0.05, ** P < 0.01, *** P < 0.001 compared with controls. 







Fig. 5.11: CDE and TAA long-term treatment induce increased CD11b
+
 cell numbers. Frozen 
liver sections of mice treated with CDE or TAA for five and seven months and controls were labelled 
for the cholangiocyte/LPC marker panCK and the monocyte-derived macrophage marker CD11b 
using immunofluorescence. Representative images are shown. The scale bar depicts 100 μm. CV, 
central vein; PV, portal vein. 








Fig. 5.12: Rearrangement of F4/80
+
 cells following long-term CDE or TAA treatment. Formalin-
fixed, paraffin-embedded liver sections of CDE, TAA and control mice treated for 3, 5 and 7 months 
were immunohistochemically labelled for the KC marker F4/80. Representative images are shown. 
The scale bar represents 200 μm. CV, central vein; PV, portal vein. 




5.4.3.3 Liver progenitor cell response 
Since LPCs are associated with CLD and carcinogenesis, and both regimens showed 
their expansion in the first six weeks of treatment (see 3.4.3), the following 
paragraph investigates the dynamics and different phenotypes of CDE- and TAA-
induced LPCs during injury progression and tumour formation. 
Immunohistochemical staining for the biliary cell and LPC marker panCK revealed a 
progressive expansion of the LPC response following long-term exposure to either 
CDE or TAA (Fig. 5.13 and Fig. 5.14A). In the CDE model, panCK
+
 cells were 
limited to periportal areas after three months (1.7 ± 0.8 positive pixel per FOV), 
infiltrated the parenchyma after five months (3.7 ± 1.9% positive pixel per FOV) and 
further expanded up to seven months of treatment (8.6 ±3.4% positive pixel per 
FOV) (Fig 5.13 and Fig. 5.14A). 
In contrast to TAA, which resulted in minor animal-to-animal variations, CDE 
treatment caused high discrepancies within experimental groups that increased over 
time. As a result, mice from the 5- and 7-month time point were further subdivided 
into groups defined by low and high LPC responses (Fig 5.14B). Despite the 
relatively low number of animals available for analysis at that stage (5 months, n = 6; 
7 months, n = 7), the respective, associated LPC expansions differed significantly 
between the groups after five (low LPC response group, 1.3 ± 0.2%; high LPC 
response group, 9 ± 1% positive pixel per FOV) and seven months of treatment (low 
LPC response group, 0.9 ± 0.02%; high LPC response group, 14.4 ± 3.8% positive 
pixel per FOV). Furthermore, when correlated to tumour development, the data 
suggest a positive correlation between the magnitude of the LPC response and 
tumour formation since only the high LPC group showed severe neoplastic changes. 
The results in the groups with low versus high LPC numbers were also consistent 
with a low versus high inflammatory response (Fig. 5.15). Thus, to further 
investigate the process of tumour formation in the CDE model, only mice of the high 
LPC response group were used for further characterisations. The distribution of 
TAA-induced panCK
+
 cells followed the previously observed pattern in damaged 
centrilobular regions (3 months, 4.3 ± 0.8%; 5 months, 7.5 ± 0.5%; 7 months, 9 ± 
1.4% positive pixel per FOV) and resembled a honeycomb structure with strong 
central-to-central zonation. 









Fig. 5.13: Expansion of panCK
+
 cells in response to long-term CDE and TAA treatment. 
Formalin-fixed, paraffin-embedded liver sections of mice exposed to CDE, TAA or control treatment 
for 3, 5 and 7 months were immunohistochemically labelled for the biliary and LPC marker panCK. 
Representative images are shown. The scale bar depicts 200 μm. CV, central vein; PV, portal vein. 
 








Fig. 5.14: Long-term CDE and TAA treatment induced the expansion of panCK
+
 cells. Control, 
CDE and TAA liver sections were immunohistochemically labelled with the biliary cell and LPC 
marker panCK. (A) Animals of all experimental groups after 3, 5 and 7 months of treatment. (B) CDE 
mice treated for 5 and 7 months, respectively, further categorised according to their low or high 
panCK
+
 LPC response. Positive pixel counts were performed in five non-overlapping fields of view 
(FOV) per sample. Data are expressed as mean ± SEM. n = 4 to 7 mice per group. * P < 0.05, ** P < 
0.01, *** P < 0.001 compared with controls. 











Fig. 5.15: Correlation between the magnitude of panCK and CD45 expression in CDE- and 
TAA-treated mice. Immunohistochemical analysis of the cholangiocyte and LPC marker panCK and 
the inflammatory cell marker CD45 in CDE- (black) and TAA-treated (red) mice from the 5- and 7-
month time points revealed a positive correlation between the magnitudes of both marker expressions. 




As shown in Chapter 4, CDE- and TAA-induced LPCs represented a heterogeneous 
cell population including several single positive cells in addition to the bulk of 
double positives when simultaneously staining for different commonly used LPC 
markers. Therefore, the expression profiles of the markers panCK, CK19, CD133 
and EpCAM were further investigated during injury progression and carcinogenesis 
in order to evaluate distinct LPC phenotypes and the abundance of these 
subpopulations. Co-localisation studies with the markers panCK and CK19 (Fig. 
5.16, Fig. 5.17 and Fig 5.18), CK19 and EpCAM (Fig 5.19, Fig. 5.20 and Fig. 5.21), 
as well as panCK and CD133 (Fig. 5.19 and Fig. 5.22) revealed a high degree of 
overlap in expression profiles but also distinct single positive populations in both 


















fluorescent labelling with CK19 and Ki67 identified proliferating LPCs after five and 




 cells in damaged lobular 
areas of CDE- and TAA- livers (Fig. 5.23). 
As illustrated in Chapter 4.4.4, the TAA maintenance phase induced several panCK
+
 
cells that co-expressed CD44, a marker previously associated with CSCs (Yang et al. 
2008b; Zhu et al. 2010). Since LPCs are discussed as candidates for pre-cancerous 
cells during carcinogenesis (for review see 1.8.4 and 1.9.2), potentially tumour-
initiating phenotypes were investigated in response to long-term CDE and TAA 




 subpopulation revealed that CDE only 
induced double positive cells starting after 5 months of treatment consistent with 
increased LPC expansion (Fig. 5.24), whereas in the TAA regimen their presence 
was observed at all investigated time points (Fig. 5.25). Additional co-localisation of 
the commonly used hepatic CSC marker EpCAM in CD44
+
 LPCs further suggested a 








 cells (Fig. 
5.26). 
 








Fig. 5.16: Characterisation of the LPC markers panCK and CK19 in control mice. Frozen liver 
sections of mice fed a control diet were fluorescently labelled with the biliary and LPC markers 
panCK and CK19. Representative images are shown. The scale bar represents 100 µm and inserted 
boxes define the area of magnification. 












 LPCs following long-term CDE 
treatment. Frozen liver sections of CDE mice treated for 3, 5 and 7 months were fluorescently 
labelled with the biliary and LPC markers panCK and CK19. Representative images are shown and 


















 LPCs following long-term TAA 
treatment. Frozen liver sections of TAA mice treated for 3, 5 and 7 months were labelled with the 
biliary and LPC markers panCK and CK19 using immunofluorescence. Representative images are 
shown. The scale bar represents 100 µm and inserted boxes highlight the field of magnification. 
 
 








Fig. 5.19: Expression profiles of the markers panCK, CK19, CD133, EpCAM and CD44 in 
controls. Frozen liver sections of 5-month old mice fed a control diet were fluorescently labelled with 
the biliary and LPC markers panCK, CD133, CK19 and EpCAM, as well as with the macrophage and 
CSC marker CD44. Representative images are shown. The scale bar depicts 100 µm and inserted 


















 LPCs following long-term CDE 
exposure. Frozen liver sections of mice treated with CDE for 3, 5 and 7 months were labelled with 
the biliary cell and LPC markers CK19 and EpCAM using immunofluorescence. The scale bar 









 (yellow) cells. 












 LPCs following long-term TAA 
exposure. Frozen liver sections of TAA-treated mice of 3, 5 and 7 months were fluorescently labelled 
with the biliary cell and LPC markers CK19 and EpCAM. The scale bar depicts 100 μm and inserted 









 (yellow) cells. 






Fig. 5.22: CDE- and TAA-induced LPC populations defined by the markers panCK and CD133. 
Frozen liver sections of mice treated with CDE and TAA for five months were fluorescently labelled 
with the biliary cell and LPC markers panCK and CD133. Representative images are shown. The 
















Fig. 5.23: CDE and TAA treatment induce LPC proliferation during CLD progression and 
carcinogenesis. Frozen liver sections of CDE and TAA mice treated for five and seven months were 
fluorescently labelled for the biliary cell and LPC marker CK19 and the proliferation marker Ki67. 
Representative images are shown and the scale bar depicts 100 μm. Arrows highlight examples of 
proliferating LPCs. 








Fig 5.24: Co-localisation of panCK and CD44 in CDE-induced CLD progression and 
carcinogenesis. Frozen liver sections of CDE mice treated for 3, 5 and 7 months were labelled with 
the LPC marker panCK and the CSC marker CD44 using immunofluorescence. The scale bar depicts 














Fig. 5.25: Co-localisation of panCK and CD44 in TAA-induced CLD progression and 
carcinogenesis. Frozen liver sections of mice treated with TAA for 3, 5 and 7 months were 
fluorescently labelled with the LPC marker panCK and the CSC marker CD44. The scale bar 











Fig 5.26: Co-localisation of CD44 and EpCAM during CDE- and TAA-induced carcinogenesis. 
Frozen liver sections of CDE and TAA mice after 7 months of treatment were fluorescently labelled 
with the LPC and CSC marker EpCAM and the CSC marker CD44. Representative images are shown. 
The scale bare represents 50 µm and the inserted boxes identify the area of magnification. Arrows 










Irrespective of the underlying cause of CLD, fibrosis and cirrhosis are the most 
common risk factors for hepatocarcinogenesis. Assessment of collagen deposition 
using Sirius Red staining revealed distinct model-specific fibrogenic responses 
following long-term treatment with CDE and TAA, differing greatly form healthy 
livers, where thin collagen fibers were primarily detected around portal tracts and 
central veins (Fig. 5.27). In both regimens, fibrosis increased during the time course. 
In CDE mice at three months, collagen accumulation was mainly seen in portal and 
central areas and characterised by a distinct pericellular and “chicken wire” 
formation. With prolonged time on the diet, the fibrotic response differed greatly 
between mice of the same time points, which prompted the definition of two 
different phenotypes. The first group showed mild pericentral fibrosis with chicken 
wire appearance (zone 3 fibrosis). In the second group fibrosis progressively 
increased to advanced stages after five and seven months of treatment and was 
marked by perisinusoidal or pericellular collagen deposition throughout the 
parenchyma (lobular fibrosis) (Fig. 5.28). Interestingly, only the advanced fibrosis 
group was associated with tumour formation. In contrast to the CDE model, TAA 
maintained the previously established fibrogenic pattern (see maintenance phase in 
3.4.4) in pericentral areas and bridging central-to-central septa at three months. 
During injury progression and carcinogenesis, thicker collagen fibres and wider 
bridging septa were detected, a typical feature for liver cirrhosis (Fig. 5.29). Livers of 
all experimental groups indicated a strong correlation between the excess of collagen 
deposition and the degree of LPC expansion and inflammation (data not shown). 
5.4.3.5 Tissue regeneration niche hosting LPCs, activated HSCs and inflammatory 
cells 





 HSCs and CD45
+
 inflammatory cells after 7 months of 
treatment, illustrated the cells’ close spatial relationship in the tumour-surrounding 
tissue of CDE and TAA mice (Fig. 5.30). However, the zonation provoked by TAA 
displayed a more distinct pattern and the enhanced accumulation was consistent with 
previously observed lobular areas of severe tissue damage. 







Fig. 5.27: Sirius Red staining of control mice. Formalin-fixed, paraffin-embedded liver sections of 
3-, 5- and 7-month old control mice were assessed for collagen accumulation using Sirius Red. 
Representative images are shown. The scale bar depicts 250 μm and inserted boxes identify the 
enlarged area. 





Fig 5.28: Sirius Red staining of CDE-treated mice. Collagen accumulation in formalin-fixed, 
paraffin-embedded liver sections of CDE mice was assessed by Sirius Red staining after 3, 5 and 7 
months of treatment. Representative images are shown. The scale bar represents 250 μm and inserted 
boxes highlight the area of magnification. 







Fig. 5.29: Sirius Red staining of TAA-treated mice. Formalin-fixed, paraffin-embedded liver 
sections of mice exposed to TAA for 3, 5 and 7 months were assessed for collagen deposition by 
Sirius Red staining. Representative images are shown. The scale bar depicts 250 μm and inserted 
boxes define enlarged areas.  








Fig 5.30: CDE- and TAA-induced regeneration niche in tumour-surrounding tissue. CDE and 
TAA liver sections after seven months of treatment were fluorescently labelled for the cholangiocyte 
and LPC marker panCK, the inflammatory cell marker CD45, the activated HSC marker αSMA and 
DAPI for nuclear quantitation. Representative images are illustrated for both experimental groups. 
The scale bar represents 50 µm and inserted boxes identify areas of magnification. 




5.4.4 Characterisation of CDE- and TAA-induced tumours 
As a progression from gross liver morphology analyses of CDE- and TAA-treated 
mice, the studies in this paragraph examine the corresponding histopathology and 
phenotypes of advanced tumours. The most common method for evaluating 
characteristics of neoplasms is the use of haematoxylin and eosin stains, which 
identified a great variety of neoplastic changes and enabled a clear discrimination of 
nodules from the surrounding tissue in both models. Tumours induced in the TAA 
regimen comprised large polygonal cells with abundant eosinophilic cytoplasm and 
atypical stripped nuclei as well as moderate basophilic cell infiltrates (Fig. 5.31). 
Similar characteristics were identified in CDE-induced tumours, however with 
weaker eosinophilic cytoplasm and enriched small basophilic cells (Fig. 5.32), and 
were often marked by steatosis and the presence of Mallory-Denk bodies. 
Furthermore, tumour-associated ductular structures were occasionally observed in 
the CDE model (Fig. 5.32C). Reticulin staining revealed an altered stromal network 
of collagen III-composing fibres in livers of CDE- and TAA-treated mice. 
Thickening of hepatic cell plates and diffuse reticulin structures were detected within 
tumours, and reticulin crowding at the interface of tumorous and non-tumorous tissue 
indicated invasive tumour growth into the surrounding tissue (Fig. 5.31 and Fig. 
5.32).  
Morphological analyses suggested a HCC phenotype for both CDE and TAA 
tumours; however, reports in the literature have mainly associated TAA treatment 
with CC development. Therefore, immunohistochemical staining for the markers 
CK7, CK19 and CPS1 was performed to further assess the tumour phenotypes. In 
both models, CK7 and CK19 expression was limited to cholangiocytes and LPCs, 
mainly detected in the tumour-surrounding tissue. The tumour itself was negative for 
both markers but positive for CPS1, consistent with an HCC phenotype (Fig. 5.33). 
Additionally, CDE tumours showed rare incidences of CK7
+
 bile-like structures 






Fig. 5.31: Histology of TAA-induced tumours. Formalin-fixed, paraffin-embedded liver sections of mice treated with TAA for seven months were utilised to analyse the 
histology of advanced tumours by haematoxylin and eosin, and Reticulin staining. (A-C) show low magnification images of liver sections, and (D-I) illustrate representative 





Fig. 5.32: Histology of CDE-induced tumours. The histology of advanced tumours was examined by haematoxylin and eosin, and Reticulin staining using formalin-fixed, 
paraffin-embedded sections of CDE mice treated for seven months. Low magnification images of liver sections are shown in (A and B), and (C-I) show representative images 
of analysed neoplasms. The scale bar depicts 500 (A, B), and 50 μm (C-I), respectively. 






Fig. 5.33: CK7, CK19 and CPS1 expression in CDE- and TAA-induced tumours. Formalin-fixed, 
paraffin-embedded tissue sections of advanced tumours induced by CDE and TAA treatment for 
seven months were immunohistochemically labelled for the HCC marker CPS1 and the biliary/LPC 
and CC markers CK7 and CK19. Representative images are shown and the scale bar represents 
200μm. NT, non-tumorous tissue; T, tumour. 




Immunohistochemical evaluation revealed the presence of CD45
+
 inflammatory cells 
and F4/80
+
 KCs in CDE- and TAA-induced HCC, however positively stained cells 
were more abundant in the CDE model. Moreover, the spatial arrangement and 
increased magnitude of F4/80
+
 cells in the tumour mass compared to non-cancerous 
surrounding tissue was highly distinct in CDE mice, suggesting a massive KC 
invasion (Fig. 5.34). Furthermore, labelling with the proliferation marker Ki67 
demonstrated proliferating hepatocytes and small cell infiltrates in CDE- and TAA-
associated HCCs, with a higher proliferative state of CDE tumours (Fig. 5.35). Sirius 
Red staining identified similar HCC fibrosis patterns in response to both models 
showing fine and moderate collagen deposition within tumours (Fig. 5.36). Finally, 
the distribution of LPCs was assessed using immunohistochemistry and the biliary 
and LPC marker panCK. The data showed that both regimens provoked tumours that 
hosted panCK
+
 LPCs and those without panCK expression (Fig. 5.37). Further 





 subpopulation (Fig. 5.37). 
 





Fig. 5.34: Inflammatory pattern in CDE- and TAA-induced tumours. The inflammatory signature 
of advanced tumours was evaluated using formalin-fixed, paraffin-embedded tissue sections of mice 
treated for seven months with CDE or TAA, and immunohistochemical staining for the inflammatory 
marker CD45 and the KC marker F4/80. Representative images are shown and the scale bar depicts 
200 μm. T, tumour. 






Fig. 5.35: Immunohistochemical assessment of Ki67
+
 cells in CDE- and TAA-induced tumours. 
Formalin-fixed, paraffin-embedded liver sections of advanced CDE and TAA tumours were 
immunohistochemically labelled for the proliferation marker Ki67. Representative images are shown 
and the scale bar depicts 200 μm. T, tumour. 
 
 
Fig. 5.36: Fibrosis state of CDE- and TAA-induced tumours. Formalin-fixed, paraffin-embedded 
sections of advanced tumours induced by seven months of CDE (A, low; B, moderate) or TAA (C, 
low; D; moderate) treatment were assessed for collagen deposition using Sirius Red staining. 
Representative images are shown and the scale bar depicts 200 μm. T, tumour. 






Fig. 5.37: Assessment of LPCs in CDE- and TAA-induced advanced tumours. Formalin-fixed, 
paraffin-embedded sections of advanced tumours induced by seven months of CDE (A, B) or TAA 
(C, D) treatment were stained for the cholangiocyte and LPC marker panCK using 
immunohistochemistry. Corresponding frozen tissue sections were fluorescently labelled with the 
LPC and CSC marker EpCAM, and CD44. Representative images are shown and the scale bar depicts 





 cells. T, tumour. 





Chapter 3 discussed in detail the dynamics of disease parameters associated with 
CDE and TAA-induced early stages of injury including the induction, establishment 
and maintenance phase. As demonstrated in the literature, both treatments represent 
valuable models for studying hepatocarcinogenesis and are frequently used to 
investigate HCC, and in the case of TAA also CC (Becker 1983; Knight et al. 2008; 
Darweish et al. 2014; Boulter et al. 2015). Therefore, the following chapter extends 
the comprehensive comparison of the two models to a time course of seven months 
through snapshot analyses after 3, 5 and 7 months, and thus covers stages of injury 
progression and tumour formation. 
The data emphasise that long-term treatment with CDE and TAA generally induces 
similar kinetics of disease parameters, illustrated by increasing hepatic injury, 
inflammation, LPC expansion and fibrosis that predispose to cancer development. 
However, substantial differences were observed in the magnitude and spatial 
arrangements of investigated parameters at individual time points. Moreover, it is 
important to mention that TAA treatment caused a much more homogenous tissue 
response compared to high animal-to-animal variations provoked by the CDE diet. 
The succession of events for TAA is sustained hepatic injury, progressive 
inflammation, LPC response and fibrosis and eventually cirrhosis and HCC 
development - reflecting the pathological dynamics seen in viral hepatitis patients 
(Ferrell 2000). The CDE model induced excessive hepatic fat loading and 
progressive hepatic injury, as well as the progressive inflammation, LPC response 
and fibrosis, and eventually HCC development without cirrhosis. These dynamics 
resemble the conditions found in NAFLD patients (Ferrell 2000). Investigations of 
the spatial arrangements of these parameters revealed that the area of tissue damage 
in the TAA model persisted in centrilobular regions and formed central-to-central 
bridging septa, illustrated by the panCK
+
 LPC expansion and the CD45
+
 
inflammatory response. Additionally, Sirius Red-detected collagen deposition 
produced a consistent fibrogenic pattern directed to the central site of injury. In 
contrast, evaluation of CDE mice illustrated varying degrees of steatosis 
predominantly in zone 3, periportal and intralobular inflammation and LPC 
expansion, and different fibrosis patterns including portal “chicken wire”, zone 3 and 
lobular perisinusoidal or pericellular fibrosis. Therefore, the CDE regimen may be 




considered a model for the more severe form of NAFLD, NASH, which is marked by 
steatosis, severe lobular inflammation and hepatocyte ballooning (Takahashi and 
Fukusato 2014). 
On the background of progressive CLD, both regimens effectively induced primary 
liver cancer with advanced tumours emerging after five months of treatment. This 
demonstrates a rapid tumour development in our cohort of CDE mice compared to 
other studies, where HCC developed after 12-14 months of CDE treatment (Davies et 
al. 2006; Knight et al. 2008). Histological assessment of neoplasms indicated that 







phenotype, a profile that is commonly used to distinguish between HCC and CC 
(Kakar et al. 2007). These results differ from studies in the literature that mainly 
report CC development and only rarely report HCCs in rats in response to TAA 
treatment (Becker 1983; Al-Bader et al. 2000; Guest et al. 2014; Sekiya et al. 2012). 
It is worth noting that this study only used male mice for TAA treatment, while 
TAA-induced CC was mainly observed in female mice (Guest et al. 2014). Different 
genetic backgrounds of mice may also influence study outcomes. Consequently, 
standardised protocols are needed to induce similar response kinetics to be able to 
compare results between different laboratories.  
Further characterisation of CDE- and TAA-induced HCCs demonstrated the presence 
of CD45
+
 inflammatory cells infiltrating the entire tumour mass, a high proliferative 
state marked by Ki67
+
 cells and low to moderate fibrosis levels illustrated by Sirius 
Red-visualised collagen deposition. Interestingly, in contrast to TAA, CDE tumours 
showed a high abundance of F4/80
+
 TAMs, which formed a distinct distribution 
pattern compared to the tissue surrounding area. The immune response in cancer is a 
general diagnostic tool for poor outcomes, in which TAMs represent the major player 
in HCC (Capece et al. 2013; Zhang et al. 2010b). Therefore, the CDE diet represents 
a valuable model for the study of HCC-related inflammatory modulation. Analogous 
to the high variation of tissue injury responses, the emerging tumours in the CDE 
model displayed several different forms of HCC. The morphology of CDE tumours 
included varying degrees of steatosis and steatohepatitis, as well as CK7
+
 bile-like 
structures within the tumour, most likely representing pseudoglandular formations, a 
typical feature of rapidly proliferating HCCs (Yeh 2010). Several CDE-induced 
steatotic HCCs resembled the distinctive histological variant that is mainly seen in 




patients suffering from NASH and termed steatohepatitic HCC (SH-HCC) (Salomao 
et al. 2010). In future studies, neoplasms will be analysed using 
immunohistochemical staining for glypican-3, glutamine synthetase and heat shock 
protein 70. In human diagnostics positive expression of these markers clearly 
distinguishes HCCs from high grade dysplastic nodules in cirrhotic and 
hepatocellular adenomas in non-cirrhotic livers (Schlageter et al. 2014). 
A cohort study in HCV patients demonstrated a positive correlation between the DR, 
the inflammatory response and the degree of fibrosis (Prakoso et al. 2014). Similar 
results were obtained in CDE- and TAA-induced CLD progression and 
carcinogenesis. Immunohistochemical staining of panCK
+
 LPCs strongly suggested a 
positive correlation between tumour formation and the magnitude of the LPC 
response in CDE mice. Moreover, the degree of the inflammatory response and 
tissue fibrosis seemed to be intricately linked to the magnitude of LPC expansion. 
Due to time constrictions a limited number of animals was analysed and the trend 
described in this study will be further examined using more mice of this time course. 
The observed temporal and numerical relationship between investigated disease 
parameters suggested potential interactions between their cellular components. As 





 HSCs and CD45
+
 inflammatory 
cells, and most likely orchestrated the tissue response during injury induction (CDE), 
and the establishment and maintenance phase (TAA). Furthermore, a communication 
between these cellular players has been proposed in several studies using CDE as 
initiator of CLD (Van Hul et al. 2009; Ruddell et al. 2009; Tirnitz-Parker et al. 2014; 
Elsegood et al. 2015). Immunofluorescent triple staining of the cellular components 
of the regeneration niche during carcinogenesis demonstrated a close spatial 
relationship in tumour-surrounding areas and suggested that the interaction between 
LPCs, activated HSCs and inflammatory cells may play a role in the modulation of a 
tumour-favouring microenvironment. Interestingly, immunofluorescent 
characterisation using different LPC markers illustrated an increasing diversity 
within the LPC response during both CDE- and TAA-induced progressive CLD and 
carcinogenesis. Despite a general great overlap, several single positive 

















. They may identify different 




stages during lineage commitment and/or define phenotypes that fulfil different roles 
during liver regeneration and cancer development. A study in chronic viral hepatitis 
patients suggested EpCAM
+
 hepatocytes to be a recent progeny of amplifying LPCs 
(Yoon et al. 2011). 
LPCs are discussed in the literature as potential precursor cells during 
hepatocarcinogenesis (see 1.8.4 for review). Data in this chapter support this 
hypothesis in the CDE and TAA model. Firstly, a correlation between the degree of 
LPC expansion and tumour development was demonstrated in both regimen, and 




 LPCs. Secondly, within the 
panCK
+
 LPC population, several CD44-expressing cells were detected. It was 
previously shown that CD44 identified tumour-initiating cells in the liver when co-
expressed with other CSC markers (Yang et al. 2008c; Yang et al. 2008b; Zhu et al. 
2010) and thus may represent a valid feature to identify pre-cancerous LPC 




 LPCs was 




 cells located in tumours and the 
surrounding tissue, since EpCAM not only labels LPCs, but also identifies hepatic 
CSCs (Yamashita et al. 2008; Yamashita et al. 2009; Kimura et al. 2010). In future 
studies, a potential precursor-product relationship will be further investigated using 
FACS-isolated CD44
+
 LPCs and subsequent functional (tumorigenicity assays) and 












Defining the relationship between the DR/LPC response and 
HCC development in human CLD 
 





A detailed characterisation of the disease parameters associated with CDE- or TAA-
induced murine CLD progression and carcinogenesis was provided in the previous 
chapter. Both regimens provoked tumour development in response to long-term 
treatment and it was further suggested that there is a positive correlation between 
LPCs and HCC occurrence in mice. This chapter focuses on human 
hepatocarcinogenesis and investigates the relationship between the DR, LPC 
expansion, and HCC development.  
The DR and associated LPC activation in human liver disease has been well 
characterised in chronic cholestatic liver disease, ALD, NAFLD and viral hepatitis 
(Roskams and Desmet 1998; Lowes et al. 1999; Roskams et al. 2003a; Clouston et 
al. 2005)). Furthermore, a positive correlation between disease parameters including 
fibrosis and inflammation, and expanding bile ductules/LPCs was established in 
HBV- and HCV- infected patients (Libbrecht et al. 2000a; Clouston et al. 2005; 
Prakoso et al. 2014). Cytokeratins represent the most common markers used to 
identify the DR and the LPC compartment. In particular, CK7 and CK19 expression 
were both localised with the DR/LPCs in ALD, obesity, NAFLD, NASH and viral 
hepatitis (Richardson et al. 2007; Jung et al. 2008; Meriden et al. 2010; Liew et al. 
2012). A high degree of overlap between the expression profiles of CK7, CK9 and 
panCK in HCV patients illustrated that these markers identify the same injury 
response (Prakoso et al. 2014). Furthermore, CK7 and EpCAM expression positively 
correlated with disease severity in alcoholic hepatitis and the authors suggested 
potential value as mortality predictors in patients (Sancho-Bru et al. 2012). Although 
several immunohistochemical studies demonstrated a positive correlation between 
the disease severity and the DR/LPC response in CLD patients, the role of expanding 
LPCs during hepatocarcinogenesis requires further investigation. 




6.2 Study Aims 
The aim of this chapter was to examine the relationship between the abundance of 
LPCs, their lobular distribution, and potential tumour occurrence in CLD patients. 
Therefore, the LPC response has been analysed in two groups of patients (still on-
going). The first set of samples was derived from CLD patients with advanced stages 
of fibrosis and a known history of no HCC development, whereas the second group 
included patients who later developed HCC. 
6.3 Methods 
A retrospective study was performed using human biopsy material and de-identified 
clinical data. Tissue samples of two cohorts were included in the study. These were 
obtained from the Alfred Hospital in Melbourne (VIC, Australia) and Fremantle 
Hospital in Fremantle (WA, Australia). The Melbourne cohort comprised 25 liver 
biopsies obtained from individual CLD patients, who developed HCC one to 12 
years after the biopsy (HCC group). The degree of tissue fibrosis and inflammation 
was evaluated at Royal Alfred Hospital using Scheuer’s scoring system (0-4). The 
Fremantle cohort contained liver biopsies from five patients, who developed HCC 
six to 12 years after the biopsy (HCC group) and 25 liver biopsies from CLD patients 
without liver tumours up to the date of commencing this study (followed patient 
history for 7 to 17 years after biopsy) (non-HCC group). The stage of tissue fibrosis 
in the second cohort was assessed at Fremantle Hospital using Scheuer’s scoring 
system (0-4). Ductular reactions and LPC responses were evaluated in all patients 
using paraffin-embedded sections and immunohistochemistry staining for the 
common biliary cell and LPC marker CK7, EpCAM and Sox9. Histopathological 
analysis of sections was performed blinded to the clinical data. The appearance of 
positive CK7 staining was scored according to the magnitude and lobular distribution 
of the DR and LPCs in whole section scans on a three-point scale, modified after 
Prakoso et al. (Prakoso et al. 2014) (Table. 6.1). Due to cohort-specific tissue 




fixation methods, the background staining varied greatly between sections, however 





DR and/or LPC expansion limited to portal tract 
2 
(moderate) 
DR and/or LPC expansion in zone 1 and up to 50% of zone 2 of the liver lobule 
3 
(severe) 
DR and/or LPC expansion into zones 1, 2 and 3 of the liver lobule 
 
Table. 6.1: Description of the three-point scoring system for the DR/LPC response. 





6.4.1 Patient characteristics of the non-HCC and the HCC group  
To evaluate the DR and LPC response in CLD patients and correlate their appearance 
with tumour formation, two groups of patients have been analysed and compared 
(Table 6.2). The first group included CLD patients with advanced stages of fibrosis 
and cirrhosis (F3, 76% and F4, 24% of patients, respectively) but no signs of 
developing tumours are referred to as non-HCC group. We have previously 
established that the DR and LPC responses correlate with the severity of the 
underlying chronic liver disease (Lowes et al. 1999; Prakoso et al. 2014). As most 
cases of HCC develop on a background of moderate to severe fibrosis, only F3 and 
F4 patients were included in the non-HCC group to identify true differences with 
regards to the appearance and the magnitude of the DR/LPC responses as potential 
associates of HCC development. 
The second set of CLD patients, defined as HCC-group, was derived from patients 
who later developed HCC and showed various stages of fibrosis and cirrhosis at the 
time of the biopsy (F0, 3.7%; F1, 7.4%; F2, 22.2%; F3, 11.1%; F4, 37%). Patients 
with different aetiologies were included in the study; however, CLD was mainly 
caused by viral hepatitis infections (HBV and HCV). Characteristics of individual 
patients are shown in Table 6.3 and Table 6.4. 
. 










 Non-HCC group HCC group 
 n % n % 
Total 25 100 27 100 
Male 13 52 23 85.2 
Age 34-51 - 36-69 - 
Mean ± SEM 41.9 ± 1.1 - 50.8 ± 1.9 - 
Fibrosis stage     
F0 - - 1 3.7 
F1 - - 2 7.4 
F2 - - 6 22.2 
F3 19 76 3 11.1 
F4 6 24 10 37 
N/A - - 5 18.5 
 
Table 6.2: Patient data of the non-HCC and HCC group. Gender, age and fibrosis stage of patients 




Patient Sex Age at biopsy Date of biopsy Fibrosis Inflammation HBV HCV 
N1 M 49 2009 3 N/A   
N2 M 41 2005 3 N/A   
N3 M 39 2005 3 N/A   
N4 M 37 2005 3 N/A   
N5 M 37 2003 3 N/A  yes 
N6 M 48 2004 3 N/A   
N7 M 46 2003 3 N/A  yes 
N8 M 44 2003 3 N/A   
N9 M 49 2005 3 N/A   
N10 M 40 2001 3 N/A   
N11 M 36 2001 4 N/A  yes 
N12 M 41 2002 4 N/A   
N13 M 51 2009 4 N/A  yes 
N14 F 40 2009 3 N/A  yes 
N15 F 39 2008 3 N/A   
N16 F 38 2003 3 N/A   
N17 F 35 2001 3 N/A  yes 
N18 F 34 1999 3 N/A  yes 
N19 F 38 2001 3 N/A  yes 
N20 F 49 2005 4 N/A   
N21 F 47 2005 4 N/A   
N22 F 47 2004 4 N/A   
N23 F 46 2003 3 N/A   
N24 F 43 2000 3 N/A  yes 
N25 F 34 2005 3 N/A   




Patient Sex Age at biopsy Age at HCC detection Fibrosis Inflammation HBV HCV 
T1 M 44 47 4 2 yes yes 
T2 M 36 47 4 1 no yes 
T3 M 43 44 2 2 no yes 
T4 F 69 79 2 2 no yes 
T5 M 58 63 1 3 yes no 
T6 M 44 56 4 1 yes yes 
T7 M 27 32 2 1 yes no 
T8 M 66 70 1 2 no yes 
T9 M 53 56 2 2 yes yes 
T10 M 56 57 4 3 no yes 
T11 M 55 62 4 2 no yes 
T12 M 45 53 4 2 no yes 
T13 F 56 61 0 1 yes yes 
T14 F 58 64 3 3 yes yes 
T15 M 60 64 3 3 yes no 
T16 M 45 51 3 3 yes yes 
T17 M 57 61 4 3 no yes 
T18 M 45 53 2 1 no yes 
T19 M 45 52 4 3 no yes 
T20 F 57 66 2 2 no yes 
T21 M 47 55 4 N/A yes yes 
T22 M 48 56 4 2 yes yes 
T23 M 47 57 N/A N/A  yes 
T24 M 47 58 N/A N/A  yes 
T25 M 52 64 N/A N/A  yes 
T26 M 69 75 N/A N/A  yes 
T27 M 42 52 N/A N/A  yes 
Table 6.4: Characteristics of individual HCC patients. N/A, not assessed. 




6.4.2 Ductular reaction and LPC expansion in the non-HCC vs. HCC group 
Immunohistochemical staining of the biliary cell and LPC marker CK7 revealed that 
the DR mainly appeared in periportal areas identified by increasing numbers of CK7
+
 
biliary structures and irregular strings of bile duct epithelium. Moreover, in the 
periphery of portal tracts, CK7
+
 single cells and small groups of cells without a 
lumen, and therefore defined as LPCs, were detected, which occasionally expanded 
further into the parenchyma. The magnitude and lobular distribution of the DR and 
LPCs was evaluated using a three-point scoring system defined as mild (1), moderate 
(2) and severe responses (3) (Table 6.1 and Fig. 6.1). The non-HCC group mainly 
showed mild (44%) and moderate responses (48%) with increased ductular structures 
and limited LPC expansion. On the other hand, in the HCC group all categories were 
evenly represented (mild, 30%; moderate, 33%; severe, 37%), demonstrating more 
prominent expansion of LPCs into the parenchyma (Table 6.5 and Fig.6.2). There 
was a significant positive correlation between the appearance and degree of the 
DR/LPC response and the risk to develop HCC in CLD patients (Fig. 6.3). 
In the HCC group, tissue fibrosis increased significantly with a stronger DR/LPC 
response, whereas the severity of inflammation did not significantly change between 
the mild, moderate and severe response group even though a trend of increasing 
inflammation was observed (Fig. 6.4). However, a significant positive correlation 
was detected between the severity of the DR/LPC response and the corresponding 
tissue fibrosis stage (Fig. 6.5A), and tissue inflammation (Fig. 6.5B), respectively. 
Since the non-HCC group patients were limited to more advanced fibrosis stage (F3 
and F4), a correlation was not performed. 





Fig. 6.1: Mild, moderate and severe DR and LPC response. Formalin-fixed, paraffin-embedded 
sections from patients of the non-HCC and HCC group were immunohistochemically labelled for the 
biliary cell and LPC marker CK7. Representative images of the mild, moderate and severe DR/ LPC 
response are shown. The scale depicts 200 μm. 







 Non-HCC group HCC group 
 n % n % 
Total 25 100 27 100 
DR/ LPCs     
1 11 44 8 30 
2 12 48 9 33 
3 2 8 10 37 
 






Fig. 6.2: Parenchymal infiltration of CK7
+
 LPCs in non-HCC and HCC patients. Representative 
images of parenchymal CK7
+
 LPC infiltration in livers of non-HCC and HCC patients are shown. The 
scale depicts 100 μm. 












Fig 6.3: DR and LPC response in the non-HCC and HCC group. The graph shows the average 
score ± SEM for the DR/LPC response in non-HCC and HCC patients. *p > 0.05 (Mann Whitney test) 









Fig 6.4: The relationship between the DR/LPC response and other CLD disease parameters in 
the HCC group. This graph shows (A) the fibrosis and (B) inflammation status of HCC patients in 
the three categories of DR and LPC response. *p < 0.05 (Kruskal Wallis test) 









Fig 6.5: The DR/LPC response in correlation to other CLD disease parameters of the HCC 
group. Stages of the DR/LPC response (1-3) in individual patients of the HCC-group were correlated 
to (A) the fibrosis score and (B) the inflammation score. Multiple data points may be present 
overlying an individual point. Shown is the trend line with R
2









Support for the hypothesis that LPC activation and proliferation might be associated 
with an increased risk of HCC development in human livers came from several 
studies that linked LPCs and the DR to progressing injury patterns (Clouston et al. 
2005; Lowes et al. 1999; Prakoso et al. 2014; Wood et al. 2014). Moreover, 
pharmacological inhibition of the LPC compartment has been demonstrated to 
decelerate disease progression and reduce HCC formation (Davies et al. 2006; 
Knight et al. 2008; Lee et al. 2010a). Additionally, in combined HCC-CC, 
background activation of LPCs is associated with multifocal occurrence and 
recurrence (Cai et al. 2012).  
This chapter investigated the appearance of the DR and LPC response in CLD 
patients and assessed a potential link to HCC. The samples included in this 
retrospective study were particularly valuable since the history of patient data as well 
as their outcome was known. Characterisation of CK7
+
 DRs/LPC expansions 
suggested a positive correlation between the magnitude/distribution of the LPC 
response and HCC development. Furthermore, patients in the HCC group illustrated 
a more prominent parenchymal infiltration of LPCs, marked by CK7
+
 single cells 
and small groups of cells. However, to validate this observation, additional patient 
cohorts will need to be analysed. In CLD such as ALD, NAFLD and HCV infection, 
a positive correlation between the degree of fibrosis and LPC expansion has been 
demonstrated (Roskams et al. 2003a; Sancho-Bru et al. 2012; Prakoso et al. 2014). 
This study confirmed and extended the previous findings in chronically injured livers 
of patients, who later developed HCC by showing a positive correlation between 
LPCs and tissue fibrosis, as well as between LPCs and tissue inflammation, 
respectively. 
Due to the known positive correlation between LPCs and the corresponding tissue 
fibrosis (Roskams et al. 2003a; Clouston et al. 2005; Sancho-Bru et al. 2012), only 
F3 and F4 patients were incorporated in the non-HCC group to include samples with 
increased DRs/LPCs. Due to the shortage of biopsy material from CLD patients with 
a known long-term course of the disease, all stages of fibrosis were included in the 




HCC group. This may cause a potential underestimation of differences in LPC 
expansion between non-HCC and HCC patients. However, despite this, the study 
was able to demonstrate a statistically significant association. Therefore, further 
analyses are planned using a more homogenous set of samples regarding underlying 
aetiology and fibrosis stage. In addition, a more detailed characterisation of the LPC 
population using markers associated with human LPCs such as AFP, CD133, CK19 
and EpCAM (Spee et al. 2010; Porretti et al. 2010; Sancho-Bru et al. 2012; Villano 
et al. 2014), as well as assessing the proliferation status of LPC subpopulations may 
reveal a specific phenotype associated with HCC development. 
Overall, the results further support the theory that LPCs play a role in human 
hepatocarcinogensis. Whether there is a direct causation in the form of a precursor-
product relationship or a regulatory function of LPCs remains to be determined. 
However, considering published data and the results of this study, the LPC 
compartment represents a promising cellular target to therapeutically influence 
disease outcomes. Furthermore, co-localisation studies may help to identify cell 
populations with potential tumour-initiating characteristics showing a distinct 









 populations found in CDE- and TAA-induced carcinogenesis (see 
Chapter 5) may be candidate phenotypes that will also be investigated and correlated 

















Irrespective of clinical presentations and the underlying cause, most CLDs are 
accompanied by expanding ductular epithelial cell structures and proliferating LPC 
arrangements. Together with induced inflammatory, vascular, neural and ECM 
changes, these cellular components form the injury niche, termed the ductular 
reaction (Gouw et al. 2011; Williams et al. 2014). This compartment is activated in 
response to severe liver injury caused by viral, toxic or carcinogenic stimuli when 
residual hepatocytes may no longer meet the tissue demand due to cell cycle arrest 
and senescence. Upon activation LPCs proliferate and repopulate the liver mass by 
migrating towards the site of injury and differentiating into the major hepatic cell 
types, hepatocytes and cholangiocytes (Suzuki et al. 2008; Sackett et al. 2009; 
Forster et al. 2011; Shin et al. 2011; Liu et al. 2015). These processes are regulated 
by the local microenvironment, which includes cell-cell and cell-matrix interactions 
in close association with HSC activation and inflammation (Ruddell et al. 2009; 
Boulter et al. 2013; Dwyer et al. 2014; Grzelak et al. 2014; Tirnitz-Parker et al. 
2014).  
Orthotopic liver transplantation is still the most effective treatment for end-stage 
CLD and as donors are short in numbers, alternative treatment options are urgently 
needed. A great potential lies in cell therapy approaches and LPCs have been 
suggested as promising cellular sources due to their high regenerative potential (Dan 
and Yeoh 2008; Forster et al. 2011). Thus, further studies on LPC-mediated 
regeneration are required, including the study of appropriate animal models before 
results can be translated into human injury settings. 
The aim of Chapter 3 was to thoroughly characterise and compare two common 
murine CLD models, based on CDE and TAA treatment, respectively. Evaluation of 
the injury induction (days 3 and 7), establishment (days 14 and 21) and maintenance 
phase (day 42) revealed that the injury response dynamics differed significantly 
between both regimens. In the CDE model, markers of overall liver damage 
including ALT levels, apoptosis, lipid accumulation and oxidative stress, as well as 
inflammation and fibrosis peaked during the induction phase before normalising 
during injury establishment and maintenance. However, in response to increased 
levels of known regulating factors associated with LPC activation in the induction 
phase, including TWEAK, TNF, LTβ, IL6, IFN and HGF (Matthews et al. 2004; 
Brooling et al. 2005; Knight et al. 2005c; Ruddell et al. 2009; Tirnitz-Parker et al. 




2010; Ishikawa et al. 2012), numbers of LPCs (panCK
+
 cells) were increasing until 
they reached a steady-state level in the establishment phase. On the other hand, the 
TAA model provoked a progressive (chronic) injury response with disease 
parameters persistently upregulated or gradually increasing throughout the time 
course of six weeks. 
In addition to discrepancies in temporal kinetics, the data illustrated for the first time 
significant spatial differences between both regimens. The CDE diet induced a 
mainly periportal injury response, where inflammatory cells, HSCs and LPCs formed 
the regeneration niche in the induction phase. Since inflammatory cells and 
myofibroblasts are both known to facilitate LPC activation (Tirnitz-Parker et al. 
2010; Elsegood et al. 2015) portal areas represented the anchoring point for 
crosstalk-mediated expansion of LPCs and HSCs into the surrounding parenchyma 
(Ruddell et al. 2009). In contrast, TAA-induced centrilobular damage provoked an 
injury cascade in central areas initiated by injured hepatocytes, inflammatory cells 
and potentially LSECs, which together may activate HSCs and the formation of the 
LPC-hosting regeneration niche during later stages of the injury establishment phase. 
The limited migration of LPCs initiated from portal areas and their accumulation and 
expansion from central areas may be mediated through relocation of the DR to the 
damage-burden area. Kaneko and colleagues showed a structural flexibility of the 
hepatobiliary system in response to tissue injury (Kaneko et al. 2015). They 
demonstrated a unidirectional expansion of biliary branches towards central areas in 
the TAA model versus CDE-induced branching around portal tracts. Further studies, 
involving ink injection assays, are planned to investigate this hypothesis. Injection of 
ink into the common bile duct visualises the potential relocation of functional biliary 
branches. Consistent with model-specific spatial distribution patterns highlighted in 
Chapter 3, collagen deposition was induced periportally in the CDE model versus 
pericentrally in the TAA model. A comparison to human pathologies revealed that 
the CDE-induced pattern is typically observed in fibrosis resulting from autoimmune 
or chronic viral hepatitis and chronic biliary diseases or cholestasis (Ferrell 2000), 
whereas TAA-induced fibrosis resembled the pattern illustrated in ALD or NAFLD 
(Ferrell 2000). 
It is widely accepted that LPCs represent a transit amplifying cell population. To 
date, there is no LPC specific marker available and they share markers with other cell 




types in the liver such as cholangiocytes and hepatocytes, as well as haematopoietic 
and mesenchymal cells (Petersen et al. 1998; Petersen et al. 1999; Petersen et al. 
2003; Yovchev et al. 2008; Guest et al. 2014). Often a combination of different 
markers is used to identify distinct LPC populations. The aim of Chapter 4 was to 
characterise the expression profile of common LPC markers and identify different 
populations induced by CDE or TAA treatment. 
Evaluation of the proliferation status revealed that CDE treatment induced biliary 





 cells in portal areas. In contrast, the TAA model provoked increased 
proliferation of this cell population in central areas consistent with the well-
established regeneration niche during the injury maintenance phase. This emphasised 
diverse LPC response dynamics and as illustrated in Chapter 3 confirmed a CDE-
driven periportal induction and further expansion of LPCs into the parenchyma, 
whereas TAA induced a shift of the LPC compartment from initially portal (during 
the injury induction phase), to central areas during the maintenance phase. 
In addition to differences in timing and location, co-localisation analyses of the 
common LPC markers A6, CD133, CK19, E-cadherin, EpCAM, MIC1-1C3 and 
panCK (Suzuki et al. 2008; Dorrell et al. 2011; Espanol-Suner et al. 2012; 
Schievenbusch et al. 2012) revealed distinct expression profiles of cell populations 
within the pool of LPCs in both regimens. While the CDE model mainly produced 
homogenous double-positive LPC phenotypes, TAA treatment provoked many 





















. Furthermore, CD44 identified a small 
subpopulation of panCK
+
 LPCs in the TAA model, whereas CD90 was only 
demonstrated to be expressed in a limited number of CDE-induced LPCs. 
Recently, it has been highly debated whether LPCs truly contribute to tissue repair 
during CLD. In addition to their hepatocytic differentiation potential in vitro, 
numerous studies have shown that LPCs are capable of replacing damaged 
hepatocytes in mice in vivo. This has been demonstrated following their isolation 
from CDE- or DDC-injured mouse livers or human livers, and subsequent 
transplantation into a chronic injury setting (Suzuki et al. 2008; Forster et al. 2011; 
Shin et al. 2011; Huch et al. 2015; Lu et al. 2015). 




Lineage tracing experiments are valuable strategies to follow distinct LPC 
phenotypes in their endogenous environment throughout induced liver injury. Using 
this approach, several studies provided contradictory results regarding the function of 
LPCs during CLD (Sackett et al. 2009; Furuyama et al. 2011; Espanol-Suner et al. 
2012; Tarlow et al. 2014a; Lu et al. 2015; Shin et al. 2015). However, caution has to 
be taken when interpreting the study outcomes. Chapter 3 illustrated that the 
temporal and spatial dynamics of disease parameters varied greatly between 
experimental models. Moreover Chapter 4 highlighted that the induced LPC 
population included model-specific subpopulations with distinct phenotypes. A study 
by Lu and colleagues demonstrated that distinct LPC subpopulations showed 







 developed frequent colonies of packed 













populations generated infrequent small colonies with mesenchymal characteristics 
(Lu et al. 2015). Consequently, the above-mentioned discrepancies between studies 
focussing on LPC function may reflect the usage of different experimental models 
and/or markers utilised for labelling potential LPC progenies. Irrespective of the 
markers used for lineage tracing (Sox9, Foxl1 and OPN), LPCs did not generate new 
hepatocytes in the DDC model. However, their differentiation into cholangiocytes 
was reported (Espanol-Suner et al. 2012; Tarlow et al. 2014a; Shin et al. 2015). In 





 LPCs (Espanol-Suner et al. 2012; Shin et al. 2015). It is important to mention 
that the pathology between both models differs significantly. The DDC model 
represents a cholestatic liver injury model (Liedtke et al. 2013), whereas the CDE 
model resembles injury dynamics seen in NAFLD, as shown in Chapter 3. 
Furthermore, studies using CCl4 induction showed different outcomes, illustrated by 
(i) Espanol-Suner et al., who generated LPC-derived hepatocytes labelled by OPN, 
versus (ii) Tarlow et al. who excluded the contribution of LPCs in tissue regeneration 
following Sox9 expression (Espanol-Suner et al. 2012; Tarlow et al. 2014a). 
Further support for marker-specific study outcomes is provided by studies relying on 
CDE-induced CLD. Tracing of the LPC markers OPN and Foxl1, respectively, 
revealed that these LPC populations are required for hepatocyte development, 
whereas Sox9- and CK19-expressing cells were found to only rarely differentiate 




into hepatocytic lineage (Espanol-Suner et al. 2012; Tarlow et al. 2014a; Lu et al. 
2015; Shin et al. 2015). Other factors that may influence these diverse study 
outcomes include the genetic background and gender of mice, but also variations in 
the protocol of animal models between different laboratories. The study that claimed 
a minor contribution of CK19-expressing cells to the replacement of hepatocytes 
during CDE-induced liver regeneration was performed with female mice (personal 
communication) (Lu et al. 2015), whereas most studies utilise male mice (often not 
mentioned). It was demonstrated that male and female individuals may produce 
different consequences in response to liver damage (Durazzo et al. 2014). 
Furthermore, minor tracing of Sox9 into the hepatocytic lineage in response to CDE 
treatment may be provoked by a lower concentration of ethionine, the carcinogenic 
compound of the diet (Tarlow et al. 2014a). The authors used 0.1% ethionine 
compared to the traditional 0.15% used in studies that showed hepatocytic LPC 
differentiation. 
Consequently, when using different markers and experimental models, it is not clear 
whether the same LPC population is targeted/being investigated and importantly, 
context-specific LPC responses may influence the study outcome. Overall this 
highlights the importance of a detailed characterisation of the underlying models, and 
the urgent need for standardised techniques in order to accurately compare results 
between laboratories using the same experimental models. The results presented in 
this thesis are an important stepping stone. Further experiments are planned to define 
CDE- and TAA-induced LPC subpopulations. A multicolour flow cytometry 
experiment has been designed based on simultaneous labelling of cells with the 
markers CK19, CD24, CD44, CD133, EpCAM, Fn14, Integrin α5β6, MIC1-1C3 and 
OPN. With this approach, LPCs will be isolated from CDE and TAA time courses 
and a “developmental tree” of LPC populations will be generated. Distinct 
subpopulations will then be isolated for a detailed characterisation and functional 
analyses. 
Despite the availability of HBV vaccination and improved methods to treat HCV 
infections, the worldwide number of HCC-related deaths is steadily increasing 
(Altekruse et al. 2014; Wang et al. 2014). Therefore it is of high interest to study the 
gradual process of HCC development to be able to therapeutically prevent a 
transition at the pre-tumorigenic stage. 




The CDE and TAA regime represent promising experimental models to study 
processes related to hepatocarcinogenesis (Becker 1983; Knight et al. 2008; Guest et 
al. 2014; Darweish et al. 2014; Boulter et al. 2015). However, it is fundamental to 
thoroughly characterise the injury-related parameters and apply the right conditions 
to specific research questions. Therefore, in addition to the induction, establishment 
and maintenance phase of the CDE and TAA model analysed in Chapters 3 and 4, 
the aim of Chapter 5 was to further characterise stages of CLD progression and 
tumour formation. Investigations on the level of hepatocyte damage, inflammation, 
LPC expansion and fibrosis revealed that both regimens provoked progressively 
increasing levels of all investigated disease parameters throughout the time course of 
seven months. However, substantial differences were observed in the magnitude and 
spatial arrangements of investigated parameters. In the CDE model, excessive 
hepatic fat loading and progressive hepatic injury, as well as the progressive 
inflammation, LPC response and fibrosis, and eventually HCC development without 
the appearance of cirrhosis resemble the conditions found in NAFLD and NASH 
patients (Ferrell 2000; Takahashi et al. 2014). Inflammation and fibrosis is induced 
at the site of tissue damage, which is located in periportal and intralobular areas. In 
contrast, in the TAA model, sustained hepatic injury, progressive inflammation, LPC 
response, fibrosis and eventually cirrhosis and HCC development reflect the 
pathological dynamics seen in viral hepatitis patients (Ferrell 2000). Moreover, the 
localisation of tissue damage and the following injury response remained in 
pericetral and central-to-central bridging areas. The conditions described in both 
regimens predisposed the liver to HCC development. Both CDE and TAA treatment 
induced frequent incidences of primary HCC formation, contradictory to studies in 
the literature that mainly reported TAA-induced CCs (Becker 1983; Al-Bader et al. 
2000; Sekiya et al. 2012; Guest et al. 2014). 
Besides their potential beneficial role during tissue regeneration, LPCs have been 
associated with the formation of liver cancer and have even been proposed to 
represent one candidate for the cell of origin (Davies et al. 2006; Knight et al. 2008; 
Shupe and Petersen 2011; He et al. 2013; Guest et al. 2014; Lee et al. 2010a). 
Therefore, further studies on their role during hepatocarcinogenesis are needed. 
Chapter 3 and 4 showed that LPC expansion occurred during phases of injury 
induction, establishment and maintenance in response to CDE and TAA treatment, 




respectively. Moreover, in Chapter 5 it was demonstrated that the number of LPCs 
further increased during disease progression and carcinogenesis and incorporated 
















cells. In particular the CDE model suggested a 
positive correlation between the degree of LPC expansion and HCC development. 
These data emphasise that LPCs play a role during CDE- and TAA-induced 
carcinogenesis and will be strengthend through analysis of additional animals from 
this time course. In addition, several HCCs induced in both regimens included 
numerous cells with a LPC phenotype within their tumour mass. The identification of 
potentially pre-cancerous LPC subpopulations that may initiate tumorigenesis 









cells with CD44 and EpCAM 
representing CSC markers (Yamashita et al. 2008; Yang et al. 2008b; Zhu et al. 
2010; Yamashita et al. 2009; Kimura et al. 2010). The characteristics and the 
tumour-initiating potential of isolated CD44
+
 LPCs will be further investigated using 
FACS and subsequent analyses including functional assays (soft agar assay and 
xenograft transplantation) and the evaluation of an HCC- and CSC-associated gene 
expression profile. 
Previous studies including lineage tracing, immunohistochemistry and gene 
expression profiling produced contradictory results regarding a potential tumour-
initiating potential of LPCs (Sekiya et al. 2012; Guest et al. 2014; Mu et al. 2015; 
Kowalik et al. 2015; Shin et al. 2016). A study by Sekiya and colleagues proposed 
that CC development in TAA-treated mice originates from hepatocytes (Sekiya et al. 
2012), whereas Guest et al., using the same model, claimed cholangiocytes/LPCs as 
cellular origin (Guest et al. 2014). Recently Mu and colleagues investigated the cell 
of origin during HCC development using mice with OPN-traced 
cholangiocytes/LPCs and the injury models DEN, DEN+CCL4, DEN+CDE, 
DEN+DDC, and CDE alone. The authors came to the conclusion that HCC 
originates from hepatocytes and not from the biliary/LPC compartment (Mu et al. 
2015). However, it should be mentioned that the animals in this study illustrated a 
weaker LPC response when exposed to the CDE diet than demonstrated in this 
thesis. Moreover, only 30% of mice developed HCC after one year of treatment or 
longer, whereas this thesis showed that 45% of mice had developed intermediate and 




advanced stages of HCC already after seven months of treatment, possibly reflecting 
different degrees of induced hepatocyte damage in the two studies. Overall these 
findings demonstrate that even with the use of the same carcinogenesis-inducing 
agent (here TAA and CDE), different results can be generated, highlighting once 
more the importance of standardised protocols between laboratories. 
A summary of the injury dynamics observed in the murine CLD models investigated 
in this thesis, CDE versus TAA, is given in Fig. 7.1. The CDE model provoked a 
two-phasic injury pattern since the six-week time course induced a rapid increase of 
disease parameters during the injury induction phase and a normalisation thereafter; 
whereas, long-term treatment caused a progressive increase. The only outstanding 
parameter was the LPC compartment, which was activated during the injury 
induction and co-regulated with the inflammatory and fibrogenic responses. 
However, in contrast to normalisation of inflammation and fibrosis, LPC numbers 
further increased in a progressive fashion through to carcinogenesis. On the other 
hand, the TAA model induced a rather continuously progressive injury response of 
all investigated parameters throughout the time course. 
Since Chapter 5 proposed a correlation between the LPC response and HCC 
development in mice, the aim of Chapter 6 was to investigate the degree or 
appearance of the DR and LPC response in CLD patients and to assess a potential 
link to HCC. Several studies have demonstrated an association between LPC 
activation and proliferation, and an increased risk of developing HCC (Davies et al. 
2006; Knight et al. 2008; Lee et al. 2010a). This hypothesis is supported through 
data generated by characterising the CK7
+
 DR/LPC response. In particular, a 
significant positive correlation between the magnitude and distribution of the LPC 
response and HCC development was demonstrated. Further experiments are planned, 
which define the characteristics of the illustrated LPC response by analysing 
expression profiles of markers that have been associated with human LPCs such as 
AFP, CD133, CK19 and EpCAM (Porretti et al. 2010; Spee et al. 2010; Sancho-Bru 
et al. 2012; Villano et al. 2014). In addition, their proliferation status will be 
investigated and co-localisation studies with CSC markers might identify potential 
tumour-initiating phenotypes. 








Fig. 7.1: Injury response dynamics in the CDE and TAA model. D, day; M, month. 




In conclusion, this thesis aimed to characterise two common murine CLD models, 
CDE versus TAA, and to describe the microenvironment and phenotypes of the 
associated LPC responses during the stages of injury induction, establishment, 
maintenance, progression and carcinogenesis. Furthermore, the relationship between 
LPCs and HCC development in humans was investigated. Firstly, it was shown that 
the dynamics and patterns of disease parameters greatly rely on the stimulus and do 
not fully represent a particular pathological condition in humans. This thesis 
highlights the importance of choosing the appropriate experimental conditions 
including the most suitable model and time point to address specific research 
questions. Secondly, this thesis introduced the TAA regimen as suitable model for 
the study of LPC biology during CLD and HCC formation. Thirdly, HCC 
development in both regimens was associated with the degree of the LPC response, 
which further suggests their active contribution to the formation of HCC. Whether 
there is a direct precursor-product relationship or this is mediated through regulation 
of functions by providing a pro-tumorigenic environment remains to be clarified. 
Lastly, the magnitude and distribution of the DR/LPC response was positively 
correlated to HCC formation in CLD patients. This finding may be relevant for 
clinical applications, since a qualitative assessment of the DR/LPC response will 
potentially identify patients at greater risk of development of HCC on the 
background of CLD. Overall this thesis further supports the hypothesis that LPCs 
represent a promising cellular target to therapeutically influence disease outcomes. 
Further investigation is required to potentially identify distinct phenotypes that may 
play different roles in regeneration versus carcinogenesis. With this knowledge 
therapeutic approaches can be developed that may support LPC-mediated 
regeneration, while inhibiting cancer development through inactivation of the 
appropriate phenotypes. 
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